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Abstract
Double-blind randomised controlled trial of percutaneous
tibial nerve stimulation versus sham electrical stimulation
in the treatment of faecal incontinence: CONtrol of
Faecal Incontinence using Distal NeuromodulaTion
(the CONFIDeNT trial)
Emma J Horrocks,1* Stephen A Bremner,2 Natasha Stevens,2
Christine Norton,3 Deborah Gilbert,1 P Ronan O’Connell,4
Sandra Eldridge2 and Charles H Knowles1
1National Centre for Bowel Research and Surgical Innovation, Blizard Institute,
Queen Mary University of London, London, UK
2Pragmatic Clinical Trials Unit, Blizard Institute, Queen Mary University of London, London, UK
3Florence Nightingale Faculty of Nursing and Midwifery, King’s College London, London, UK
4School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
*Corresponding author e.j.horrocks@qmul.ac.uk
Background: Faecal incontinence (FI) is a common condition which is often under-reported. It is
distressing for those suffering from it, impacting heavily on their quality of life. When conservative
strategies fail, treatment options are limited. Percutaneous tibial nerve stimulation (PTNS) is a minimally
invasive outpatient treatment, shown in preliminary case series to have significant effectiveness; however,
no randomised controlled trial has been conducted.
Objectives: To assess the effectiveness of PTNS compared with sham electrical stimulation in the
treatment of patients with FI in whom initial conservative strategies have failed.
Design: Multicentre, parallel-arm, double-blind randomised (1 : 1) controlled trial.
Setting: Eighteen UK centres providing specialist nurse-led (or equivalent) treatment for pelvic
floor disorders.
Participants: Participants aged > 18 years with FI who have failed conservative treatments and whose
symptoms are sufficiently severe to merit further intervention.
Interventions: PTNS was delivered via the Urgent® PC device (Uroplasty Limited, Manchester, UK), a
hand-held pulse generator unit, with single-use leads and fine-needle electrodes. The needle was inserted
near the tibial nerve on the right leg adhering to the manufacturer’s protocol (and specialist training).
Treatment was for 30 minutes weekly for a duration of 12 treatments. Validated sham stimulation involved
insertion of the Urgent PC needle subcutaneously at the same site with electrical stimulation delivered to
the distal foot using transcutaneous electrical nerve stimulation.
Main outcome measures: Outcome measures were assessed at baseline and 2 weeks following
treatment. Clinical outcomes were derived from bowel diaries and validated, investigator-administered
questionnaires. The primary outcome classified patients as responders or non-responders, with a responder
defined as someone having achieved ≥ 50% reduction in weekly faecal incontinence episodes (FIEs).
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Results: In total, 227 patients were randomised from 373 screened: 115 received PTNS and 112 received
sham stimulation. There were 12 trial withdrawals: seven from the PTNS arm and five from the sham arm.
Missing data were multiply imputed. For the primary outcome, the proportion of patients achieving a
≥ 50% reduction in weekly FIEs was similar in both arms: 39 in the PTNS arm (38%) compared with 32 in
the sham arm (31%) [odds ratio 1.28, 95% confidence interval (CI) 0.72 to 2.28; p= 0.396]. For the
secondary outcomes, significantly greater decreases in weekly FIEs were observed in the PTNS arm than in
the sham arm (beta –2.3, 95% CI –4.2 to –0.3; p= 0.02), comprising a reduction in urge FIEs (p= 0.02)
rather than passive FIEs (p= 0.23). No significant differences were found in the St Mark’s Continence Score
or any quality-of-life measures. No serious adverse events related to treatment were reported.
Conclusions: PTNS did not show significant clinical benefit over sham electrical stimulation in the
treatment of FI based on number of patients who received at least a 50% reduction in weekly FIE. It would
be difficult to recommend this therapy for the patient population studied. Further research will concentrate
on particular subgroups of patients, for example those with pure urge FI.
Trial registration: Current Controlled Trials ISRCTN88559475.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 19, No. 77. See the NIHR Journals Library website
for further project information.
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Plain English summary
Faecal incontinence occurs when a person passes faeces (stools) without the usual control. It is a distressingand common condition, although it is under-reported because of embarrassment. There are few treatment
options available. Percutaneous tibial nerve stimulation (PTNS) is a relatively new treatment, which involves
electrically stimulating a nerve at the ankle using a very small needle (similar to acupuncture). Few studies
have been performed to quantify how successful it is, but early results of PTNS suggest that it is as good as
other more expensive and invasive treatments.
The aim of this research was to determine how effective PTNS is in the treatment of patients with faecal
incontinence by comparing it with sham treatment (fake stimulation). This was carried out by comparing
the number of people who experienced successful treatment in the PTNS group with the sham group.
Treatment was considered ‘successful’ if faecal incontinence episodes were reduced by half or more.
In total, 227 patients in 18 UK specialist centres took part. They were randomly allocated, 115 to PTNS and
112 to sham stimulation. Each patient filled in bowel diaries and questionnaires before and 2 weeks after
treatment to compare the arms.
The results showed that the proportion of patients in whom treatment was successful was similar in both
groups (38% in the PTNS group compared with 31% in the sham treatment group). This means that PTNS
is not significantly better than sham stimulation. This results will be important in guiding whether or not
PTNS should be made available to patients in the NHS and beyond.
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Scientific summary
Background
Faecal incontinence (FI) poses a significant UK public health problem, with an estimated prevalence of
11–15% among adults. It is known to be an under-reported problem that significantly impacts on quality
of life. It often causes social and psychological disability, leading to stigmatisation and social exclusion.
Management of FI is challenging owing to a widespread lack of expertise, high prevalence and multiple
aetiologies. Neuromodulation is a relatively new treatment modality for FI. It is based on recruitment
of residual anorectal neuromuscular function pertinent to continence by electrical stimulation of the
peripheral nerve supply, without the need for surgery to the anus itself.
Tibial nerve stimulation is a minimally invasive neuromodulatory modality. The tibial nerve contains afferent
and efferent fibres originating from the fourth and fifth lumbar nerves and first, second and third sacral
nerves. Thus, stimulation of the tibial nerve is thought to lead to improved continence in a similar way to
sacral nerve stimulation but without the need for a permanent surgically implanted device. Tibial nerve
stimulation is an outpatient treatment which can be delivered by any trained health-care professional.
Two main delivery methods are described: percutaneous tibial nerve stimulation (PTNS) and transcutaneous
tibial nerve stimulation (TTNS). The main perceived advantage of PTNS over TTNS is the proximity of the
needle to the tibial nerve, enabling higher treatment amplitude to be delivered while avoiding the painful
skin sensations associated with transcutaneous treatment.
Observational studies of PTNS have shown improvements in most outcome measures (bowel diary,
Cleveland Clinic Incontinence Score and quality-of-life measures) after treatment, compared with baseline.
A small three-arm RCT of PTNS versus TTNS versus sham showed effects of both treatments over sham,
with PTNS appearing superior.
Percutaneous tibial nerve stimulation may offer a repeatable, low-cost (estimated at £5916 for the first
10 years based on 6-monthly top-up sessions) minimally invasive outpatient technique. It may, therefore,
offer a genuinely new option in the pathway to treat FI.
Objectives
The aim of this study was to assess the clinical effect of PTNS compared with sham electrical stimulation in
the treatment of patients with significant FI. Clinical outcomes, derived from bowel diaries and validated,
investigator-administered questionnaires, were assessed at baseline and 2 weeks following a 12-week
course of treatment. Outcomes were as follows.
Primary outcome
Responder versus non-responder, defined as a patient achieving ≥ 50% reduction in faecal incontinence
episodes (FIEs) per week.
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Secondary outcomes
l Percentage change in FIEs per week (i.e. patients achieving ≥ 25%, ≥ 75% or 100% reduction in
weekly FIEs).
l Change in FIEs per week as a continuous measure.
l Change in symptom severity score: St Mark’s Continence Score (SMCS).
l Change in disease-specific quality-of-life scores:
¢ Gastrointestinal Quality of Life Index
¢ Faecal Incontinence Quality of Life Index.
l Change in generic health-related quality-of-life measures: Short Form Questionnaire-36 items.
l Change in patients’ health status and overall health using European Quality of Life-5
Dimensions questionnaire.
l Change in a patient-centred outcomes visual analogue scale questionnaire.
l Likert scale of patients’ global impression of success (scale of 0–10).
l Qualitative data:
¢ patient-perceived impression of change in use of incontinence pads and constipating medications
¢ patient-perceived impression of change in urinary symptoms
¢ patient impression of the treatment in general
¢ patient-perceived allocation (PTNS or sham).
Other outcomes recorded at each visit
l Stimulation parameters.
l Adverse events and concomitant medications.
Methods
This study was a UK-based multicentre, pragmatic, parallel-arm, double-blind, randomised controlled trial.
There was equal allocation between the arms, with stratification by sex and centre.
Centres with specialist expertise in FI and adequate staffing (at least two staff members), which
demonstrated expertise with PTNS, were invited to participate in the study. All adult patients with FI
symptoms sufficiently severe to warrant intervention in whom appropriate conservative therapies had failed
were invited to participate. Inclusion and exclusion criteria were as follows.
Inclusion criteria
l Faecal incontinence sufficiently severe to warrant intervention (as recommended by the principal
investigator at each site).
l Failure of appropriate conservative therapies.
l Age ≥ 18 years.
Exclusion criteria
l Inability to provide informed consent for the research study.
l Inability to fill in the detailed bowel diaries required for outcome assessments (this excluded participants
who do not speak/read English).
l Neurological diseases, such as diabetic neuropathy, multiple sclerosis and Parkinson’s disease (including
any participant with painful peripheral neuropathy).
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l Anatomical limitations that would prevent successful placement of needle electrode.
l Other medical conditions precluding stimulation, for example bleeding disorders, certain cardiac
pacemakers, peripheral vascular disease or ulcer, lower leg cellulitis.
l Congenital anorectal anomalies or absence of native rectum due to surgery.
l A cloacal defect.
l Present evidence of external full-thickness rectal prolapse.
l Previous rectal surgery (rectopexy/resection) done < 12 months previously (24 months for cancer).
l Stoma in situ.
l Chronic bowel diseases such as inflammatory bowel disease leading to chronic uncontrolled diarrhoea.
l Pregnancy or intention to become pregnant.
l Previous experience of sacral nerve stimulation or PTNS.
Each patient was scheduled to attend for 14 study visits, the first for eligibility checking, visits 2–13 for
collection of baseline data followed by delivery of treatment (PTNS or sham) and the final study visit
for the collection of outcome data. Participants who recorded zero incontinent episodes on initial bowel
diary were not excluded from the study.
Percutaneous tibial nerve stimulation was delivered via the Urgent® PC device (Uroplasty Limited, Manchester,
UK), a hand-held pulse generator unit, with single-use leads and fine needle electrodes. The needle was
inserted near the tibial nerve on the right leg, adhering to the manufacturer’s protocol (and specialist training).
Treatment was for 30 minutes weekly for 12 treatments. Validated sham stimulation involved insertion of
the urgent PC needle subcutaneously at the same site with electrical stimulation delivered to the distal foot
using transcutaneous electrical nerve stimulation. Participants were blinded to treatment allocation, and all
equipment was hidden from their view. Standard instructions were read to all participants prior to every
treatment, with patient contact limited to questions regarding adverse events, concomitant medications,
loperamide and incontinence pad usage in order to standardise treatment. To maintain treatment quality,
each researcher underwent individual training on how to deliver PTNS and sham treatment, and technique
was assessed at 6-monthly intervals.
Randomisation, with allocation concealment, was undertaken using a bespoke web-based computer
program held at Nottingham Clinical Trials Unit. Following input of participant details, immediate
on-screen randomisation occurred. Allocation was on a 1 : 1 basis, with initial stratification by sex and
then, because the numbers of males was expected to be very small and we wanted to achieve an overall
balance of males in each group, stratification of females only by centre.
Sample size calculation was based on an estimated PTNS treatment response of 55% and a sham response
of 35%. Overall, 212 participants were required for the analysis with 80% power at the 5% significance
level. Statistical analysis, on an intention-to-treat basis, was carried out using Stata version 12.1 (StataCorp
LP, College Station, TX, USA), interfacing with Realcom Impute (2007, Centre for Multilevel Modelling,
University of Bristol, Bristol, UK), which was used to multiply impute missing outcome and baseline covariate
data. Per-protocol analysis, sensitivity analyses and subgroup analyses were subsequently performed.
Results
Eighteen UK centres recruited participants for the trial between 23 January 2012 and 31 October 2013.
In total, 373 participants were screened and, of these, 227 (61%) were randomised. Of these,
115 participants were randomised to receive PTNS and 112 randomised to receive sham electrical
stimulation. The number of participants per site ranged from 1 to 45 (median 10 patients). There were
12 participant withdrawals, seven from the trial and five from treatment.
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Baseline
Ninety per cent of the participants recruited were female and the mean age was 57 years, with a range of
20–85 years. Mean symptom duration was 8 years, with a range of 5 months to 50 years. Demographics
and clinical symptom profiles of the two arms were evenly matched.
Baseline bowel diaries demonstrated a median of 6.0 FIEs per week among PTNS patients, comprising a
median of 3.0 urge FIEs and a median of 2.0 passive episodes. Patients in the sham arm experienced a
median of 6.9 FIEs per week, with a slightly higher rate of passive FI (median 3.0 episodes) than urge
episodes (median 2.5 episodes).
Baseline SMCSs were similar between the arms, with a mean of 14.4 (standard deviation 3.7) in the PTNS
arm and 15.4 (standard deviation 4.1) in the sham arm. All 211 participants who completed the SMCS had
significant FI, on the basis of their score being > 5.
Primary outcome
The percentage of patients achieving a ≥ 50% reduction in weekly FIEs was similar in both arms, at 38%
in the PTNS arm and 31% in the sham arm [odds ratio 1.283, 95% confidence interval (CI) 0.722 to
2.281; p= 0.396].
Secondary outcomes
No significant difference was observed between the PTNS and sham arms in the number of participants
achieving ≥ 25%, ≥ 75% and 100% reduction in weekly FIEs. There was, however, a significantly greater
decrease in total weekly FIEs in the PTNS arm than in the sham arm (difference in means –2.3, 95% CI
–4.2 to –0.3; p= 0.02). This included a reduction in the number of urge FIEs weekly (–1.5, 95% CI –2.7 to
–0.2; p= 0.02) but not in the number of passive FIEs (–0.64, 95% CI –1.67 to 0.40; p= 0.23).
No significant difference in SMCSs was observed between the two arms following treatment (difference in
means –0.047, 95% CI –1.033 to 0.939; p= 0.93). No significant differences were seen in the disease-specific
(Faecal Incontinence Quality of Life Index and Gastrointestinal Quality of Life Index) or generic (Short Form
Questionnaire-36 items) quality-of-life measures between the PTNS and sham arms following treatment.
The improvement in the patient-centred outcomes score was significantly greater in the PTNS arm than in
the sham arm (difference in means –0.545, 95% CI –1.081 to –0.008; p= 0.047). No significant difference
existed in patients’ global impression of success between the PTNS and the sham arms (difference in
means 0.808, 95% CI –0.055 to 1.672; p= 0.068).
There were virtually no differences between the two arms either at baseline or post treatment in respect of
either the European Quality of Life-5 Dimensions index or the visual analogue scale, with scores on both
scales remaining unchanged over time.
Other outcomes
In the PTNS arm, 57 out of 107 (54%) participants thought that they had received PTNS and 48 out of 107
(46%) participants thought that they had received sham treatment. In the sham arm of the trial, 32 out of
103 (31%) participants thought that they had received PTNS and 71 out of 103 (69%) participants thought
that they had received sham treatment. These results are indicative of effective blinding.
Among participants who used loperamide, the majority in both the PTNS arm (33 out of 49; 67%) and the
sham arm (32 out of 38; 84%) reported no change in its use throughout the trial. Equal proportions in
each arm (4% in PTNS vs. 5% in sham) reported increasing loperamide use. The proportion of patients
who were able to reduce their loperamide use was higher in the PTNS arm than in the sham arm (29% vs.
11%); however, this difference was found not to be significant (p= 0.06).
SCIENTIFIC SUMMARY
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Serious adverse events
There were four serious adverse events during the trial; however, none was related to the trial treatment
and all were resolved.
Conclusions
The CONFIDeNT (CONtrol of Faecal Incontinence using Distal NeuromodulaTion) study was an adequately
powered, well-conducted, definitive trial, carried out to a high standard with an absence of any
methodological flaws or serious breaches.
Percutaneous tibial nerve stimulation did not show significant benefit over sham electrical stimulation in the
treatment of FI based on the proportions of patients who reported at least a 50% reduction in weekly FIEs.
However, among patients who received PTNS, mean total weekly FIEs and mean urge weekly FIEs were
significantly reduced, and patient-centered outcomes were significantly improved, compared with patients
who received sham treatment.
Based on the evidence presented it would be hard to justify recommending this therapy for the patient
population in the trial.
In view of the relatively low costs associated with this treatment and its high acceptability, there may be a
justification in continuing to treat a subgroup of patients with troublesome urge FI symptoms in whom
directed therapy may cause symptomatic improvement. Further studies of PTNS should be directed at those
with urge FI to determine the clinical effectiveness.
Trial registration
This trial is registered as ISRCTN88559475.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Faecal incontinence (FI) poses a significant UK public health problem. Its prevalence is difficult to accurately
assess, although the best studies estimate this at 11–15% in the adult population1 and as high as 50% in
care homes.2,3 As prevalence and severity increase with age,4 FI is expected to become a greater problem in
an increasingly aged population. It is known to be an under-reported problem, with many symptomatic
patients suffering in silence.5–8 FI has a significant impact on quality of life, causing social and psychological
disability,9,10 and often leads to people suffering from stigmatisation and social exclusion.5,11,12 The
attendant socioeconomic burden of FI is high not only because of the cost of health-care utilisation, but
also because of job absenteeism.13,14
Management of faecal incontinence
Management of FI is challenging because of a widespread lack of expertise, high prevalence and multiple
aetiologies. Initial management involves a tailored stepwise approach, beginning with more conservative
strategies (diet, toilet training and medications) and moving on to appropriate nurse-led bowel retraining
programmes and psychosocial support. Combinations of these treatments often prove effective;15,16
however, many patients suffer refractory symptoms, for which the National Institute for Health and Care
Excellence recommends moving to more invasive measures.17 Depending on local expertise, surgery – for
example sphincter repair, artificial sphincter, dynamic graciloplasty or a permanent stoma – may be the
only option for these patients. Surgical procedures are invasive and have, at best, variable success rates
with significant risk of morbidity.18–21
Neuromodulation is a relatively new treatment modality for FI which is bridging the gap between
conservative strategies and invasive surgery in centres where expertise exists. It is based on recruitment
of residual anorectal neuromuscular function pertinent to continence by electrical stimulation of the
peripheral nerve supply, without the need for surgery to the anus itself.
Sacral nerve stimulation (SNS) employs direct electrical stimulation to the sacral nerve roots (mainly the S3
nerve root) and is a safe, effective treatment for FI, with short-, medium- and long-term median success
rates reported as 63% (range 33–66%), 58% (range 52–81%) and 54% (range 50–58%) respectively.22–28
SNS has become the first-line surgical treatment option for FI.17 Despite largely favourable data, SNS
requires two operations and is not without risk of morbidity.29 Although it is cost-effective compared with
other surgical options,30 SNS does have high associated costs, recently estimated as £20,484 for the first
10 years of a patient’s treatment,31,32 because of the combination of equipment, hospital admission and
ongoing care.
Tibial nerve stimulation in faecal incontinence
Tibial nerve stimulation is a minimally invasive neuromodulatory modality. The tibial nerve contains afferent
and efferent fibres originating from the fourth and fifth lumbar and first, second and third sacral nerves.
Thus, stimulation of the tibial nerve is thought to lead to similar changes in anorectal neuromuscular
function as observed with SNS (owing to shared sacral root effects) but without the need for a permanent
surgically implanted device. Tibial nerve stimulation (TNS) is an outpatient treatment, which can be
delivered by any trained health-care professional, and is consequently much cheaper than SNS. Initially
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described for urinary incontinence,33 TNS was first used for FI in 2003.34 Since then, there have been
several publications regarding the use of TNS to treat FI. Two main delivery methods are described:
1. Percutaneous tibial nerve stimulation (PTNS) involves electrical stimulation via a needle placed adjacent
to the tibial nerve just above the ankle. This is delivered via the Urgent® PC neuromodulation system
(Uroplasty Limited, Manchester, UK). Treatment is typically delivered as 12 30-minute treatments, given
either weekly for 12 weeks or twice-weekly for 6 weeks.
2. Transcutaneous tibial nerve stimulation (TTNS) involves electrical stimulation which is delivered via
two-pad electrodes placed over the tibial nerve just above the ankle. This is usually delivered via a
transcutaneous electrical nerve stimulation (TENS) machine. Treatment regimens vary considerably,
although administration is usually in 20- to 30-minute sessions over a period of weeks or months.
The main advantage of PTNS over TTNS is the proximity of the needle to the tibial nerve, enabling higher
treatment amplitude to be delivered while avoiding the painful skin sensations associated with
transcutaneous treatment.
Evidence for percutaneous tibial nerve stimulation in
faecal incontinence
Published studies of PTNS include nine case series34–42 (one study34 included a ‘control’ group for
comparison), one small single-centre randomised single-blind trial (PTNS vs. TTNS vs. sham),43 one
comparative case-matched study (PTNS vs. SNS)44 and one prospective clinical audit with a ‘pseudo’
case–control model (PTNS vs. SNS).31 A recent review by the authors summarises the results.45 Five
publications are from the same institution and report results from an accumulating database. Interpretation
and comparison of these studies is hampered by a lack of standardised and universally accepted outcome
measures, observer and patient blinding, performance and interpretation bias and attrition bias.
When considering data from bowel diaries to assess treatment success (the most universally accepted
method in the SNS literature), two studies39,43 reported that 63% and 82% of patients had a ≥ 50%
reduction in the weekly number of faecal incontinence episodes (FIEs) immediately after treatment. Two
studies reported longer-term follow-up, with 59% of patients experiencing treatment success after 1 year39
and 53% at a median of 22 months,42 based on the same outcome measure. When considering FIEs as a
count, six studies1–3,6,8,9 reported this outcome, with a median reduction from five episodes to one per
week immediately following treatment (a statistically significant reduction in three of these studies36,38,42)
and a median reduction from six episodes to one in the two studies that reported this outcome in the
longer term (at 1 year39 and at a median of 29 months42), which led to a statistically significant reduction
in both.
The randomised single-centre study of PTNS versus TTNS versus sham treatment in 30 patients43 reported
that 82% of patients in the PTNS group, 45% of patients in the TTNS group and 13% of those in the
sham group had ≥ 50% reduction in the weekly number of FIEs immediately after treatment. This was
statistically significant across all groups (p= 0.035).
In summary, the observational studies of PTNS showed improvements in most outcome measures (bowel
diary, Cleveland Clinic Incontinence Score and quality-of-life measures) after treatment compared with
baseline. A small three-arm RCT of PTNS versus TTNS versus sham showed effects of both treatments over
sham, with PTNS appearing superior.45
It seems that PTNS may offer a low-cost (estimated at £5916 for the first 10 years based on 6-monthly
‘top-up’ sessions)31 minimally invasive outpatient technique with almost no associated morbidity.46 If this is
true, and PTNS offers similar efficacy to SNS, PTNS may be considered as a genuinely new option in the
pathway between conservative management and the more invasive surgical procedure of SNS.
INTRODUCTION
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Limitations of the current published evidence for percutaneous
tibial nerve stimulation in faecal incontinence
To our knowledge, no double-blind placebo-controlled trial of PTNS in patients with FI has been
performed. Thus, notably, the effect of PTNS in FI, over and above that of meetings with a nurse specialist
alone, remains unknown. This is important because:
1. PTNS is available in several centres in the UK and, although much cheaper than SNS, there is still a cost
associated with its use. Increasing numbers of centres are using it, but many are doing so with
speculation that it is little more than an expensive form of acupuncture.
2. The possible placebo effect of PTNS should not be underestimated:
i. High placebo responses are almost universally observed in trials of therapy for functional47,48 and
organic48,49 colorectal diseases.
ii. Therapeutic responses have been achieved by acupuncture alone in FI,50 noting that the medial ankle
is an established acupuncture site for the viscera (‘sanyinjiao’ or ‘spleen 6’).
iii. Regular meetings with a specialist nurse may confer some benefit even without formal
bowel retraining.51
3. The influence of unblinded observers, especially when interpreting bowel diary data, is also a potential
source of bias.
Study aims
We aimed to assess the clinical effect of PTNS, compared with sham electrical stimulation, in the treatment
of patients with significant FI in whom conservative management strategies have already failed.
We also planned to test the effect of PTNS versus sham electrical stimulation on:
1. improvements in validated incontinence scores
2. patient-centred FI-related symptoms
3. disease-specific and generic quality-of-life measures.
Hypothesis
A 12-week course of PTNS results in a clinical response rate of 55% compared with a sham response rate
of 35%, with clinical response defined as a reduction in the weekly number of FIEs of ≥ 50%.
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Chapter 2 Methods
Overview: study design
The CONFIDeNT (CONtrol of Faecal Incontinence using Distal NeuromodulaTion) study was a UK-based
multicentre, pragmatic, parallel-arm, double-blind, randomised controlled trial comparing PTNS with
sham electrical stimulation, with equal allocation, stratified by sex and centre, in the treatment of FI,
and assessing outcomes following a standard 12-week treatment schedule. The detailed trial protocol is
available to view online (www.nets.nihr.ac.uk). The study method is summarised in a flow diagram
(see Appendix 1). Events occurring at each visit are detailed in Appendix 2. All case report forms used can
be seen in Appendix 3.
Study outcomes
Clinical outcomes
These were assessed at baseline (prior to therapy) and 2 weeks following completion of a 12-week course
of treatment. Clinical outcomes were derived from 2-week bowel diaries and a series of validated,
investigator-administered questionnaires.
Primary
Responder versus non-responder: responder defined as a patient achieving ≥ 50% reduction in total FIEs
per week, as recorded on a 2-week self-completed bowel diary.
Secondary
l Percentage change in FIEs per week (i.e. patients achieving ≥ 25%, ≥ 75% or 100% reduction in
weekly FIEs).
l Change in FIEs per week as a continuous measure.
l Change in symptom severity score: St Mark’s Continence Score (SMCS). A score from 0 (best) to
24 (worst) with > 5 indicating significant symptoms.52
l Change in disease-specific quality-of-life scores:
¢ Gastrointestinal Quality of Life Index (GIQoL):53 a score from 0 (worse) to 180 (best)
¢ Faecal Incontinence Quality of Life Index (FIQoL):54 a score with four domains scored from 1 (worst)
to 4 (best).
l Change in general quality-of-life measures: Short Form Questionnaire-36 items (SF-36).55 A score with
eight domains with scores given as percentages.
l Change in patients’ health status and overall health using European Quality of Life-5 Dimensions
(EQ-5D)56 questionnaire.
l Change in patient-centred outcomes questionnaire. A derivative of the International Consultation on
Incontinence Modular Questionnaire – Bowel57 with a score from 1 (best) to 80 (worst).
l Likert scale of patients’ global impression of success (scale of 0–10).
l Qualitative data:
¢ patient-perceived impression of change in use of incontinence pads and constipating medications
¢ patient-perceived impression of change in urinary symptoms
¢ patient impression of the treatment in general
¢ patient-perceived allocation (PTNS or sham).
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Other outcomes recorded at each visit:
l stimulation parameters
l adverse events and concomitant medications.
In addition to this, patients completed a bowel diary after six treatments and this formed a further
secondary outcome.
Clinical centres
Centres with specialist expertise in FI, including nurse-led (or equivalent) incontinence services, were invited
to participate in the study. Centres had to demonstrate experience with PTNS, having previously completed
a full set of 12 treatments in a minimum of three patients. Each centre also required a minimum of
two staff members to run the trial and ensure satisfactory blinding.
Study population
All adult patients attending the specialist continence or pelvic floor clinics at each of the centres were
considered for participation in the study. This included patients with FI symptoms sufficiently severe to
warrant intervention and in whom appropriate conservative therapies, such as diet, pelvic floor exercises,
biofeedback and loperamide, had failed. Specialist investigations including structural and functional
anorectal assessment were not mandatory, and anal sphincter injury was not a contraindication.
Inclusion criteria
l Faecal incontinence sufficiently severe to warrant intervention (as recommended by the principal
investigator at each site).
l Failure of appropriate conservative therapies.
l Age ≥ 18 years.
Exclusion criteria
l Inability to provide informed consent for the research study.
l Inability to fill in the detailed bowel diaries required for outcome assessments (this will exclude
participants who do not speak/read English).
l Neurological diseases, such as diabetic neuropathy, multiple sclerosis and Parkinson’s disease (including
any participant with painful peripheral neuropathy).
l Anatomical limitations that would prevent successful placement of needle electrode.
l Other medical conditions precluding stimulation, for example bleeding disorders, certain cardiac
pacemakers, peripheral vascular disease or ulcer, lower leg cellulitis.
l Congenital anorectal anomalies or absence of native rectum as a result of surgery.
l A cloacal defect.
l Present evidence of external full-thickness rectal prolapse.
l Previous rectal surgery (rectopexy/resection) done < 12 months prior to the study (24 months
for cancer).
l Stoma in situ.
l Chronic bowel diseases such as inflammatory bowel disease leading to chronic uncontrolled diarrhoea.
l Pregnancy or intention to become pregnant.
l Previous experience of SNS or PTNS.
METHODS
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Following in-depth discussion with the research ethics committee, it was decided that, as some of the
outcome questionnaires had not been validated in languages other than English, we should exclude
people who do not understand written or spoken English from the study.
Data collection
We planned that each patient should attend for 14 visits and the events that occurred at each visit were
as follows.
Visit 1: interest – eligibility
At this appointment, or over the telephone, a local researcher trained in good clinical practice determined
eligibility by interview on the basis of defined inclusion and exclusion criteria listed on case report form
(CRF) 1. The participants’ details were recorded on the screening log, and each participant was allocated a
unique participant identifier number (see below). These data were used to complete the Consolidated
Standard of Reporting Trials (CONSORT) flow chart and to generate reports on non-recruited patients for
discussion at management group meetings.
Eligible subjects were provided with adequate explanation of the aims, methods, expected benefits and risks of
participating in the study and given a patient information sheet containing this information. Participants were
allowed 1 week to consider their participation (in accordance with good clinical practice). Participants who
remained interested were provided with a bowel diary to complete over the next 2 weeks. Each participant
was counselled on how to fill this diary in. Appointments were then booked for visits 2–14, with visit 2 being
at least 2 weeks later to allow time for diary completion.
Unique participant identifier codes
Once a participant was registered on the screening log, he or she was allocated a unique participant
identifier code. This consisted of six characters: three letters followed by three numbers. The letters
denoted the study centre code, and the number was allocated on a consecutive basis, for example 001
for the first participant, and so on.
Visit 2: consent – confirm eligibility – baseline assessment – randomisation –
first intervention
At this appointment, a member of the local team (trained in informed consent) answered any further
questions and then asked the participant to sign the study consent form (also countersigned by the local
researcher). All prospective participants were reminded of the need to be logistically able to complete the
full protocol of 12 sessions at weekly intervals. Once the consent form was signed, the local investigator
confirmed eligibility by recording data on CRF 1. If the participant was a female of childbearing potential,
a urine pregnancy test was performed at this point.
The researcher then recorded all baseline data of FI history, past medical history and medication usage
(using CRF 2 – initial assessment). The participant was asked to fill in the questionnaires (CRF 3) and to
hand in the completed bowel diary, which was checked for completeness. Prior to randomisation the
consent form, eligibility criteria (CRF 1) and initial assessment (CRF 2) were verified by another member of
the research team.
Participants who failed to complete the bowel diary properly were given another 2-week bowel diary to
complete and returned 2 weeks later for the trial to commence. If they failed a second attempt, they
became a screen failure, and were withdrawn. Another participant was recruited in their place.
The researcher performed the randomisation, recorded this information on CRF 4 and (now unblinded)
delivered the first 30-minute intervention (real PTNS or sham). Parameters of stimulation were recorded
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(CRF 5). The participant’s details were entered on the enrolment log, and a general practitioner (GP) letter,
informing the GP of the participant’s involvement in the trial, was sent out.
Visits 3–13: intervention – interim information
At appointments 3–13, an unblinded researcher (who might be the same person as in visit 2) delivered the
30-minute intervention, having checked CRF 4 to confirm randomisation allocation. They enquired about
adverse events, concomitant medication usage and pad usage, and recorded these on CRF 5.
At visit 7, participants were given a 1-week interim bowel diary to complete between visits 7 and 8.
This bowel diary was collected and checked at visit 8.
At visit 13, participants were given a 2-week bowel diary to complete prior to attending visit 14,
2 weeks later.
Visit 14: final study visit
The final study visit was performed by a blinded member of the research team (i.e. somebody who was
not present at visits 2–13). At this appointment, the bowel diary was collected and checked for
completeness. The participant was then asked to complete the questionnaire document (CRF 3) and the
post-treatment questionnaire (CRF 6).
The researcher then ensured that all documents were present and filled in correctly, prior to the principal
investigator completing and signing off CRF 7. The participant was then unblinded as to treatment
allocation and further follow-up was arranged as necessary.
Participants who failed to complete the interim bowel diary between visits 7 and 8 attempted this again
the following week, and this was recorded as a protocol deviation. Participants who failed to complete the
final bowel diary were again asked to complete this after visit 14, and they returned for another final study
visit 2 weeks later. This was also a protocol deviation.
After completion of trial
After visit 14, participants who received ‘sham’ stimulation were offered PTNS on an open-label basis.
Participants who received real PTNS and who derived significant benefit were offered ‘top-up’ sessions as
per local departmental protocols. Participants who received real PTNS but derived no significant benefit
were offered further treatments on an ‘open-label’ basis, following local departmental protocols.
Study procedures: delivery of percutaneous tibial nerve
stimulation or sham
Participants received PTNS or sham using the recommended standard of 12 weekly 30-minute outpatient
stimulations. Appendix 4 details exactly how PTNS and sham electrical stimulation were administered.
Treatments were tailored to participants’ needs but protocol tolerance stipulated a minimum of 10 treatments,
no fewer than 5 days or greater than 10 days apart, to be completed in 13 weeks. Treatments given outside
these windows were classed as a protocol deviation.
Percutaneous tibial nerve stimulation was delivered via the Urgent® PC neuromodulation system, a
reusable external pulse generator that provides visual and auditory feedback. It has an adjustable current
setting from 0 to 9mA in pre-set 0.5-mA increments, a fixed-pulse frequency of 20 Hz and a pulse width
of 200 microseconds.
Transcutaneous electrical nerve stimulation was used for the delivery of sham electrical stimulation (Biostim
M7 TENS unit, Biomedical Life Systems, Vista, CA, USA). The sham treatment was a modification of that
used and validated in the pivotal level I trial of Peters et al.58 in overactive bladder (OAB) syndrome.59
METHODS
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However, this was improved upon by inserting (at the same site) the Urgent® PC needle in all subjects.
In the Peters study, the Urgent PC® needle was used in the PTNS arm, but the sham arm employed an
acupuncture technique using a Streitberger needle, which does not puncture the skin.
Treatments were always given in individual treatment rooms, with participants lying supine on a clinical
couch. They were asked to remove clothing and shoes so as to bare legs from the knees downwards. A
‘gardener’s kneeling stool’ was placed over both legs, just below the knees, and a sheet draped over this
to hide the participant’s feet from their view (Figure 1). Once the participant was comfortable, but prior to
equipment set-up, each researcher read a standardised paragraph to the participant, informing them of
what to expect. This read:
I am now going to start the nerve stimulation treatment. I will be inserting a small electrode needle,
like an acupuncture needle, into your leg and putting sticky electrodes onto your foot. When I turn the
machine on you will be asked when you can first feel an electrical sensation in your ankle or foot. I
will carry on increasing the intensity of this until it is slightly uncomfortable, then I will turn it down a
little if necessary. Occasionally you may also feel numbness or slight movement of your toes. This is
normal. I will set the machine up and leave it running for 30 minutes. You may or may not continue to
feel the stimulation during this time – this is normal also. After 30 minutes have elapsed I will remove
the needle and sticky electrodes (the machine automatically turns off at this time). If the treatment
becomes uncomfortable at any point please let me know and I will turn it down or stop the machine.
All participants then had an Urgent® PC machine and a TENS machine set up on their right foot, unless
there was a reason why the right foot could not be used, under which circumstances the left foot was
used. In the true PTNS arm, the Urgent® PC was used as normal, and the TENS machine left turned off. In
the sham arm, the TENS machine was used to provide the electrical stimulation and the Urgent® PC was
turned on only to provide the auditory stimulus. Following satisfactory treatment commencement, the
sheet was draped fully over the participant’s feet, ensuring that accidental unblinding could not take place.
The researcher then filled in the paperwork for this visit and left the room, returning after 30 minutes to
remove the equipment.
FIGURE 1 Photographs of equipment set-up.
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Treatment arm
After checking equipment, which should have included the Urgent® PC machine, lead wire, alcohol wipe
and electrode needle with tube assembly, the site of needle insertion was identified on the lower inner
aspect of the right leg approximately three finger breadths (5 cm) cephalad to the medial malleolus and
approximately one finger breadth (2 cm) posterior to the tibia. The area was cleaned with ethanol and the
needle electrode–guide tube assembly placed over the identified insertion site at a 60° angle between
electrode and ankle. The 34-gauge needle electrode was gently tapped to pierce the skin and thence
advanced using a rotating motion approximately 2 cm. The lead wire was then connected to the stimulator
and to the ipsilateral calcaneal reference electrode (Figure 2a). The lead wire was then taped to the
participant’s leg so that the PTNS participant experienced the same sensations as the sham participant.
The TENS machine was connected to two electrodes, one placed under the little toe and one on top of the
foot (Figure 2b). The TENS machine was not turned on. The setting for PTNS therapy was determined by
increasing the current slowly while observing the participant’s sensory response (appropriate response
being in great toe or sole of foot) or motor response (plantar flexion of foot or great toe). Current was
then reduced by one level for therapy, and continued for 30 minutes, at which point the electrode
was removed.
(a) (b)
FIGURE 2 Equipment set-up. (a) PTNS needle and calcaneal electrode and (b) TENS surface electrode placements.
METHODS
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Sham arm
The same protocol was followed as for the treatment arm. The only difference was that the needle was
inserted only 2mm into the skin and subcutaneous tissue, that is just in far enough not to fall out and not
deep enough to be close to the tibial nerve. The lead was then taped to the participant’s leg near to, but
not touching, the needle. The purpose of this was to prevent unblinding in the event of the participant
inadvertently seeing the equipment. The PTNS surface electrode (see Figure 2a) on the calcaneus was also
attached. The two active TENS surface electrodes were employed as shown in Figure 2b, with one placed
under the little toe and one on top of the foot. Once all equipment was set up, the practitioner picked
up both the Urgent® PC machine and the TENS machine, one in each hand. Both machines were turned on.
The TENS machine was set to a pulse frequency of 10 Hz and a pulse width of 200 microseconds. Then,
after pressing buttons simultaneously on the Urgent® PC machine and the TENS machine, the practitioner
increased the adjustable current setting (which ranged from 0 to 10mA in pre-set 1-mA increments on the
TENS machine). The setting for therapy was determined in the usual way by observing the participant’s
sensory reactions or their foot for toe/ankle extensor motor responses, and if necessary the current was
reduced by one level for therapy. The reason both machines were used together was so that the audible
sounds produced by the Urgent® PC stimulator were the same in both the PTNS and the sham arms, to
decrease auditory variation between the study arms.
This sham treatment was shown in a departmental pilot to be both more acceptable and more realistic
than that described by Peters et al.,58 which involved the placement of a Streitberger needle. We also
confirmed that this sham, using TENS to deliver the electrical stimulation, does not stimulate the posterior
tibial nerve (proven in a neurophysiological pilot by the consultant neurophysiologist).
Treatment quality control
The importance of quality control and standardisation of technique between individuals and centres was
recognised. In order to keep the quality high, each researcher was taught and certified to give PTNS by a
uroplasty-approved trainer. Each researcher also underwent a personal training session at the site initiation
visit by the trial research fellow (EH) on how to deliver PTNS and sham according to the CONFIDeNT
protocol. Each researcher was then observed delivering both treatments. Six-monthly site visits throughout
the duration of the trial involved assessment of technique. Retraining was undertaken where necessary.
Withdrawal criteria
Participants were withdrawn from the treatment or the trial if they fulfilled any of the criteria below at any
point following delivery of the first treatment.
Withdrawn from treatment only (follow-up data still collected)
l Participant no longer wished to be involved in trial treatments.
l Participant developed a medical condition listed in the exclusion criteria.
l Participant became pregnant or intended to become pregnant.
l Unblinding occurred.
l Participant had an intercurrent illness.
Withdrawn from the trial (no follow-up data collected)
l Participant was lost to follow-up (could not be contacted by telephone or other means).
l Participant no longer wished to be involved in the trial.
l Death.
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Early withdrawal was documented carefully and all participants were followed up in the NHS in the usual
way. In the case of each participant who withdrew, permission was sought to use the data that had
already been collected.
Randomisation
Participants were randomised, with allocation concealment, using a bespoke web-based computer program
held at Nottingham Clinical Trials Unit. Each centre randomised its own participants to receive either PTNS
or sham following baseline data collection and immediately prior to delivery of the first treatment. The
computer program required the researcher to input the unique participant identifier code, sex and date of
birth, and immediate on-screen randomisation occurred. Allocation was on an equal basis with initial
stratification by sex and then stratification of females by centre. Stratification by sex was used to reduce the
potential confounding effects of variation in outcomes between male and female participants. As males
represent only 10% of patients and only one or two male participants were expected from each centre
(owing to differing pathophysiologies60), randomisation stratified on centre would increase the probability
that all the males were allocated to PTNS or sham by chance. To avoid this situation, only females were
stratified by centre, achieving a near balance of PTNS and sham arms and allowing comparability by centre.
Blinding
Blinding of participants
Participants were blinded to allocation, but had knowledge of the 50% chance of receiving sham
treatment. For both PTNS and sham interventions (1) a standardised description of the technique was
read from a card prior to each treatment, which described what the patient should expect – an electrical
sensation variably in the ankle or foot with or without motor responses in the foot (note: there is
significant variability in conscious sensation and motor responses even between participants undergoing
only PTNS); (2) the lower extremity was draped from view, ensuring participants had no knowledge of
equipment set-up; and (3) the audible sounds present during PTNS and sham treatments were identical.
Performance bias considerations
In order to avoid either arm receiving more advice or reassurance, the interaction of the administering
researcher was standardised and limited to a general welcome, addressing any concerns (while recording
adverse events) and answering questions regarding loperamide dosages and incontinence pad use
(both recorded in outcome variables). The standardised description of the technique (as stated above)
was read to the participant, the equipment set up and fully covered and then participant left to receive
the 30-minute treatment.
Blinding of trial staff
At least two researchers were available at each site to run the study, one of whom performed the
randomisation and all treatments, and was necessarily unblinded, while the other remained blinded and
carried out the final data collection. Blinding and unblinding procedures are detailed in Appendix 5.
Sample size calculation
Data published at the time of sample size calculation35,39,46,61 and our own data36 on 50 patients suggested
a 60% success rate for PTNS based on our chosen primary outcome measure. There were no RCT data
for PTNS in FI; however, the pivotal level I SumiT trial of PTNS in OAB symptoms,58 which used a similar
global response assessment of urinary incontinence and intention-to-treat analysis, observed a moderate or
marked improvement in symptoms in 55% in the PTNS arm and only 21% in the sham arm. On the basis
that placebo responses are frequently higher for bowel than for bladder symptoms,47–49 we selected a
METHODS
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sham response rate of 35% while keeping the more conservative estimate of treatment response of
55% (the difference of 20% we believe remains clinically important in relation to other therapies such
as SNS). In total, 212 participants were required to detect this difference with 80% power at the 5%
significance level. We expected to screen 235 participants at baseline to allow for a 10% failure to attend
for randomisation, baseline data collection and first treatment.
Statistical methods
Statistical methods are detailed in the statistical analysis plan (see Appendix 6). This document was drawn
up by the trial statisticians and reviewed by the Trial Steering Committee (TSC) and Data and Safety
Monitoring Committee (DSMC), and received formal sign-off from both committees prior to unblinding
and analysis.
The analysis was carried out using Stata version 12.1 (StataCorp LP, College Station, TX, USA), interfacing
with Realcom Impute (2007, Centre for Multilevel Modelling, University of Bristol, Bristol, UK), which was
used to multiply impute missing outcome and baseline covariate data.62
All patients randomised who received the first treatment were included in the intention-to-treat analysis of
the primary end point. Those in whom post-treatment data were unavailable at 14 weeks for any reason
(loss to follow-up or failure to complete treatment) had their outcome multiply imputed under the
assumption of data missing at random using variables prognostic of outcome, such as measure of outcome
made at baseline, and others predictive of ‘missingness’ (i.e. the reason it is missing) such as mean number
of FIEs per week at baseline, age, sex and, where available, mid-study bowel diary data. The numbers of
variables included in each imputation model were limited by the relatively small number of study centres.
Multilevel multiple imputation was performed using the multivariate normal distribution in Realcom
Impute, using treatment allocation, patient sex and allocation as auxiliary variables. After a burn-in of
1000 runs of the Monte Carlo Markov chain sampler, missing values were filled every 500th run to create
a total of 10 completed data sets for analysis. The data were analysed in Stata and the results pooled by
Rubin’s rules.62
The final analysis was adjusted for variables that were selected prior to data extraction. A decision was
made to fit fixed effects for sex, randomisation and baseline level of outcome and to fit a random effect
for study centre. In order to handle potential clustering effects of patients within centre, the intracluster
correlation coefficients (ICCs) and their 95% confidence intervals (CIs) for the outcomes by centre were
estimated using the user-contributed Stata command sea_obi, which allows the ICC to be negative.63
Random-effects models were fitted by restricted maximum likelihood estimation (e.g. xtmixed. . ., reml).
For outcomes with a negative ICC, linear regression models were fitted (without clustering) using the
regress command.
For binary outcomes, logistic mixed-effects models were used, adjusting for baseline mean number of FIEs
per week and sex and with a random effect for study centre. Estimates from these models are presented
as adjusted odds ratios with 95% CIs. For continuous outcomes, linear mixed-effects models were used,
adjusting for baseline measure of outcome and sex, and with a random effect for study centre. Estimates
from these models are presented as adjusted difference in means.
Per-protocol analysis was carried out for all outcome measures to include those patients who received a
full course of treatment as per the protocol, that is at least 10 treatments in 13 weeks that were no fewer
than 5 and no more than 10 days apart. Sensitivity analyses were performed for all outcome measures,
excluding any patients who had reported no episodes of FI in their 14-day baseline bowel diary,
and excluding those centres that had randomised fewer than five patients.
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Subgroup analyses for the primary outcome, fitting an interaction term between the categorical variable
defining the subgroups and the randomisation variable, were performed, as follows:
l males versus females
l severity of FI (those with ≥ 7 weekly FIEs vs. those with < 7 weekly FIEs)
l age (< 40 years, 40–60 years and > 60 years)
l type of FI (both urge and passive, urge only or passive only).
Ethical arrangements and research governance
This trial was granted ethical approval in June 2010 (Research Ethics Committee reference 10/H0703/25).
The trial was conducted in compliance with the principles of the Declaration of Helsinki (1996),64 and in
accordance with all applicable regulatory requirements including but not limited to the Research
Governance Framework for Health and Social Care,65 trust and research office policies and procedures, and
any subsequent amendments. The trial was compliant with the approved protocol and research ethics
committee conditions of approval, and in line with good clinical practice guidelines.66
Information regarding study participants was kept confidential and managed by each study site in
accordance with the Data Protection Act,67 NHS Caldicott Guardian Agreements,68 The Research
Governance Framework for Health and Social Care65 and research ethics committee approval.
Important changes to protocol after study commencement
Following study commencement, two amendments were made to the protocol, one major and one minor,
but with no change to the study intervention. The following were amended:
l The post-treatment information questionnaire (CRF 6) was amended following recommendation by the
TSC. It suggested that the recording of week-by-week incontinence pad and loperamide usage was
neither satisfactory nor accurate, and that this information would be better captured by questionnaire
at the end. Thus, two extra questions were added to the final questionnaire.
l Cleveland Clinic Incontinence Score was updated to the SMCS. This was used throughout but
misnamed in the original protocol.
l Clarification was added to the protocol to include details of the per-protocol analysis criteria.
l Statistical analysis section was updated:
¢ Multiple imputation method for handling missing outcome data rather than the last value carried
forward method was included on recommendation from the Health Technology Assessment, as this
is the widely accepted standard.
¢ Regression models fitted to estimate treatment effect were changed from fixed centre effects to
random centre effects.69
l Centre eligibility criteria were updated to remove the absolute requirement of a minimum of
five participants recruited, following discussion with the TSC that this was an arbitrary and
unnecessary requirement.
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Trial oversight
The trial was under the auspices of the chief investigator and the pragmatic clinical trials unit at Barts and
The London School of Medicine and Dentistry. The project was overseen by a TSC.
The TSC had an independent chairperson, and met every 6 months throughout to provide overall
supervision and ensure the trial was conducted to the rigorous standards set out in the Medical Research
Council’s guidelines for good clinical practice.66 Specifically, the TSC’s role was to ensure:
1. that the views of users and carers were always taken into consideration
2. the scientific rigour of the study and adherence to protocol
3. that project milestones were met
4. that expertise/advice was provided to the Trial Management Group (TMG).
Membership of the TSC was:
l senior statistician – Sandra Eldridge
l independent chairperson – Professor Christine Norton, Professor of Nursing (King’s College London)
l independent external member – Professor Ronan O’Connell, clinical and research expertise in lower
gastrointestinal neuromodulation (University College Dublin)
l patient and public involvement representative – Deborah Gilbert, chief executive (Bowel & Cancer
Research charity).
The TMG was responsible for day-to-day project delivery in each participating centre. It met monthly and
was answerable to the TSC. The group was responsible for overseeing and managing:
1. trial recruitment and retention rates
2. site initiation, training, monitoring, compliance and correction/preventative actions
3. data management (collection, quality control, entry and query management)
4. adverse and serious adverse event (SAE) reporting
5. study milestones
6. study reporting
7. budget expenditure and accruals.
The TMG comprised:
l chief investigator – Charles Knowles
l academic clinical fellow – Emma Horrocks
l trial manager – Natasha Stevens
l trial statistician – Stephen Bremner.
A DSMC was appointed to monitor unblinded comparative data and make recommendations to the TSC.
The DSMC initially met together with the TSC, and subsequently 2 weeks prior to the TSC to enable any
findings/recommendations to be submitted to the TSC. DMSC meeting timings and conclusions can be
seen in Appendix 7. A DAMOCLES DSMC charter70 was adopted (see Appendix 8), and an independent
pragmatic clinical trials unit statistician provided the DSMC with an unblinded comprehensive report prior
to each meeting.
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The DSMC comprised:
l independent lead – Professor Dion Morton, Professor of Surgery, University of Birmingham
l independent member – Professor Elaine Denny, Professor of Health Sociology, University
of Birmingham
l independent statistician – Dr Daniel Altmann, Senior Lecturer in Medical Statistics, London School of
Hygiene & Tropical Medicine, University of London.
Patient and public involvement
Patient and public involvement was considered at all stages of this trial from conception to dissemination.
This is described in detail in Appendix 9.
METHODS
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Chapter 3 Results
Participant flow
The CONSORT diagram shows the flow of participants through the trial (Figure 3). Non-completing
participants either withdrew from treatment (and remained in the trial) or withdrew from the trial (in which
case no further data were collected from them). Permission was, however, sought to use the data that
had already been collected.
Failed screening (n = 146)
   Withdrew consent, n = 1
   Failed eligibility criteria, n = 46a
   Lost to follow-up, n = 3
   Declined to participate, n = 96
PTNS (n = 115) Sham (n = 112)
Total withdrawals (n = 4)
   Lost to follow-up, n = 1
   Commitment of weekly treatment, n = 1b
   Perceived lack of efficacy, n = 2
Completed six treatments, n = 111
Mid-treatment data collected, n = 111
Completed six treatments, n = 110
Mid-treatment data collected, n = 109
Completed treatment, n = 108
Follow-up data collected, n = 110
Analysed, n = 115
Completed treatment, n = 107
Follow-up data collected, n = 109
Analysed, n = 112
Patients screened (n = 373)
Patients randomised (n = 227)
•
•
•
•
•
•
•
Total withdrawals (n = 2)
   Lost to follow-up, n = 1
   Adverse event, n = 1
•
•
Total withdrawals (n = 3)
   Commitment of weekly treatment, n = 2b
   Adverse event, n = 1
•
•
Total withdrawals (n = 3)
   Lost to follow-up, n = 1
   Commitment of weekly treatments, n = 2b
•
•
Failed eligibility criteria (n = 46)
• No faecal incontinence, n = 13
• Previous sacral nerve stimulation, n = 9
• Neurological disease, n = 8
• Symptoms not severe enough, n = 5
• Unable to speak English, n = 4
• Sphincter repair < 12 months, n = 3
• Conservative management, n = 1
• Heart problem, n = 1
• Unable to complete bowel diary, n = 1
• Ulcerative colitis, n = 1
FIGURE 3 Flow of patients through the study. a, See eligibility criteria box; b, withdrawal from treatment only.
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Trial recruitment
Seventeen of the 18 UK centres recruited participants for the trial between 23 January 2012 and 31 October
2013. The remaining centre was unable to participate because of staff shortages. Trial centres were Barts
Health NHS Trust, London; Aintree University Hospitals NHS Foundation Trust, Liverpool; University Hospital
Southampton NHS Foundation Trust, Southampton; Sandwell and West Birmingham NHS Trust, Birmingham;
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield; The Community Specialist Colorectal Clinic,
Ching Way Medical Centre, London; Leicester General Infirmary, Leicester; Queen’s Medical Centre,
Nottingham; Castle Hill Hospital, Hull; University College Hospital, London; Bristol Royal Infirmary, Bristol;
St Mark’s Hospital, London; Guy’s and St Thomas’ Hospital, London; Poole Hospital NHS Foundation Trust,
Poole; Leeds Royal Infirmary, Leeds; Pilgrim Hospital, Boston, Lincolnshire; and University Hospital of South
Manchester, Wythenshawe. Centre recruitment rate is shown in Figure 4.
In total, 373 participants were screened and, of these, 227 (61%) were randomised. The overall recruitment
rate is shown in Figure 5. The number of participants per site ranged from 1 to 45. There were 12 participant
withdrawals: seven from the trial and five from treatment (see Figure 3).
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FIGURE 4 Recruitment of sites.
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Data quality
Data return was generally very high and quality was very good. Data from bowel diaries were 97.7%
complete. This was probably a consequence of bowel diary training for each patient prior to completing
the diary and the vigilant checking of bowel diaries on return. Questionnaire completion was also very
good (mean 90.4%, range 77.6–100%). For all data, percentages were calculated from the corrected
denominator; however, as data return was so high, individual values for number of patients for each
outcome have not been recorded in the tables. These are available in Appendix 10.
Baseline data
In total, 227 participants were randomised: 115 to receive PTNS and 112 to receive sham
electrical stimulation.
Baseline findings
Ninety per cent of participants were female, with a mean age of 57 years (range 20–85 years). Mean
symptom duration was 8 years (range 5 months to 50 years). Baseline demographics and clinical data are
summarised in Table 1. Previous treatments and relevant past medical history are summarised in Tables 2
and 3 respectively. Complete lists of past medical history and regular medications are presented in
Appendices 11 and 12. Demographics of the two arms were evenly matched for age and sex as per
stratification. Of note, approximately 40% of participants appeared to have concomitant symptoms of FI
and evacuatory difficulties (39% in PTNS arm and 44% in sham arm), and approximately 60% had
concomitant urinary symptoms (61% in PTNS arm and 64% in sham arm).
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FIGURE 5 Participant recruitment.
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TABLE 2 Previous treatments
Treatment PTNS Sham
Antidiarrhoeal medications, n (%) 77 (67) 67 (60)
Biofeedback, n (%) 56 (49) 59 (53)
Pelvic floor exercises, n (%) 37 (32) 36 (32)
Fibre supplementation, n (%) 18 (16) 30 (27)
Laxatives/suppositories/irrigation, n (%) 20 (17) 16 (14)
Anal sphincter repair, n (%) 4 (3) 4 (4)
Other anal surgery, n (%) 11 (10) 8 (7)
Defecatory advice, n (%) 9 (8) 7 (6)
Other, n (%) 5 (4) 8 (7)
TABLE 1 Baseline demographic and clinical data
Outcome PTNS Sham
Sex (female), n (%) 104 (90) 101 (90)
Age (years), median (IQR) 58 (50–67) 58 (48–65)
Duration of symptoms (months), median (IQR) 60 (24–168) 48 (24–108)
Obstetric history,a n (%) 95 (91) 96 (95)
Vaginal deliveries only,a n (%) 90 (95) 96 (100)
C-sections only,a n (%) 5 (5) 0 (0)
Episiotomies or tears,a n (%) 78 (87) 82 (85)
Passive FI, n (%) 88 (77) 86 (77)
Urge FI, n (%) 94 (82) 93 (83)
Flatus incontinence, n (%) 74 (64) 83 (74)
Evacuatory difficulties, n (%) 44 (39) 49 (44)
Straining, n (%) 34 (30) 37 (33)
Digitation, n (%) 12 (10) 15 (13)
Urinary symptoms, n (%) 70 (61) 72 (64)
Urinary urgency, n (%) 50 (43) 49 (44)
Urinary urge incontinence, n (%) 39 (34) 42 (38)
C-section, caesarean section; IQR, interquartile range.
a Females only (% calculated from females only).
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Bowel diary data at baseline
Baseline bowel diaries demonstrated a median of 6.0 FIEs per week in PTNS patients, comprising a median
of 3.0 urge faecal incontinent episodes and a median of 2.0 passive episodes. In the sham arm there was a
median of 6.9 FIEs per week, but with a slightly higher rate of passive FI (median 3.0 episodes) than urge
episodes (median 2.5 episodes) (Table 4).
TABLE 3 Past medical history
Outcome PTNS Sham
Hysterectomy,a n (%) 30 (29) 24 (24)
Vaginal operation,a n (%) 3 (3) 2 (2)
Pelvic operation,a n (%) 19 (18) 16 (16)
Abdominal operation, n (%) 28 (24) 30 (27)
Anal operation, n (%) 6 (5) 9 (8)
Neck or back pain, n (%) 15 (13) 21 (19)
OAB, n (%) 15 (13) 7 (6)
Diverticular disease, n (%) 4 (3) 6 (5)
Irritable bowel syndrome, n (%) 1 (1) 4 (4)
a Females only (% calculated from females only).
TABLE 4 Descriptive statistics of bowel diary data at baseline
Outcome PTNS Sham
FIEs per week
Median (IQR) 6.0 (2.0–14.0) 6.9 (2.5–16.0)
Mean (SD) 9.9 (11.2) 10.4 (10.9)
Urge FIEs per week
Median (IQR) 3.0 (0.9–8.0) 2.5 (0.5–7.0)
Mean (SD) 5.3 (7.2) 4.8 (5.9)
Passive FIEs per week
Median (IQR) 2.0 (0.0–7.5) 3.0 (0.0–8.0)
Mean (SD) 4.6 (6.0) 5.7 (7.6)
IQR, interquartile range; SD, standard deviation.
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Other baseline outcome measures
Baseline SMCSs were similar between the arms, with a mean score of 14.4 (standard deviation 3.7) in the
PTNS arm and of 15.4 (standard deviation 4.1) in the sham arm. All 211 patients who completed their
SMCS had significant FI on the basis of their score being > 5 (Table 5).
TABLE 5 Descriptive statistics of other outcome measures at baseline
Outcome PTNS Sham
SMCSa
Median (IQR) 14.0 (12.0–17.0) 16.0 (13.0–18.0)
Mean (SD) 14.4 (3.7) 15.4 (4.1)
SMCS > 5, n (%) 110 (100) 101 (100)
FIQoL scores
Lifestyleb
Median (IQR) 2.7 (1.8–3.4) 2.5 (1.7–3.6)
Mean (SD) 2.6 (0.9) 2.6 (1.0)
Coping and behaviourb
Median (IQR) 1.7 (1.2–2.3) 1.6 (1.1–2.6)
Mean (SD) 1.9 (0.7) 1.9 (0.9)
Depression and self-perceptionb
Median (IQR) 3.1 (2.0–3.4) 2.6 (2.0–3.7)
Mean (SD) 2.8 (0.9) 2.7 (0.9)
Embarrassmentc
Median (IQR) 2.0 (1.7–2.7) 2.0 (1.3–2.7)
Mean (SD) 2.2 (0.8) 2.1 (0.8)
Patient-centred outcomesd
Median (IQR) 8.9 (7.8–9.8) 9.2 (8.3–10.0)
Mean (SD) 8.5 (1.6) 8.7 (1.7)
GIQoLe
Median (IQR) 130.0 (113.0–141.0) 126.5 (109.0–139.0)
Mean (SD) 126.7 (18.8) 123.8 (20.2)
SF-36 scores (%)
Physical functioning
Median (IQR) 70.0 (45.0–90.0) 65.0 (40.0–85.0)
Mean (SD) 65.7 (27.4) 61.4 (28.4)
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TABLE 5 Descriptive statistics of other outcome measures at baseline (continued )
Outcome PTNS Sham
Role-physical
Median (IQR) 50.0 (0.0–100.0) 25.0 (0.0–75.0)
Mean (SD) 46.4 (42.1) 36.4 (41.4)
Bodily pain
Median (IQR) 60.0 (40.0–90.0) 57.5 (32.5–90.0)
Mean (SD) 61.3 (30.0) 58.2 (31.5)
General health
Median (IQR) 50.0 (35.0–70.0) 50.0 (30.0–70.0)
Mean (SD) 51.2 (23.4) 50.3 (23.8)
Vitality
Median (IQR) 45.0 (30.0–57.5) 50.0 (30.0–60.0)
Mean (SD) 43.9 (22.1) 42.7 (22.8)
Social functioning
Median (IQR) 62.5 (37.5–75.0) 62.5 (37.5–87.5)
Mean (SD) 58.4 (28.8) 59.3 (31.6)
Role-emotional function
Median (IQR) 66.7 (0.0–100.0) 33.3 (0.0–100.0)
Mean (SD) 58.4 (28.8) 59.3 (31.6)
Mental health
Median (IQR) 60.0 (44.0–76.0) 64.0 (48.0–76.0)
Mean (SD) 60.3 (21.0) 60.8 (21.6)
EQ-5D index scoref
Median (IQR) 0.73 (0.62–0.85) 0.73 (0.62–0.85)
Mean (SD) 0.69 (0.27) 0.63 (0.34)
IQR, interquartile range; SD, standard deviation.
a 0 (best) to 24 (worst).
b 1 (best) to 4 (worst).
c 1 (best) to 4.4 (worst).
d 1 (best) to 10 (worst).
e 36 (worst) to 180 (best).
f –0.594 (worst) to 1 (best).
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Primary outcome
The percentage of patients achieving a ≥ 50% reduction in weekly FIEs was similar in both arms at 38%
(39 out of 103) for PTNS and 31% (32 out of 102) for sham treatment (unadjusted odds ratio 1.333;
adjusted odds ratio 1.283, 95% CI 0.722 to 2.281; p= 0.396) (Tables 6 and 7).
TABLE 6 Results of intention-to-treat analysis (n= 227)
Outcome Odds ratio 95% CI p-value
≥ 50% reduction FIEs (primary outcome) 1.283 0.722 to 2.281 0.396
≥ 25% reduction in FIEs 1.264 0.730 to 2.190 0.404
≥ 75% reduction in FIEs 1.615 0.770 to 3.388 0.205
100% reduction in FIEs 1.635 0.592 to 4.514 0.344
Difference in means
Change in FIEs –2.262 –4.185 to –0.339 0.021
Change in urge FIEs –1.456 –2.693 to –0.219 0.021
Change in passive FIEs –0.635 –1.668 to 0.397 0.228
FIQoL embarrassment 0.036 –0.151 to 0.223 0.706
FIQoL coping 0.013 –0.171 to 0.197 0.889
FIQoL lifestyle 0.086 –0.075 to 0.248 0.290
FIQoL depression 0.014 –0.297 to 0.324 0.927
SF-36 physical functioning –1.854 –6.992 to 3.284 0.479
SF-36 role-physical 1.113 –8.866 to 11.092 0.826
SF-36 bodily pain –1.026 –6.815 to 4.764 0.728
SF-36 general health –0.158 –4.749 to 4.433 0.946
SF-36 vitality –3.142 –8.129 to 1.845 0.215
SF-36 social functioning 5.209 –0.740 to 11.157 0.087
SF-36 role emotional –4.815 14.802 to 5.171 0.343
SF-36 mental health –0.509 –4.831 to 3.814 0.817
SMCS –0.047 –1.033 to 0.939 0.925
Patient-centred outcomes –0.545 –1.081 to –0.008 0.047
EQ-5D index score –0.017 –0.078 to 0.044 0.583
GIQoL –1.300 –5.168 to 2.568 0.506
Likert scale of success 0.808 –0.055 to 1.672 0.068
IQR, interquartile range; SD, standard deviation.
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Secondary outcomes
Percentage change in faecal incontinence episodes
No significant difference was observed between the PTNS and sham arms in the number of participants
achieving > 25%, > 75% and 100% reductions in weekly FIEs (see Table 6 and Figure 6).
Change in faecal incontinence episodes as a continuous measure
There was a greater decrease in total number of FIEs per week in the PTNS than the sham arm (difference
in means –2.3, 95% CI –4.2 to –0.3) episodes per week, and this difference was significant (p= 0.02).
This comprised a reduction in urge FIEs (–1.5, 95% CI –2.7 to –0.2; p= 0.02) but not in passive FIEs
(–0.64, 95% CI –1.67 to 0.40; p= 0.23) per week (see Table 6 and Figures 7 and 8). There was very little
continued improvement from mid-treatment to end of treatment (indicating that those who are likely to
respond to treatment will have done this by week 6).
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FIGURE 6 Adjusted odds ratios and 95% CIs of percentage reduction in FIEs: PTNS vs. sham.
TABLE 7 Descriptive statistics for bowel diary outcomes at baseline and end of treatment
Outcome
Baseline End of treatment
PTNS Sham PTNS Sham
FIEs per week
Median (IQR) 6.0 (2.0–14.0) 6.9 (2.5–16.0) 3.5 (1.0–10.0) 4.8 (1.5–12.8)
Mean (SD) 9.9 (11.2) 10.4 (10.9) 6.4 (7.6) 9.1 (10.7)
Urge FIEs per week
Median (IQR) 3.0 (0.9–8.0) 2.5 (0.5–7.0) 1.5 (0.0–4.5) 1.5 (0.5–5.5)
Mean (SD) 5.3 (7.2) 4.8 (5.9) 3.0 (4.2) 4.4 (6.5)
Passive FIEs per week
Median (IQR) 2.0 (0.0–7.5) 3.0 (0.0–8.0) 1.5 (0.0–5.0) 1.5 (0.0–6.5)
Mean (SD) 4.6 (6.0) 5.7 (7.6) 3.4 (4.6) 4.7 (6.6)
IQR, interquartile range; SD, standard deviation.
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Change in symptom severity score: St Mark’s Continence Score
No significant difference in SMCS was observed between the PTNS and sham arms following treatment
(difference in means –0.047, 95% CI –1.033 to 0.939; p= 0.93) (Table 8 and see Table 6).
Change in quality-of-life measures
No significant differences were seen in the disease-specific (FIQoL and GIQoL) or generic (SF-36)
quality-of-life measures between the PTNS and sham arms following treatment (Table 9 and Figures 9
and 10; see also Table 6).
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FIGURE 7 Adjusted difference in mean (95% CI) number of FIEs per week: PTNS vs. sham.
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TABLE 9 Descriptive statistics for quality-of-life outcomes at baseline and end of treatment
Outcome
Baseline End of treatment
PTNS Sham PTNS Sham
FIQoL scores
Lifestylea
Median (IQR) 2.7 (1.8–3.4) 2.5 (1.7–3.6) 3.0 (2.2–3.7) 2.9 (1.9–3.7)
Mean (SD) 2.6 (0.9) 2.6 (1.0) 2.8 (0.9) 2.8 (1.0)
Coping and behavioura
Median (IQR) 1.7 (1.2–2.3) 1.6 (1.1–2.6) 1.9 (1.3–2.6) 1.7 (1.2–2.9)
Mean (SD) 1.9 (0.7) 1.9 (0.9) 2.0 (0.8) 2.0 (1.0)
Depression and self-perceptiona
Median (IQR) 3.1 (2.0–3.4) 2.6 (2.0–3.7) 3.1 (2.2–3.7) 2.6 (2.0–3.9)
Mean (SD) 2.8 (0.9) 2.7 (0.9) 2.9 (1.0) 2.8 (1.0)
Embarrassmentb
Median (IQR) 2.0 (1.7–2.7) 2.0 (1.3–2.7) 2.7 (1.7–3.0) 2.3 (1.7–3.0)
Mean (SD) 2.2 (0.8) 2.1 (0.8) 2.4 (0.8) 2.3 (0.9)
GIQoL scoresc
Median (IQR) 130.0 (113.0–141.0) 126.5 (109.0–139.0) 135.0 (115.0–148.0) 134.0 (120.0–146.0)
Mean (SD) 126.7 (18.8) 123.8 (20.2) 132.0 (20.6) 131.6 (20.5)
SF-36 scores (%)
Physical functioning
Median (IQR) 70.0 (45.0–90.0) 65.0 (40.0–85.0) 75.0 (47.5–90.0) 70.0 (45.0–90.0)
Mean (SD) 65.7 (27.4) 61.4 (28.4) 67.1 (27.7) 63.8 (29.0)
continued
TABLE 8 Descriptive statistics for SMCS at end of treatment
Outcome
Baseline End of treatment
PTNS Sham PTNS Sham
SMCS
Median (IQR) 14.0 (12.0–17.0) 16.0 (13.0–18.0) 14.0 (11.0–17.0) 15.0 (11.0–18.0)
Mean (SD) 14.4 (3.7) 15.4 (4.1) 13.9 (4.3) 14.6 (4.6)
SMCS > 5
n (%) 110 (100) 101 (100) 104 (100) 101 (100)
IQR, interquartile range; SD, standard deviation.
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TABLE 9 Descriptive statistics for quality-of-life outcomes at baseline and end of treatment (continued )
Outcome
Baseline End of treatment
PTNS Sham PTNS Sham
Role-physical
Median (IQR) 50.0 (0.0–100.0) 25.0 (0.0–75.0) 62.5 (0.0–100.0) 25.0 (0.0–100.0)
Mean (SD) 46.4 (42.1) 36.4 (41.4) 54.4 (44.1) 46.2 (44.8)
Bodily pain
Median (IQR) 60.0 (40.0–90.0) 57.5 (32.5–90.0) 67.5 (45.0–90.0) 67.5 (35.0–90.0)
Mean (SD) 61.3 (30.0) 58.2 (31.5) 64.3 (28.3) 62.1 (31.0)
General health
Median (IQR) 50.0 (35.0–70.0) 50.0 (30.0–70.0) 55.0 (30.0–75.0) 50.0 (35.0–70.0)
Mean (SD) 51.2 (23.4) 50.3 (23.8) 52.8 (24.6) 50.6 (23.9)
Vitality
Median (IQR) 45.0 (30.0–57.5) 50.0 (30.0–60.0) 50.0 (25.0–60.0) 50.0 (35.0–65.0)
Mean (SD) 43.9 (22.1) 42.7 (22.8) 45.6 (22.2) 46.7 (23.1)
Social functioning
Median (IQR) 62.5 (37.5–75.0) 62.5 (37.5–87.5) 75.0 (50.0–87.5) 62.5 (37.5–87.5)
Mean (SD) 58.4 (28.8) 59.3 (31.6) 66.4 (28.6) 60.6 (31.7)
Role-emotional function
Median (IQR) 66.7 (0.0–100.0) 33.3 (0.0–100.0) 100.0 (0.0–100.0) 83.3 (0.0–100.0)
Mean (SD) 58.4 (28.8) 59.3 (31.6) 61.7 (45.3) 60.2 (44.1)
Mental health
Median (IQR) 60.0 (44.0–76.0) 64.0 (48.0–76.0) 64.0 (48.0–84.0) 64.0 (52.0–76.0)
Mean (SD) 60.3 (21.0) 60.8 (21.6) 62.7 (25.1) 63.0 (21.4)
IQR, interquartile range; SD, standard deviation.
a 1 (best) to 4 (worst).
b 1 (best) to 4.4 (worst).
c 36 (worst) to 180 (best).
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FIGURE 9 Adjusted difference in means (95% CI) for FIQoL: PTNS vs. sham.
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Change in patient-centred outcomes score
Improvement in patient-centred outcomes (i.e. a reduction in score) was significantly greater in the PTNS
arm than in the sham arm (difference in means –0.545, 95% CI –1.081 to –0.008; p= 0.047) (Table 10;
see also Table 6).
Likert scale of patients’ global impression of success (scale 0–10)
No significant difference existed in patients’ global impression of success between the PTNS and sham
arms (difference in means 0.808, 95% CI –0.055 to 1.672; p= 0.068) (Table 11; see also Table 6).
European Quality of Life-5 Dimensions analysis
There were virtually no differences between the two arms either at baseline or after treatment in respect
of EQ-5D index and visual analogue scale (VAS) scores, with scores on both scales remaining unchanged
over time (Table 12 and see Table 6). The full report can be viewed in Appendix 13.
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FIGURE 10 Adjusted difference in means (95% CI) for SF-36: PTNS vs. sham.
TABLE 11 Descriptive statistics for Likert scale of success outcome at end of treatment
Outcome PTNS Sham
Median (IQR) 4.8 (0.0–6.8) 2.1 (0.0–4.9)
Mean (SD) 4.0 (3.3) 3.2 (3.1)
IQR, interquartile range; SD, standard deviation.
TABLE 10 Descriptive statistics for patient-centred outcomes at end of treatment
Outcome
Baseline End of treatment
PTNS Sham PTNS Sham
Median (IQR) 8.9 (7.8–9.8) 9.2 (8.3–10.0) 8.4 (6.9–9.4) 9.3 (7.6–10.0)
Mean (SD) 8.5 (1.6) 8.7 (1.7) 7.8 (2.0) 8.4 (2.1)
IQR, interquartile range; SD, standard deviation.
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Other outcomes
In the PTNS arm, 57 out of 107 (54%) participants thought that they had received PTNS and 48 out of
107 (46%) thought that they had received sham treatment (Figure 11). In the sham arm, 32 out of
103 (31%) participants thought that they had received PTNS and 71 out of 103 (69%) participants
thought that they had received sham treatment. Overall, 208 patients answered this question, of
whom 62% perceived correctly and 38% perceived incorrectly.
Only 13% (8 out of 61) of patients in the PTNS arm experienced slight or substantial improvement in
urinary symptoms and the figure in the sham arm was similar, at 11% (7 out of 64). Most symptomatic
patients reported no effect: 39% in the PTNS arm and 50% in the sham arm. Indeed, more patients in the
PTNS arm than in the sham arm reported a worsening of urinary symptoms (10% vs. 5%) (Figure 12).
Of participants who used loperamide at baseline, the majority in both the PTNS (33 out of 49= 67%) and
sham (32 out of 38= 84%) arms reported no change in use throughout the trial. Similar percentages in
each arm (4% in PTNS vs. 5% in sham) reported increasing loperamide use. A higher percentage of
patients in the PTNS arm than in the sham arm reduced their loperamide use (29% vs. 11%) (Figure 13).
Other potentially relevant concomitant medication usage can be seen in Appendix 14. There has been
minimal concomitant medication usage and this has not been considered significant.
Of the participants who used incontinence pads, the majority [56% (44 out of 79) in PTNS arm and 49%
(35 out of 72) in sham arm] reported no change in use over the period of the trial. Similar percentages of
participants reduced their pad usage through the course of the trial (15% in the PTNS arm and 14% in the
sham arm), while 4% participants in the sham arm had to increase their pad usage compared with none in
the PTNS arm (Figure 14).
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FIGURE 11 Participants’ perception of treatment.
TABLE 12 Descriptive statistics for EQ-5D outcome at end of treatment
Outcome
Baseline End of treatment
PTNS Sham PTNS Sham
EQ-5D index, mean (SD) 0.69 (0.27) 0.63 (0.34) 0.68 (0.28) 0.65 (0.34)
EQ-5D VAS, mean (SD) 64.50 (21.72) 64.04 (21.24) 64.25 (22.32) 63.69 (23.66)
SD, standard deviation.
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FIGURE 14 Effect of treatment on incontinence pad usage.
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FIGURE 13 Effect of treatment on loperamide use.
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Per-protocol analysis
Per-protocol analysis was carried out subsequent to the intention-to-treat analysis. To be included in these
analyses, patients were required to have at least 10 treatments within 13 weeks, with 10 treatments no
fewer than 5 days and no more than 10 days apart. This was to ensure that patients attended for
treatments regularly and in a time frame spread evenly throughout the treatment duration.
In total, 197 of the 227 patients completed the treatment per protocol. Table 13 presents the results of
the analysis of the primary outcome. The conclusion from this analysis remains unchanged and other
important outcomes remain unchanged apart from the Likert scale of success, which shows that those in
the PTNS arm were more likely than those in the sham arm to perceive that the treatment was successful;
this difference was statistically significant.
TABLE 13 Results of per-protocol analysis (n= 197)
Outcome Odds ratio 95% CI p-value
≥ 50% reduction FIEs (primary outcome) 1.269 0.688 to 2.341 0.446
≥ 25% reduction in FIEs 1.247 0.698 to 2.228 0.456
≥ 75% reduction in FIEs 1.631 0.781 to 3.409 0.194
100% reduction in FIEs 1.658 0.590 to 4.655 0.338
Difference in means
Change in FIEs –2.233 –4.275 to –0.191 0.032
Change in urge FIEs –1.486 –2.778 to –0.194 0.024
Change in passive FIEs –0.600 –1.663 to 0.463 0.268
SMCS 0.202 –0.855 to 1.258 0.708
GIQoL –1.750 –5.864 to 2.364 0.401
FIQoL embarrassment 0.059 –0.141 to 0.260 0.563
FIQoL coping –0.007 –0.211 to 0.196 0.944
FIQoL lifestyle 0.093 –0.079 to 0.266 0.286
FIQoL depression 0.030 –0.302 to 0.361 0.853
SF-36 physical functioning –0.601 –5.964 to 4.761 0.826
SF-36 role-physical 1.562 –9.062 to 12.186 0.772
SF-36 bodily pain –2.933 –8.975 to 3.108 0.341
SF-36 general health 0.612 –3.989 to 5.213 0.794
SF-36 vitality –2.872 –7.967 to 2.224 0.268
SF-36 social functioning 5.665 –0.518 to 11.848 0.074
SF-36 role emotional –6.562 –16.988 to 3.863 0.216
SF-36 mental health –0.300 –4.633 to 4.033 0.892
Patient-centred outcomes –0.593 –1.141 to –0.044 0.034
EQ-5D index score –0.020 –0.082 to 0.042 0.524
Likert scale of success 0.934 0.037 to 1.831 0.042
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Subgroup analyses
Preplanned subgroup analyses were performed for the primary outcome only. The following subgroups
were selected:
l sex (male vs. female)
l FI severity (> 7 episodes per week vs. < 7 episodes per week on initial bowel diary)
l age (< 40 years, 40–60 years, > 60 years)
l both urge and passive incontinence, only urge, only passive.
The primary outcome was negative for each of these subgroup analyses (see Appendix 15).
Sensitivity analysis
Sensitivity analysis was carried out, removing the patients who scored ‘zero’ on their initial bowel diaries
(see Appendix 16). This excluded 16 patients, nine from the PTNS arm and seven from the sham arm.
The primary outcome was negative for this analysis (odds ratio 1.325, 95% CI 0.736 to 2.385; p= 0.348).
Further sensitivity analysis was carried out excluding patients who were recruited from poorly recruiting
centres (defined as centres recruiting fewer than five patients) (see Appendix 17). This excluded
four patients from two centres, two from each arm. The primary outcome was negative for this analysis
(odds ratio 1.234, 95% CI 0.693 to 2.196; p= 0.476).
Centre effect
Data were analysed to allow for a centre effect, that is, outcomes among patients being treated by the
same study centre may be correlated, indicating that treatment at some centres may be more effective.
The ICC was very small (< 0.001 for most outcomes), indicating no significant centre effect. The only
outcomes for which the ICC was substantial were ≥ 75% reduction (ICC= 0.222) in FIEs, 100% reduction
in FIEs (ICC= 0.012), change in passive FIEs (ICC= 0.106), FIQoL coping (ICC= 0.104), SF-36 social
functioning (ICC= 0.012), SF-36 mental health (ICC= 0.038), EQ-5D (ICC= 0.019) and the Likert scale of
success (ICC= 0.02).
Serious adverse events
There were four SAEs during the trial (Table 14). None was related to the trial treatment and all
were resolved.
Adverse events
A total of 204 adverse events were noted in the trial, 107 in the PTNS arm and 97 in the sham arm.
Table 15 reports severity by relatedness in each arm. There were seven mild related adverse events in
each arm.
Related and possibly related adverse events can be seen in Table 16. A full list of all adverse events can be
seen in Appendix 18.
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TABLE 14 Serious adverse events
SAE Allocation Grade
Duration
(days) Action Relatedness Outcome
Flexible cystoscopy for botulinum toxin
type A (Botox®, Allergan)
PTNS Moderate 3 H U R
Sleeve gastrectomy Sham Severe 1 H U R
Pilonidal abscess Sham Moderate 26 H U R
Shoulder manipulation PTNS Severe 1 H U R
H, hospitalisation; R, resolved; U, unrelated.
TABLE 15 Adverse events: severity by relatedness
Outcome
PTNS Sham
Related Possibly related Unrelated Total Related Possibly related Unrelated Total
Mild 7 25 40 72 7 18 33 58
Moderate 0 13 17 30 0 14 21 35
Severe 0 4 1 5 0 1 3 4
TABLE 16 Related and possibly related adverse events
Outcome Adverse event PTNS Sham
Related Pain at needle site 4 3
Bruising at needle site 2 1
Altered sensation at needle site 1 0
Bleeding at needle site 0 2
Altered sensation in toe 0 1
Possibly related Pain in abdomen 4 2
Pain in back 1 0
Pain in leg or foot 13 10
Pain in perineum 0 1
Altered sensation in leg or foot 4 0
Altered sensation in perineum 0 1
Weakness in leg 0 1
Constipation 0 1
Diarrhoea 8 3
FI 0 1
Urinary symptoms 0 4
Headache/migraine 6 7
Dizziness 5 0
Nausea/vomiting 0 1
Anxiety/depression 1 1
Skin disorder 1 0
RESULTS
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Chapter 4 Discussion
A lthough PTNS and sham electrical stimulation offer some improvement in FI symptoms by reducingweekly episodes, no clinically significant benefit of PTNS over sham was demonstrated. This was
demonstrated by the primary outcome, with 38% of participants in the PTNS arm and 31% in the sham
arm achieving at least a 50% reduction in FIEs.
Some of the secondary outcome variables, namely reduction in mean total weekly FIEs, reduction in
mean urge FIEs and improvement on the patient-centred outcomes form (a derivative of the validated
International Consultation on Incontinence Modular Questionnaire – Bowel), demonstrated a significant
benefit of PTNS over sham treatment. However, the margin of clinical benefit must be considered small
even though statistical significance was achieved, as this improvement was based on a reduction in weekly
FIEs from a median of 6.0 (IQR 2.0–14.0) to a median of 3.5 (IQR 1.0–10.0), meaning that many
participants still have significant FI. It is interesting to note that, if a treatment effect was going to occur,
it would have done so by six treatments.
There was no significant improvement in the SMCS in the PTNS arm compared with the sham arm.
Patients in the PTNS arm of the trial showed no significant improvement in any of the quality-of-life
measures, compared with patients in the sham arm.
The results of this study may seem surprising when considered in the context of other published studies of
PTNS from FI. The 12 published studies on PTNS, including 10 case series, one small randomised study
and one comparative case-matched study of PTNS and SNS, allude to a 63–82% response rate using the
same primary outcome, which is considerably higher than the 38% reported here. The results of this study
are, however, closer to a recently conducted randomised study of PTNS compared with SNS, which found
that 40% of patients in the PTNS arm reported treatment success at 3 months, again significantly lower
than any other previously reported data.71 Interestingly, a double-blind placebo-controlled randomised
controlled trial of TTNS for FI in the literature shows no discernible benefit of TTNS over sham treatment in
the treatment of FI.72
These findings highlight the necessity of conducting well-designed randomised controlled trials to answer
clinical questions. The other previously published non-randomised studies are prone to significant bias,
which may account for the difference in results.
Case series provide poor evidence and are open to significant bias. First and foremost, there is no control
arm for comparison, leading to performance bias. There is no way of unpicking the effect of natural
change in disease status over time or the well-recognised placebo effect of this nurse-led face-to-face
intervention. Both of these issues can be ameliorated only by including a control arm. Selection bias in case
series is a large problem unless subjects are truly selected consecutively. In addition to this, case series are
often subject to attrition bias, as patients may be lost to follow-up or researchers may selectively report
only subjects with positive findings. In case series, both the patient and the observer are often unblinded.
This can introduce bias from both perspectives: patients may experience a high level of expectation, which
may influence reporting; and, in addition to this, bias may be introduced from the observers’ perspective,
as clinicians often have a vested interest in treatment and publication. This problem is particularly
important in trials of FI that involve bowel diary data, as diaries are notoriously poorly completed and open
to interpretation.73
The only other RCTs of PTNS in the literature are those on OAB. Of these studies, two double-blinded RCTs
that compare PTNS with sham electrical stimulation showed a statistically significant improvement in urinary
frequency and urge urinary incontinence in the active PTNS arm compared with the sham arm (71% vs. 0%
responders in the smaller study; p< 0.001;74 and 54.5% vs. 24.9% in the larger pivotal trial;58 p< 0.001).
One had a significantly smaller sample size than the other (n= 35 and n= 174 respectively).
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Both of these studies reported a higher treatment effect of PTNS than seen in the CONFIDeNT trial, and
one that is significantly beneficial compared with sham. There could be a number of reasons for this. It
could simply be a result of PTNS having efficacy in OAB but not FI. Alternatively, it could be a result of
these studies selecting purely patients who had OAB, that is patients who experience bladder urgency
(more akin to faecal urgency or urge FI), which may account for the CONFIDeNT trial showing no overall
benefit in patients, but significant reductions in urge FIEs.
The disparity could also be a factor of primary outcome measure selection. Peters et al.58 used a subjective
primary end point involving number of patients who graded their overall bladder symptoms as moderately
or markedly improved on a global response assessment. It is unclear whether or not this assessment tool
has been validated. The smaller study chose an objective primary end point, equivalent to that used in
the CONFIDeNT trial, of those patients who experienced a > 50% reduction in number of urge urinary
incontinence episodes.
Both urological studies also reported a significantly lower treatment effect of the sham, or placebo. The
placebo effect in trials of functional bowel disease is well acknowledged to be high; indeed, meta-analyses
of 45 published trials estimate the placebo response rate in functional dyspepsia to be between 6% and
72%75,76 and in 50 placebo-controlled irritable bowel syndrome trials it is estimated to be between 3%
and 84%.77–79 This may indicate that the 0% placebo effect in the Finazzi-Agro et al.74 trial is a product of
a small sample size, inadequate blinding or both. The apparently lower sham response in both studies may
be a result of a less effective sham.
The sham stimulation used was different in both urological studies and also different from that used in the
CONFIDeNT trial. In one study, the needle was placed in the medial head of gastrocnemius muscle and
electrical stimulation activated for only 30 seconds prior to the stimulator being turned off;74 in the other
study, a Streitberger needle was used, which does not pierce the skin, and electrical stimulation was
delivered via TENS. The sham chosen in the CONFIDeNT trial was designed to give a very similar feeling to
that produced by the active treatment, by giving the sensation of the skin being pierced by the needle and
by providing a constant electrical sensation.
The sham treatment in the CONFIDeNT trial was well conducted and blinding was maintained in each
treatment session with no information revealed to patients. The trial team feel that this was an
improvement on the sham used in the Peters et al.58 study of OAB, as the sham treatment was carried out
using the same needle as in the PTNS arm, and it did pierce the skin to give the same sensation as the
PTNS arm, the only difference being that the needle was not advanced as far. The sham was shown not to
stimulate the tibial nerve during neurophysiological testing.
Limitations
This study was generally conducted to a high standard and there were no major methodological flaws or
protocol violations. The effect of sham stimulation was correctly predicted at 35%. It would have been
difficult to predict such a marginal treatment effect based on the previous literature; however, the effect of
treatment was still less than our conservative estimate of 55%. The data do not indicate that the sample
size was inadequate, as the 95% CI of the primary outcome analysis precludes a clinically significant
reduction in the odds of success.
The study did, however, have some limitations. As is the nature of FI, there was significant heterogeneity in
the population of patients selected to take part in the trial. This may have affected the results, especially
given that there may have been a treatment effect among those suffering with urge FI (akin to OAB).
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Patients suffering with frequent loose stools, or those with significant constipation, may indicate different
disease pathophysiologies, thus complicating the results with regard to efficacy of PTNS. As seen from the
demographics, approximately 40% of patients in this study suffer with concomitant rectal evacuatory
problems. Similarly, it could be argued that, based on the paper by Hoturas et al.,80 which suggested that
those with urge FI benefit more from PTNS, which would go along with a similar concept that PTNS works
for OAB, the CONFIDeNT trial could have selected patients with pure urge FI. These stipulations would
have added further complexity to the trial, requiring all patients to undergo anorectal physiology testing,
and would have adversely affected recruitment by significantly reducing the number of patients eligible for
the trial. Moreover, this was a pragmatic trial testing a treatment aimed as a first-line treatment for FI, for
example in GP surgeries or nursing homes, where such patient selection would not be feasible or possible,
and results are required to be generalisable.
Another limitation of this study, and one that widely affects studies of FI, is that there is no perfect or
universally accepted outcome measure.73 Weekly FIEs, as a count, has an overdispersed Poisson
distribution, that is greater variability than expected. Therefore, attempting to define a clinically significant
mean reduction in FIE per week in a population of patients with widely dispersed starting FI frequencies is
very difficult. This study, along with many in the SNS literature, chose to counter this problem by adopting
a categorical measure of percentage reductions, that is the proportion of patients who have a ≥ 50%
reduction in FIE per week, which is likely to be a much more realistic indication of success. Although
subject to criticism, this was chosen as the primary outcome for the study not least because it has most
often been used to assess SNS, thus allowing comparisons to be drawn between the two treatment
modalities. Further, the 50% criterion has been applied as the primary end point in both of the pivotal
trials of contemporary treatments in FI,27,81 with these treatments subsequently reviewed favourably by the
US Food and Drug Administration. It could be argued that a 50% reduction in FIEs is not life-changing
because this may still signify significant FI; however, until another outcome measure is introduced into the
literature this is the most widely accepted outcome for treatment comparison. It is also important to
remember that bowel diary data were collected for only a 2-week period at the beginning and end of
treatment, and a score of ‘zero’ on a bowel diary does not necessarily signify that a patient’s incontinence
is cured (a point ignored in previous literature, in which terms such as ‘complete continence’ are used to
denote this eventuality).
Consideration has been given to the fact that, because the use of regular medications was not prohibited,
a change in antidiarrhoeal medication (e.g. loperamide) may have reduced the effect size of PTNS. The
decision was made not to limit the use of such medications, as it is likely that people would have
continued to use the medications anyway. Instead, the decision was made to record patients’ loperamide
use throughout the trial. Patients were asked each week about loperamide use; however, following the
first meeting of the TSC and DSMC, it was felt that this was not accurately recalled by patients and a
decision was made that the best way to collect this information would be to ask at the end of the trial
whether their usage had remained the same, increased or decreased. As this decision was made partway
into the trial, this information was not collected from all patients. We did, however, feel that it important
to attempt to quantify this because it is a potential confounder. The question on loperamide usage was
answered by 144 out of 227 patients (64%), and this was in the main because 55 patients completed the
trial prior to implementation of the new CRF. Those who did answer the question were evenly balanced
between treatment arms. As can be seen from the results, of those who were taking loperamide, almost
three times as many patients in the PTNS arm reduced this as in the sham arm. Simple chi-squared testing,
however, found this difference to be non-significant (p= 0.06). This calculation should be interpreted with
caution, as the numbers using loperamide at baseline were comparatively small and, because they are not
the full randomised samples, may differ systematically (i.e. there may be confounding).
Another criticism of this study could be that patients were not excluded on the basis of having ‘zero’ FIEs
reported on their baseline bowel diary, so long as the principal investigator was convinced that the
participant had FI significant enough to warrant intervention. This decision was taken because FI is often a
problem which happens in bouts and it is not impossible for a patient to experience two symptom-free
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weeks by chance. The alternatives would have been either to exclude these patients, which might have
seemed unfair given that they do have significant FI and should be entitled to try this treatment, or to give
the patients another chance to complete the bowel diary. It was felt that these patients might well then
fabricate the bowel diary if zero FIEs were to occur again, thus potentially confounding the results.
Sensitivity analysis was done removing the 16 patients to whom this applied, who happened to be spread
evenly across the two arms, and this made no difference to the overall results.
A further limitation of this study is the short follow-up period, as outcomes were assessed 2 weeks after
the end of treatment. Many trials of this nature assess outcomes at 6 months; however, there are moves
to extend this to 12 months following treatment [as per ROME IV (Rome Diagnostic Criteria for Functional
Gastrointestinal Disorders); Professor Charles Knowles, unpublished data].
Finally, this trial could be criticised for lack of formal health economic analysis. This was not performed because
of the lack of clinical effectiveness, and failure to demonstrate any changes in the EQ-5D questionnaire. The
authors acknowledge that since then a potentially more sensitive five-level questionnaire has been developed,
which might have yielded a different result.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
Chapter 5 Conclusions
The CONFIDeNT study was a well-conducted, definitive trial, carried out to a high standard with anabsence of any methodological flaws or serious breaches.
Percutaneous tibial nerve stimulation did not show significant clinical benefit over sham electrical
stimulation in the treatment of FI based on the proportions of patients who reported at least a 50%
reduction in weekly FIE. There was, however, a significant improvement in those patients who had PTNS in
mean reduction in total weekly FIE, urge weekly FIE and patient-centred outcomes compared with those
who had sham treatment.
Based on the evidence presented, it would be hard to justify recommending this therapy for the patient
population in the trial.
In view of the relatively low costs associated with this treatment and its high acceptability, there may be a
justification in continuing to treat a subgroup of patients with troublesome urge FI symptoms in whom
directed therapy may cause symptomatic improvement. Further studies of PTNS should be directed at those
with urge FI to determine whether or not this approach has value. Long-term follow-up of participants in
the CONFIDeNT study will also be useful to further gauge response to treatment.
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Appendix 1 Flow diagram of study
Identify patients from clinic or referrals with FI who have failed conservative management and who are suitable
for PTNS
Fill in screening log and allocate unique identifier number
Contact patients by telephone 1 week later
(or see in clinic if initial visit over telephone)
to follow up interest
If interested, send out or give 2-week
bowel diary and counsel on how to fill
in. Book visit 2 appointment at least 
2 weeks later and arrange visits 3–14
If not interested, fill in screening log as to why not
Cease involvement in trial and resume NHS
treatment
If patients meet inclusion/exclusion
criteria and are interested in trial, give
or send out written information 
If patients do not meet inclusion/exclusion criteria or
are not interested, fill in screening log as to why
Cease involvement in trial and resume NHS treatment
Visit 2:
Answer any outstanding questions
Consent and collect and check bowel diary
Fill in CRF 1 (eligibility criteria) ± pregnancy test
If no longer eligible, fill in screen failure CRF
CRF 2 (initial assessment)
Ask participant to fill in CRF 3 (questionnaires)
Independent trial member to check consent, CRF 1
and CRF 2 prior to randomisation
Randomise and write allocation on CRF 4
Give first treatment or sham
Fill in CRF 5 (stimulation parameters, etc.)
Add participant to enrolment log and send GP letter 
Visits 3–13:
Ask about adverse events, pad usage and
medication usage – record on CRF 5
Give intervention
At visit 7: give participant 1-week bowel diary
At visit 13: give participant 2-week bowel
diary and CRF 3 to fill in before next visit
If adverse event occurs, fill in adverse
event log. Follow adverse event standard
operating procedure in trial file. 
If in doubt, contact lead centre
If participant misses a session, catch
this up: as long as 12 sessions happen
in 13 weeks at intervals of no fewer than
5 and no more than 10 days apart (if
this does not occur, a protocol deviation
has happened and note to file CRF
should be completed) 
If a participant wants to stop being part
of the trial, fill in ‘early withdrawal
form’
Cease involvement in trial and
resume NHS treatment
Visit 14: (conducted by a blinded researcher)
Collect and check bowel diary and CRF 3
Fill in CRF 6 (post-treatment information)
Fill in CRF 7 (final study visit CRF)
Participant can be unblinded at this point if
participant requests
Arrange follow-up visit on NHS as usual to
plan further interventions as necessary
Cease involvement in trial and resume NHS
treatment
If participant has changed medication
usage, fill in the concomitant
medications log 
Visit 1: 
Inform patients about trial in person or over telephone. Ensure that participants meet inclusion/exclusion criteria 
in CRF 1
DOI: 10.3310/hta19770 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 77
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Horrocks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49

Appendix 2 Events at each visit
TABLE 17 Events at each visit
Event Visit 1
Telephone
conversation Visit 2 Visits 3–13 Visit 14
Eligibility assessment ✗
Bowel diary ✗ Visit 7–8 ✗
Consent ✗
Participant contact information sheet ✗
Eligibility assessment (CRF 1) ✗
Initial assessment (CRF 2) ✗
Questionnaires (CRF 3) ✗ ✗
Randomisation ✗
Randomisation information (CRF 4) ✗
Intervention ✗ ✗
Record stimulation parameters adverse events
and medication/pad usage (CRF 5)
✗ ✗
Adverse events log ✗ ✗ ✗
Concomitant medications log ✗ ✗ ✗
Post-treatment information (CRF 6) ✗
Final study visit information (CRF 7) ✗
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Appendix 3 Case report forms
CONtrol of Faecal Incontinence using Distal NeuromodulaTion (CONFIDeNT) 
CRF 1 – Eligibility Criteria  
Inclusion Criteria Yes No 
Faecal incontinence sufficiently severe enough to warrant intervention   
Failure of appropriate conservative therapies   
Age ≥18    
N.B. Appropriate specialist investigations including structural and functional anorectal assessment would be informative, although not mandatory. 
If any of the above criteria are answered NO the participant is not eligible for the study. If the participant is 
excluded from the study, complete the Screening Log to explain why. 
Exclusion Criteria Yes No 
Inability to provide informed consent for the research study   
Inability to fill in the detailed bowel diaries required for outcome assessments (this will exclude 
participants who do not speak / read English) 
  
Neurological diseases, such as diabetic neuropathy, multiple sclerosis and Parkinson's disease 
(any participant with painful peripheral neuropathy) 
  
Anatomical limitations that would prevent successful placement of needle electrode   
Other medical conditions precluding stimulation: e.g. bleeding disorders, certain cardiac 
pacemakers, peripheral vascular disease or ulcer, lower leg cellulitis 
  
Congenital anorectal anomalies or absence of native rectum due to surgery    
A cloacal defect   
Present evidence of external full thickness rectal prolapse   
Previous rectal surgery (rectopexy/resection)< 12 months ago (24 months for cancer)   
Stoma in situ   
Chronic bowel diseases such as inflammatory bowel disease leading to chronic uncontrolled 
diarrhoea 
  
Pregnancy or intention to become pregnant*   
Previous experience of SNS or PTNS   
*If a female participant is of child bearing potential (e.g. pre-menopausal) this includes a discussion regarding appropriate forms of contraception, 
and the avoidance of becoming pregnant during the trial. If a participant does become pregnant during the trial, they must report this immediately to 
the research staff. 
For females of child bearing potential at screening, please perform urinary pregnancy test.  
Result: POSITIVE / NEGATIVE (PLEASE CIRCLE) 
If any of the above criteria are answered YES the participant is not eligible for the study. If the participant is 
excluded from the study, complete the Screening Log to explain why. 
DECLARATION: I have reviewed this Case Report Form and confirm that, to the best of my knowledge, it 
accurately reflects the study information obtained for this participant. 
STORE IN PARTICIPANTS CRF FOLDER 
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I CONFIRM THAT THIS PARTICIPANT HAS COMPLETED THE TRIAL IN ACCORDANCE WITH 
THE APPROVED PROTOCOL, REC CONDITIONS OF APPROVAL AND IN LINE WITH GOOD 
CLINICAL PRACTICE GUIDELINES. 
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Appendix 4 Standardised percutaneous tibial
nerve stimulation and sham
 
 
CONtrol of Faecal Incontinence using Distal NeuromodulaTion 
(CONFIDeNT) 
 
Standardised PTNS and Sham 
EQUIPMENT SET UP 
 
Figure 1 
 
 
 
                                                                       1 
 
 
Figure 2 
 
 
                                                                          3 
                          2 
 
 
PTNS: Urgent ® PC neuromodulation system (Uroplasty Ltd., Manchester, UK). 
Needle: Lower inner aspect of the RIGHT leg - three finger breaths (5 cm) cephalad 
to the medial malleolus and approximately one fingerbreadth (2 cm) posterior to the 
tibia. 60-degree angle between electrode and ankle. 
Electrode: Ipsilateral calcaneus.  
TENS: Biostim M7 TENS unit, Biomedical Life Systems, Vista, California 
 Electrodes: Right foot, one under the little toe and one on top of the foot.  
 
 
 
1. Just distal to calcaneus 
on sole of foot in 
midline (active for 
PTNS) 
2. Bottom of foot just 
proximal to smallest 
toe 
3. Top of foot just above 
smallest toe 
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FOR PTNS: 
 Set up both machines.  
 Place tape over wire connected to PTNS needle (so appearance is identical to 
sham). 
 Only turn on PTNS machine - fixed-pulse frequency of 20Hz and a pulse width of 200 
microseconds 
 Continue treatment as usual – increasing amplitude until a sensory or motor 
response – reduce. 
 DO NOT ALLOW PARTICIPANT TO ALTER SETTINGS THEMSELVES  
FOR SHAM: 
 Set up both machines. With PTNS, DO NOT CONNECT LEAD TO PTNS NEEDLE.  
 Instead, tape lead near needle so it is not possible to tell at a glance if connected or 
not. 
 Pick up both the TENS and PTNS machines 
 Check TENS settings pulse frequency 10Hz and pulse width 200 microseconds. 
 Press buttons simultaneously on PTNS and TENS machines to increase Amplitude 
(participant will only feel TENS as PTNS machine is not properly connected). THE 
PARTICIPANT WILL THEN HEAR THE BEEPS FROM THE PTNS MACHINE AS IN 
THE PTNS ARM. 
 When a significant sensory or motor response is observed, turn down one setting. 
Press timer button twice – 30 mins will count down on TENS display 
 Leave the participant as usual for the 30 minute treatment. 
 DO NOT ALLOW PARTICIPANT TO ALTER SETTINGS THEMSELVES  
 
 
VERBAL EXPLANATION TO PARTICIPANT  
 “I am now going to start the nerve stimulation treatment. I will be inserting a small electrode 
needle, like an acupuncture needle, into your leg and putting sticky electrodes onto your foot. 
When I turn the machine on you will be asked when you can first feel an electrical sensation 
in your ankle or foot. I will carry on increasing the intensity of this until it is slightly 
uncomfortable, then I will turn it down a little if necessary. Occasionally you may also feel 
numbness or slight movement of your toes. This is normal. I will set the machine up and leave 
it running for 30 minutes. You may or may not continue to feel the stimulation during this time 
– this is normal also. After 30 minutes have elapsed I will remove the needle and sticky 
electrodes (the machine automatically turns off at this time). If the treatment becomes 
uncomfortable at any point please let me know and I will turn it down or stop the machine.”  
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Appendix 5 Standard operating procedures
Standard Operating Procedures (SOP) for: Randomisation and Unblinding  Procedure for 
the CONFIDeNT Study 
 
SOP Number: 5 Version Number: 1 
Effective Date: 5 JAN 2012 Review Date: 5 JAN 2015 
 
Author: Emma Horrocks, Clinical Research Fellow 
 
Authorisation: 
Name / Position Professor Charles Knowles/ Chief Investigator 
Signature 
Date 4/1/12 
 
 
Staff signatures: I have read, understood and will comply with this SOP 
Name (please print) Signature Date 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
XXXX
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Purpose and Objective: 
To define the procedure for randomisation of study participants for the CONFIDeNT 
Study. 
 
SOP Text 
 
 Responsibility Activity 
1. Research Team Performing Randomisation: 
 
On visit 2, participants will be randomised, using a web-based 
computer program, to receive either PTNS or sham. 
 
Prior to allocation, the participant must have provided informed 
consent. CRF 1 and CRF 2 (Eligibility Criteria and Initial 
Assessment) must have been completed and checked by another 
member of the research team.  CRF 3 (Questionnaires) must also 
have been completed. These documents should be completed.in 
accordance with SOP 10 – Document Completion.  
 
Details of the randomisation website are as follows: 
 
The randomisation programme is a bespoke system designed and 
held at the Nottingham Clinical Trials Unit (NCTU) and run by 
the NCTU data manager. The system is fully tested by the trial 
team and PCTU statistician. 
 
The research nurse/researcher at each site will log on using a site 
specific username and password, which will be provided by the 
Research Fellow during the Site Initiation Visit.  Following 
successful log on the researcher will select their site from the 
drop-down menu (the only other choice being the test site). They 
will then select ‘Enrol new participant’ from the list of options. 
The screen automatically appears which requires input of the 
unique participant identifier, sex, date of birth and initials of 
participant. Once these are entered, ‘click submit’. The next 
screen allows the researcher to check the details are correct, and if 
not, to amend them, or if they are correct, click ‘next form’.  The 
next page requires the researcher to again check the details, and if 
incorrect, click ‘prev form’ to go back to the previous form and 
amend the details. If the details are correct, the researcher is 
asked to check two boxes, one agreeing that the data entered is 
correct, and the other agreeing that the participant meets the entry 
criteria for the CONFIDeNT Trial, as outlined in the Protocol. If 
these two boxes are checked, the researcher can then press the 
‘randomise’ button. This will allow immediate on-screen 
randomisation with the allocation showing on the next screen. 
 
The researcher will then fill in the randomisation information on 
CRF 4. This CRF will be held in a ‘Randomisation File’ in each 
site, which contains only CRF 4. Each participant’s CRF 4 will be 
kept in a concealed envelope within this Randomisation File to 
prevent accidental unblinding to researchers not completing 
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treatment for this participant.. This ensures that prior to each 
treatment the unblinded researcher performing the treatment can 
check the randomisation allocation, but it will not be in the 
participants CRF folder to avoid accidental unblinding of other 
site researchers. 
The participants Unique Participant Identifier is made up of 3 
letters followed by 3 numbers. The letters are unique to each site 
and are documented in the CONFIDeNT trial protocol( Appendix 
A). The numbers are allocated at each site and are allocated 
sequentially to each participant during screening for  the trial, 
beginning with 001. 
 
The allocation will be known by the researcher carrying out the 
first treatment.  
 
Thereafter, at each visit, the participant will receive the PTNS or 
sham as identified by the randomisation CRF 4. 
 
Once the randomisation has been performed, an automated, 
blinded, pseudo-anonymised email will be sent to the PI at that 
site, informing them that the randomisation has taken place. An 
automated, unblinded, pseudo -anonymised email will also be 
sent to the Trial Manager, Natasha Stevens, in order to keep a 
centralised trial randomisation log. 
 
Each site will be able to log on to the randomisation tool and 
view the participants that have been randomised at their site. This 
can be done by logging on to the website, and selecting ‘View a 
summary of randomisations performed’ from the list. This will 
show details of the participants randomised but will NOT show 
randomisation allocation, in order to prevent unblinding.  
 
If CRF 4 containing the randomisation allocation is not 
completed immediately following on screen randomisation, it will 
not be possible for the research sites to access information about 
the allocation. If this occurs, the site should contact the Trial 
Manager, Natasha Stevens, contact details below, who  will be 
able to access the allocation for all participants.   
 
2. PI/ Research Team  Procedure if Randomisation Tool not working: 
 
If, for any reason, a site is unable to perform a randomisation 
using the online tool, in the first instance the site should contact 
the Research Fellow Emma Horrocks, or Trial Manager, Natasha 
Stevens (see details below). Assistance can be given over the 
phone regarding the use of the online randomisation tool. 
 
If the website or internet is not working at a particular site, 
Natasha Stevens, Trial Manager, can perform randomisation on 
behalf of the site, and relay the randomisation to the site over the 
phone and via a pseudo-anonymised email. 
 
Failing this, if the website is not functioning at any site, the 
Nottingham Clinical Trial Unit should be contacted to conduct 
randomisation. Contact details: 
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Dan Simpkins 
IT/Data Manager 
Nottingham Clinical Trials Unit 
Office 2009, 
C Floor, South Block 
Queen's Medical Centre 
Tel: XXXX  
Email: XXXX 
 
3. PI/Research Team Unblinding: 
 
If, for any reason, un-blinding is required, in the first instance the 
permission of the Local Principal Investigator should be sought. 
If they are unavailable, or this is not possible, the Academic 
Clinical Fellow, Emma Horrocks, or the Chief Investigator, 
Charles Knowles should be contacted.  
 
Emma Horrocks 
Email: XXXX  
Tel: XXXX  
 
Charles Knowles: 
Email: XXXX  
Tel: XXXX  
 
Once permission is sort, the local investigator can break the 
randomisation code by looking at CRF 4 for the appropriate 
participant. If this is not possible, because the information is 
unavailable out of hours, the lead site should be contacted.  
 
In the first instance the Trial Manager can be contacted, who can 
access the randomisation code by the computer programme, and 
if she is unavailable the Data Manager, Sandy Smith, should be 
contacted. Only the trial manager and data manager will have 
access to the randomisation data within the database. 
 
Natasha Stevens (Trial Manager) 
Email: XXXX  
Tel: XXXX  
 
Sandy Smith ( Data Manager) 
Email: XXXX  
Tel: XXXX  
   
 
 
Version Reason for Change Date Approved 
1.0   
2.0  
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Appendix 6 Statistical analysis plan
CONFIDeNT 
 
Statistical Analysis Plan 
 
Version: 1.0 
Date: 19/Jun/2014 
                          
Person(s) contributing to the analysis plan 
Name(s) and 
position(s) 
Dr Stephen Bremner, trial statistician 
Prof Sandra Eldridge, director of PCTU 
Prof Charles Knowles, chief investigator 
Emma Horrocks, trial coordinator 
Authorisation 
Position Chief or principal investigator 
Name Prof Charles Knowles 
Signature  
Date  DD/MMM/YYYY 
Position Senior trial statistician 
Name Prof. Sandra Eldridge 
 
Signature 
 
 
 
Date DD/MMM/YYYY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DOI: 10.3310/hta19770 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 77
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Horrocks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89
1. INTRODUCTION 
 
Purpose of statistical analysis plan 
 
The purpose of this document is to provide details of the statistical analyses and 
presentation of results to be reported within the principal paper(s) of the CONFIDeNT 
trial.  Subsequent papers of a more exploratory nature (including those involving 
baseline data only) will not be bound by this strategy but will be expected to follow 
the broad principles laid down in it.  Any exploratory, post hoc or unplanned analyses 
will be clearly identified in the respective study analysis report. 
The structure and content of this document provides sufficient detail to meet the 
requirements identified by the International Conference on Harmonisation (ICH) and 
the PCTU SOP (PCTU/07).   
The following were reviewed in preparation for writing this document: 
Trial application submitted 04/01/2011 
ICH E9 Guidance on statistical principals for clinical trials 
ICH E3 Structure and content of clinical study reports 
CONSORT guidelines for the reporting of randomised trials 
 
Members of the writing committee 
 
Stephen Bremner (SB) and Sandra Eldridge (SE) were primarily responsible for 
writing the Statistical Analysis Strategy with SB responsible for writing the computer 
code implementing the analysis strategy and implementing the strategy at the point of 
analysis.  Emma Horrocks and Prof Charles Knowles helped refine outcome 
definitions and choose variables for the multiple imputation.  This document was 
developed prior to examination of unblinded trial data and will not be implemented 
prior to final approval.  
 
Summary 
 
DESIGN: Pragmatic multi-centre, double-blinded, placebo-controlled trial of 227 patients 
randomised to receive the intervention (PTNS) or sham (needle insertion and electrical 
stimulation). All patients follow an assessment period, recruitment, allocation, standard 3 
month treatment protocol (one 30. min session per week for 12 weeks) with trial outcomes 
determined at 14 weeks. 
SETTING: 19 UK centres providing specialist nurse-led treatment for pelvic floor disorders.  
TARGET POPULATION: Patients aged > 18 years with faecal incontinence (FI) who have 
failed conservative treatments and whose symptoms are sufficiently severe to merit further 
intervention (80-90% female based on departmental data). 
HEALTH TECHNOLOGIES BEING ASSESSED: PTNS (Urgent ® PC neuromodulation 
system) is produced by a single manufacturer (Uroplasty ®). The equipment includes a hand 
held pulse generator unit, single use leads and fine needle electrodes. Needle insertion is 
performed in a sitting position in an outpatient setting on either leg adhering to the 
manufacturer’s protocol (and specialist training). Treatment is for 30 mins. weekly for a 
duration of 12 weeks. Validated sham stimulation - insertion of the Urgent PC needle 
subcutaneously at the same site with electrical stimulation delivered to the distal foot using 
TENS. 
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MEASUREMENT OF COSTS AND OUTCOMES: Primary outcome variable: change in 
weekly FI episodes (calculated from bowel diaries) expressed as proportion of patients 
achieving ≥ 50% reduction in FI episodes per week; Secondary outcomes: (1) percentage 
change in FI episodes per week, (2) change in mean number of FI episodes per week, (3) 
validated patient-rated quantitative outcomes including symptom severity score (St Mark’s 
score), disease-specific: FI-QOL, and generic: EQ-5D QOL measures, and SF-36, (4) FI-
specific patient-centred outcomes (5 validated key issues), (5) Likert scales of patient’s global 
impression of success (0-10), (6) Short urinary symptom assessment. Adverse events and 
anti-diarrhoeal drug usage will also be recorded. Economic analysis will measure direct NHS 
costs with utilities derived from the EQ-5D.  The proposed HE analysis will be detailed in a 
separate document. 
 
Changes from planned analysis in the protocol 
 
We decided to fit random centre effects rather than fixed effects on the basis of 
findings by Kahan & Morris (Kahan & Morris, 2013).  We also decided to multiply 
impute the data and remove any reference to last observation carried forward. 
 
STUDY OBJECTIVES AND ENDPOINTS 
 
Study objectives 
 
 Primary objectives 
 
To determine the effectiveness of PTNS versus sham electrical stimulation based on changes 
in the number of weekly FI episodes from baseline (bowel diary completed over two week 
period prior to first intervention) to end of treatment (bowel diary completed for weeks 12 
and 13) 
 
 Secondary objectives 
 
To determine the effectiveness of PTNS versus sham electrical stimulation (TENS) 
based on changes in validated incontinence scores, patient-centred FI-related 
symptoms and disease-specific and generic quality of life measures from baseline 
(bowel diary completed over two week period prior to first intervention) to end of 
treatment (bowel diary completed for weeks 12 and 13) 
 
 Exploratory objectives 
 
None 
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Outcome measures 
 
 Primary outcome  
 
Change in weekly FI episodes expressed as proportion of patients achieving ≥ 50% reduction 
in FI episodes per week.  The change is measured between pre- and post-treatment bowel 
diaries. 
The number of FI episodes per day are the sum of episodes in Q2a (rush) and Q2b 
(passive leakage) of the bowel diary.  The average number per week is the sum of all 
14 days, divided by 2.   
%change = 100% × (#FI(baseline) - #FI(end of intervention)) / #FI(baseline)   
Where #FI is the average number of episodes of FI per week.  Where %change is 
negative, this represents an increase in FI episodes; where it is positive, this represents 
a decrease in FI episodes. 
A patient achieving a ≥ 50% reduction will be classed as a treatment success, 
otherwise the patient is classed as a treatment failure. 
 
 Secondary outcomes 
 
Percentage change in FI episodes per week, from baseline (the two-week period just before 
the 1st treatment) to end of treatment i.e. bowel diary for two weeks after the 12th treatment; 
for three additional cut offs:  an improvement  ≥ 25% vs. less, an improvement ≥ 75% vs. less 
and an improvement of 100% vs. less   
Continuous change in FI episodes per week; i.e. average number of FI episodes per week for 
the two weeks post-treatment, minus average number of FI episodes per week at baseline 
(from pre-treatment two-week bowel diary). 
Continuous change in FI episodes per week (rush and passive leakage as two separate 
outcomes); i.e. average number of episodes per week for the two weeks post-treatment, minus 
average number of episodes per week at baseline (from pre-treatment two-week bowel diary). 
St Mark’s incontinence score (Vaizey et al. 1999) 
Likert scale of patient’s global impression of success 
Patient-centred FI-related symptoms  
Disease specific and generic quality of life measures 
 - EQ-5D 
 
 - SF-36 (8 domains) 
- Faecal incontinence quality of life score- four domains: coping, embarrassment, lifestyle and 
depression 
 - Gastro-intestinal quality of life score 
Short urinary symptom assessment (descriptive) 
Change in medication use: has pad usage/loperamide usage decreased/remained the 
same/increased? (descriptive) 
 
Safety outcomes  
None 
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STUDY METHODS 
 
Overall study design and plan 
 
Target for analysis:  106 intervention and 106 sham participants 
Actual number randomised: 227  
Date of first randomisation: 21/01/2012 
Date of last randomisation: 31/10/2013 
Trial design:  individually randomised, parallel group   
Blinding:    See section 3.4     
Randomised Interventions: PTNS vs. sham 
Allocation ratio:  1:1              
 
Selection of study population 
 
Inclusion Criteria 
Faecal incontinence sufficiently severe enough to warrant intervention 
Failure of appropriate conservative therapies 
Age ≥ 18 years 
Exclusion Criteria 
Inability to provide informed consent for the research study 
Inability to fill in the detailed bowel diaries required for outcome assessments (this will 
exclude participants who do not speak / read English) 
Neurological diseases, such as diabetic neuropathy, multiple sclerosis and Parkinson's disease 
(any participant with painful peripheral neuropathy) 
Anatomical limitations that would prevent successful placement of needle electrode  
Other medical conditions precluding stimulation: e.g. bleeding disorders, certain cardiac 
pacemakers, peripheral vascular disease or ulcer, lower leg cellulitis 
Congenital anorectal anomalies or absence of native rectum due to surgery  
A cloacal defect 
Present evidence of external full thickness rectal prolapse  
Previous rectal surgery (rectopexy / resection) done < 12 months ago (24 months for cancer),  
Stoma in situ  
Chronic bowel diseases such as inflammatory bowel disease leading to chronic uncontrolled 
diarrhoea 
Pregnancy or intention to become pregnant 
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Previous experience of SNS or PTNS 
Method of treatment assignment and randomisation 
 
Participants were randomised, with allocation concealment, at a ratio of 1:1 at visit 2 using a 
web-based computer programme to receive either PTNS or sham. This was performed by the 
Nottingham Clinical Trials Unit Study.  Centres inputted the sex of the participant. Sex was 
used to reduce the potential confounding effects of variation in outcomes between male and 
female participants. Males represent approximately 10% of patients and have differing pelvic 
physiology and often disease aetiology (e.g. post anal surgery rather than childbirth).  As only 
1 or 2 male patients were expected to be enrolled from each centre, randomisation was first 
stratified on sex, and then within females only, further stratified on centre reducing the 
possibility that all the males are allocated to PTNS by chance. Randomly permuted blocks of 
length randomly varying 2, 4 and 6 will be used to ensure near balance between PTNS and 
sham arms. 
 
Treatment masking (Blinding) 
 
Blinding of patients: For both interventions: (1) a standardised description of the 
techniques were read from a card. This described an electrical sensation variably in 
the ankle or foot with or without motor responses in the foot (note: there is significant 
variability in conscious sensation and motor responses even between patients 
undergoing only PTNS); (2) the equipment (identical for both interventions) was 
shown to the patient; (3) the lower extremity was be draped from view; and (4) the 
audible sounds produced by the Urgent PC unit identical. 
Performance bias considerations: Since the sham group might be expected to seek 
more advice than the treatment arm (if the hypothesis that PTNS is more effective 
than placebo is correct), the interaction of the administering nurse/physician was 
standardised so that general supportive advice given at consultations was identical for 
all participants. This was limited to a general welcome, answers to any concerns 
(whilst recording adverse events), advice on loperamide dosages and pad use (both 
recorded in outcome variables).  
Blinding of trial staff: two members of staff were available at each site to run the 
study. Randomisation into the treatment or placebo arm of the study occurred at Visit 
2, after all the documentation had been completed. At this point, the member of staff 
carrying out the PTNS or sham was unblinded. That same staff member carried out all 
12 treatments for the patient. Following the final treatment the member of staff who 
remained blinded collected all of the final data, before allowing the patient to find out 
if they were in the sham or treatment arm. In this way, the staff member conducting 
the final meeting with the patient remained blinded until the end.  
 
Sample size determination  
 
Research into treatment of FI is currently hampered by the lack of a valid and reliable 
tool that allows standardisation of outcomes. There are advantages and disadvantages 
of the numerous possible quantitative outcome variables e.g. individual symptoms 
and composite scores, and generally poor correlation of either with disease specific or 
generic quality of life measures. Of possible outcomes, the most frequently used and 
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probably least affected by subjective reporting differences is number of FI episodes 
per unit time (usually per week). This outcome, obtained directly from the mean of 2 
week bowel diary frequencies has been employed in almost all contemporary studies 
of FI interventions including recent SNS studies. The problem with this variable is 
that, being a count, it has a Poisson distribution and is over-dispersed i.e. has greater 
variability than expected. This raises major difficulties in defining a clinically 
significant mean reduction in FI episodes per week in a population of patients with 
widely dispersed starting FI frequencies. To counter this problem, almost all 
contemporary studies have adopted a primary outcome using a categorical measure of 
percentage reductions i.e. the proportion of patients who have a 50% or greater 
reduction in faecal incontinence episodes per week. We justify this approach on the 
following basis: 
The most important inferred outcome of this study will be the comparison of PTNS 
outcomes with that of other interventional treatments especially those of SNS. Since 
the primary outcome of nearly all studies of SNS has been based on the ≥ 50% 
reduction in FI episodes rule, the continued use of this outcome will better inform 
bodies such as NICE. Indeed, this outcome was used in the NICE ruling on sacral 
nerve stimulation; it was also the primary outcome in the 16-site multicentre FDA 
investigational device exemption (IDE) trial of sacral nerve stimulation in 120 
patients with FI. 
This outcome has also been the approach of choice for urinary incontinence episodes 
in the only pivotal trial of PTNS in the urology literature and also for NICE 
commissioned systematic reviews.  
Baseline and post treatment FI episodes expressed as continuous variables yield data 
from over-dispersed Poisson distributions. The arithmetic means of these variables are 
very difficult to correlate with significant clinical effect e.g. a mean change of 5 FI 
episodes per week is not possible in patients with starting frequencies of four or fewer 
and is of little or no benefit to a patient with a starting frequency of 50. The change 
variable will however remain a secondary outcome. 
 
Previous publications and our own data on 50 patients suggest a 60% success rate for 
PTNS on the basis of above justified primary outcome measure. There are no RCT 
data for PTNS in FI. However the pivotal level I SUmiT trial of PTNS in overactive 
bladder symptoms (OAB) which used a similar global response assessment of urinary 
incontinence and an intention to treat analysis, observed a moderate or marked 
improvement in symptoms in 55% PTNS group and only 21% sham group. On the 
basis that placebo responses are frequently higher for bowel rather than bladder 
symptoms we have selected a sham response rate of 35% whilst keeping this more 
conservative estimate of treatment response of 55%. We believe this difference 
remains clinically important. Two hundred and twelve patients are required to detect 
this difference with 80% power at the 5% significance level. We aimed recruit 235 
patients at baseline to allow for a 10% failure to attend the 2nd visit (allocation and 
first intervention). 
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DATA COLLECTION 
 
Baseline 
 
Age, sex, history of faecal incontinence (including type), urinary symptom history, 
previous faecal incontinence treatments, medications, past medical history, past 
obstetric history. (see CRF 2 v5 for items) 
Bowel diary (14 consecutive days) 
Gastrointestinal quality of life index, patient centred FI symptoms, SF-36 Health 
Survey, QoL scale for faecal incontinence, St. Mark’s faecal incontinence score, EQ-
5D health questionnaire (see CRF 3 v3 for detail)  
 
Follow up 
 
Visits 2-13: PTNS or tens machine settings and response (sensory or motor), adverse 
events, any change in pad usage, any changes in medication use? (see CRF 5 v3)  
Week 7:  bowel diary over 7 consecutive days 
Final visit (post treatment) (week 14): which treatment did patient think they were on? 
Any effect on urinary symptoms? Any change in loperamide or codeine use? Any 
change in pad use? How patient felt before, during and after treatment, Likert scale of 
success. 
Bowel diary over 14 consecutive days 
CRF 3 v3 
 
Timing of data collection 
 
Event Visit 1 Telephone 
Conversation 
Visit 2 Visits 3-13 Visit 14 
Eligibility assessment  X     
Bowel Diary  X  Visit 7-8 X 
Consent   X   
Participant Contact Information Sheet   X   
Eligibility assessment (CRF1)   X   
Initial assessment (CRF2)   X   
Questionnaires (CRF3)   X  X 
Randomisation   X   
Randomisation information (CRF4)   X   
Intervention   X X  
Record stimulation parameters 
adverse events and medication / pad 
usage (CRF5) 
  X X  
Adverse Events Log   X X X 
Concomitant Medications Log   X X X 
Post treatment Information (CRF6)     X 
Final Study Visit Information (CRF7)     X 
 
GENERAL ISSUES FOR STATISTICAL ANALYSIS 
 
All analyses will be conducted two sided and significance interpreted at the 5% level. 
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Blinding of the statistical analysis 
 
The trial statistician will remain blind to allocation until this analysis plan was signed 
off 
 
Analysis populations 
 
 Intent-to-treat population 
The intention-to-treat (ITT) sample is defined for this trial as all participants 
randomised into the trial, who received at least their first treatment, included in the 
intervention group to which they were randomised. 
 
 Available-case population 
N/A 
 
 Per protocol population 
Patients attending at least 10 treatment sessions in 13 weeks will be classed as 
treatment completers. 
 
 Safety population 
N/A 
 Other populations 
N/A 
 
Database  
 
 Description 
 
Data were entered by the trial manager, clinical academic fellow and data entry clerks 
onto a Microsoft Access 2010 database held on the Barts Cancer Institute secure 
server.  Data was entered at QMUL. 
 
Data quality 
 
Completeness of data was checked each time a report was generated for data 
monitoring committee meetings, and prior to final analysis.  All eligibility and 
primary outcome data were checked by a member of the trial team other than the 
person who entered it.  This was done in batches, as and when time permitted.  A 10% 
random sample of CRFs for secondary outcomes were checked and the overall error 
rate was found to be below the 2% error rate that would have necessitated a 100% 
check of the secondary outcomes data.  
 
 Database freeze and lock 
 
Once the trial team completed all data entry and checking, the data date stamped and 
frozen for transfer to Stata version 12.1 using the odbc facility in Stata. The 
statistician responsible for the analysis conducted additional data checks. These range 
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checks, logical and consistency checks which may not have been picked up by checks 
performed at the individual level. 
Discrepancies were dealt with by the trial manager checking the paper CRFs, and the 
database was locked for analysis i.e. it was transferred to a read only location.   
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Analysis software 
 
The analysis will be carried out using Stata version 12.1, interfacing with Realcom 
Impute which will be used to multiply impute missing outcome and baseline covariate 
data.  
 
Methods for withdrawals, loss to follow-up and missing data  
 
All patients randomised who receive the first treatment will be included in the intention-to-
treat analysis of primary endpoint.  Prior to the first treatment, it was anticipated that some 
patients (up to 10%) would fail to attend after eligibility was assessed due to a failure of 
compliance with the travel and attendance needs of the treatment course or study. These were 
not counted as study recruits. Those in whom post-treatment data are unavailable at 14 weeks 
for any reason (loss to follow up, failure to complete treatment) will have their outcome 
multiply imputed under the assumption of missing at random (MAR) using variables 
prognostic of outcome, such as measure of outcome made at baseline, and others that are 
predictive of missingness such as mean number of FI episodes per week at baseline, age, sex, 
and where available, mid-study bowel diary data.  See appendix (b) for details.  Multilevel 
multiple imputation will be performed using the multivariate normal distribution in Realcom 
Impute, using treatment allocation, patient sex and allocation as auxiliary variables. After a 
burn in of 1,000 runs of the MCMC sampler, missing values will be filled every 500th run to 
create a total of 10 completed datasets for analysis.  The data will be analysed in Stata and the 
results pooled by Rubin’s rules. 
 
Method for handling centre effects  
 
Study centre will be included as a random effect 
 
Method for handling randomisation stratification or minimisation factors 
 
Patient sex will be included as a fixed effect, study centre as a random effect 
 
Method for handling clustering effects  
 
The intracluster correlation coefficients (ICC) and their 95% confidence intervals for 
the outcomes by centre (level 2) will be estimated using the user-contributed Stata 
command sea_obi which allows the ICC to be negative.  Random effects models will 
be fitted by restricted maximum likelihood estimation (e.g. xtmixed …, reml).  
However, should these fail due to the between centre variance being close to zero, 
random effects models will be fitted by generalised least squares (e.g. xtregress).  If 
ICCs are estimated as  0 then we will use similar regression models without 
adjusting for clustering. 
 
Method for selecting other variables that will be adjusted for 
 
This was agreed by consensus prior to any data extraction and the decision was: fit 
fixed effects for sex, randomisation and baseline level of outcome.  
 
Multiple comparisons and multiplicity 
 
No adjustments to p-values planned 
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Method for handling non-adherence  
 
All patients randomised who receive the first treatment will be included in the 
intention-to-treat analysis of primary endpoint. 
 
Method for handling time-varying interventions 
N/A 
 
Method for handling outliers and influential points 
N/A 
 
Data from external sources 
N/A 
 
 Derived and computed variables 
 
In the bowel diary, participant’s record:  
Controlled bowel motions: No incontinence – pads or pants remained clean  
2. Uncontrolled bowel movements: Incontinence – underwear, pads or pants got dirty. 
Within this section patients are asked how many of those times they:  
a. Didn’t make it in time to the toilet (rush)  
b. Didn’t feel the bowel movement until after it had happened (passive leakage)  
The FI episodes will be calculated from those of ‘Uncontrolled bowel Movements’, 
whether this be ‘rush’ or ‘passive leakage’, by adding the two together. 
 
DESCRIPTIVE ANALYSES 
 
NB To help identify problems with missing data, outlying values, or other errors, full 
descriptive statistics MUST be produced for all variables in the database(s) 
 
Participant flow 
 
Participant throughput will be summarised in a CONSORT diagram. 
 
Representativeness of sample 
N/A 
 
Baseline comparability of randomised groups 
 
Demographics 
Age and sex distributions will be described, by trial arm 
 
Prior and concurrent medications 
Proportion of patients taking loperamide and/or codeine 
 
 
Baseline and screening conditions 
Severity of FI symptoms according to bowel diary (i.e. mean number of episodes per 
week, recorded over a 14 day period) 
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Baseline medical history 
Previous treatment for FI, and obstetric history. These are binary variables, except for 
number of previous vaginal deliveries (0, 1, 2, 3, 4, 5 or 6), and will be reported as 
number and percentage. 
 
Baseline physical exam 
N/A 
 
Cluster characteristics if cluster randomised 
N/A 
 
Characteristics of care providers where applicable 
N/A 
 
Comparison of losses to follow-up 
 
The proportion of patients withdrawing will be compared descriptively by arm 
 
Comparison of compliance to treatment and protocol 
 
The proportion of patients attending one or more treatment sessions will be compared 
descriptively. 
The distribution of the proportion of treatment sessions attended per patient will be 
compared descriptively by arm. Participants who receive ≥ 10 treatments in 13 weeks 
will be considered to have received a full set of treatments for the per protocol 
analysis. 
 
Emergency or accidental unblinding of randomised treatment 
 
It was hard to envisage any necessity to break the randomisation code. We specified 
that should this be required, in the first instance the permission of the Local Principal 
Investigator should be sought. If they were unavailable, or this was not possible, the 
Academic Clinical Fellow, Emma Horrocks, of the Chief Investigator, Charles 
Knowles should be contacted.  
Once permission had been sought, the local investigator could break the 
randomisation code by looking at CRF 4 for the appropriate participant. If this was 
not possible, because the information was unavailable out of hours, the lead centre 
should be contacted. In the first instance the Trial Manager could be contacted, who 
could break the randomisation code by the computer programme, and if she was 
unavailable the Daniel Simpkins at Nottingham Clinical Trials Unit should be 
contacted. Only the trial manager, independent statistician and Nottingham 
representative had access to the randomisation data within the database. 
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INTERIM ANALYSES AND SAFETY MONITORING ANALYSES 
 
Purpose of interim analyses 
 
None were planned 
 
ANALYSIS OF PRIMARY OUTCOME 
 
Definition of outcome measure 
 
Responder vs. non-responder: Defined as a 50% or greater reduction in FI episodes 
per week, comparing end of intervention bowel diary with baseline). i.e.  
If 100% × (#FI(baseline) - #FI(end of intervention))/#FI(baseline) ≥ 50%, class as 
responder 
Where #FI stands for the average number of FI episodes per week. Where %change is 
negative, this represents an increase in FI episodes; where it is positive, this represents 
a decrease in FI episodes. 
 
Descriptive statistics for outcome measure 
 
Number and proportion of responders (as defined above) in each arm 
 
Primary analysis 
 
A logistic regression, adjusting for mean number of FI episodes at baseline, with a 
fixed effect for treatment arm, and sex, will be fitted using the Stata command 
xtmelogit, specifying study centre as a random effect  
 
Assumption checks and actions to be taken if they do not hold 
None 
 
Other analysis supporting the primary (inc. sensitivity analyses) 
N/A 
 
ANALYSIS OF SECONDARY OUTCOMES 
 
Definition of outcome measures 
Percentage reduction in FI episodes per week  for three additional cut offs:  an improvement 
of  ≥ 25% vs. less, an improvement of ≥ 75% vs. less and an improvement of 100% vs. less   
Mean reduction in FI episodes per week (continuous); i.e. average number of FI episodes per 
week for the two weeks post-treatment, minus average number of FI episodes per week at 
baseline (from pre-treatment two-week bowel diary) 
Mean reduction in (a) uncontrolled rush FI episodes per week and (b) uncontrolled passive 
leakage FI episodes i.e. average number of FI episodes per week for the two weeks post-
treatment, minus average number of FI episodes per week at baseline (from pre-treatment 
two-week bowel diary) 
Patient centred outcomes (continuous) 
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St Mark’s score (continuous) 
FI-QOL (continuous) [the four domains will be handled as outcomes in four separate models] 
EQ-5D (continuous) 
SF-36 (continuous) [the eight domains will be handled as outcomes in eight separate models] 
Likert scale of patient’s global impression of success (0-10). (continuous) 
Short urinary symptom assessment (ordered categorical) 
Descriptive statistics for outcome measure 
Mean and SD for symmetric continuous variables  
Median, 10th & 90th centiles for skewed continuous variables 
Number and % for binary and other categorical variables  
 
Secondary analysis 
Continuous outcomes will be modelled using a mixed effects linear regression with 
the command xtmixed, adjusting for the baseline level of the outcome, sex and 
including a random effect for study centre.  It should be noted that for outcome (2), 
analysis of change in FI episodes as the outcome is less efficient than ANCOVA i.e. 
end of intervention mean number of episodes as outcome, adjusted for baseline mean 
number of episodes.  In this case the outcome variable will be mean number of FI 
episodes per week at end of treatment adjusting for the covariate, baseline measure of 
the outcome.  Binary outcomes will be modelled using a mixed effects logistic 
regression xtmelogit, adjusting for the baseline measure of the outcome, sex and 
including a random effect for study centre.  Urinary symptoms (outcome 9) will not 
be modelled. 
 
Assumption checks and actions to be taken if assumptions do not hold. 
Normality and homoscedasticity of residuals (xtmixed only), normality of random 
effects 
 
Other analysis supporting the secondary (inc. sensitivity analyses) 
N/A 
 
SAFETY AND TOLERABILITY ANALYSES 
 
Intervention exposure 
N/A 
 
All adverse events 
The PTNS treatment and sham have no recognised significant adverse effects. 
However, at each weekly visit each patient will be asked if they have suffered any 
side effects or adverse effects of the treatment. These will be documented and in the 
study database and reported to the data monitoring committee prior to each meeting 
with them. 
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Adverse events leading to withdrawal 
 
Serious adverse events 
 
Clinical laboratory evaluations 
 
SUBGROUP ANALYSES 
 
Definition of outcome measure 
 
Definition of subgroups 
 
Primary outcome –  
 Sex (male vs. female) 
 FI severity ( < or ≥ 7 episodes/wk) 
 
Secondary outcomes – 
 age (<40 years, 40 to 60 years, 60+ years),  
 
Sample size justification for the subgroup analysis 
None 
 
Descriptive analysis for subgroups 
 
Method of analysis 
 
An interaction term will be defined by multiplying the sub group dummy variables by 
the treatment assignment variable.  For age, a global test of the two interaction terms 
will be performed using a likelihood ratio test. 
 
AMENDMENTS TO VERSION 1.0 
  
 
  
-          
 not on the secondary outcomes as previously written.   
  
-           
 handle patients with fewer than 7 days of bowel diary data and the new code has   
replaced that previously in 14(a).  The code to define stool consistency outcomes was 
not included in version 1.0 and was developed during the analysis. 
  
-           
 during the analysis to include more detail and also the imputation model for the four   
 binary outcomes (primary (>= 50% reduction in FI) and three secondary (>=25%, 
>=75%, 100%)). 
 
REFERENCES 
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
104
 Kahan BC & Morris TP. Analysis of multicentre trials with continuous outcomes: 
when and how should we account for centre effects? Statist. Med 2013, 32 1136–1149 
 
Vaizey CJ, Carapeti E, Cahill JA, et al. Prospective comparison of faecal incontinence 
grading systems Gut 1999 44: 77-80 doi: 10.1136/gut.44.1.77 
APPENDICES  
 
Stata code for creating outcome variables 
 
*** Bowel diary data 
 
forvalues i = 1(1)14 { 
replace Q3_`i' = "" if Q3_`i' == "." 
encode Q3_`i', generate(x) 
drop Q3_`i' 
rename x Q3_`i' 
recode Q3_`i' (1=0)(2=1) 
label variable Q3_`i' YN 
 
replace Q4a_`i'="" if Q4a_`i' == "." 
encode Q4a_`i', generate(x) 
drop Q4a_`i' 
rename x Q4a_`i' 
recode Q4a_`i' (1=0)(2=1) 
label variable Q4a_`i' YN 
 
replace Q4b_`i'="" if Q4b_`i' == "." 
encode Q4b_`i', generate(x) 
drop Q4b_`i' 
rencode x Q4b_`i' 
recode Q4b_`i' (1=0)(2=1) 
label variable Q4b_`i' YN 
 
replace Q5_`i'="" if Q5_`i' == "." 
encode Q5_`i', generate(x) 
drop Q5_`i' 
rencode x Q5_`i' 
recode Q5_`i' (1=0)(2=1) 
label variable Q5_`i' YN 
 
generate x=real(Q1_`i') 
drop Q1_`i' 
rencode x Q1_`i' 
generate x=real(Q2a_`i') 
drop Q2a_`i' 
rencode x Q2a_`i' 
generate x=real(Q2b_`i') 
drop Q2b_`i' 
rencode x Q2b_`i' 
 
encode Q6_`i', generate(x) 
drop Q6_`i' 
rencode x Q6_`i' 
recode Q6_`i' (1=.)(6=0)(5=1)(4=2) 
label variable Q6_`i' consist 
 
DOI: 10.3310/hta19770 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 77
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Horrocks et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
105
} 
sort PIN 
compress 
 
egen controlled = rowtotal(Q1_1 Q1_2 Q1_3 Q1_4 Q1_5 Q1_6 Q1_7 Q1_8 
Q1_9 Q1_10 Q1_11 Q1_12 Q1_13 Q1_14), missing 
egen uncontrolled_a = rowtotal(Q2a_1 Q2a_2 Q2a_3 Q2a_4 Q2a_5 Q2a_6 
Q2a_7 Q2a_8 Q2a_9 Q2a_10 Q2a_11 Q2a_12 Q2a_13 Q2a_14), missing 
egen uncontrolled_b = rowtotal(Q2b_1 Q2b_2 Q2b_3 Q2b_4 Q2b_5 Q2b_6 
Q2b_7 Q2b_8 Q2b_9 Q2b_10 Q2b_11 Q2b_12 Q2b_13 Q2b_14), missing 
 
egen staining = rowtotal(Q3_1 Q3_2 Q3_3 Q3_4 Q3_5 Q3_6 Q3_7 Q3_8 Q3_9 
Q3_10 Q3_11 Q3_12 Q3_13 Q3_14), missing 
egen pads = rowtotal(Q4a_1 Q4a_2 Q4a_3 Q4a_4 Q4a_5 Q4a_6 Q4a_7 Q4a_8 
Q4a_9 Q4a_10 Q4a_11 Q4a_12 Q4a_13 Q4a_14), missing 
egen enema = rowtotal(Q4b_1 Q4b_2 Q4b_3 Q4b_4 Q4b_5 Q4b_6 Q4b_7 Q4b_8 
Q4b_9 Q4b_10 Q4b_11 Q4b_12 Q4b_13 Q4b_14), missing 
egen social = rowtotal(Q5_1 Q5_2 Q5_3 Q5_4 Q5_5 Q5_6 Q5_7 Q5_8 Q5_9 
Q5_10 Q5_11 Q5_12 Q5_13 Q5_14), missing 
egen stool = rowtotal(Q6_1 Q6_2 Q6_3 Q6_4 Q6_5 Q6_6 Q6_7 Q6_8 Q6_9 
Q6_10 Q6_11 Q6_12 Q6_13 Q6_14), missing 
 
egen m_unc_a = rowmiss(Q2a_1 Q2a_2 Q2a_3 Q2a_4 Q2a_5 Q2a_6 Q2a_7) 
egen m_unc_b = rowmiss(Q2b_1 Q2b_2 Q2b_3 Q2b_4 Q2b_5 Q2b_6 Q2b_7) 
 
generate FI_episodes = uncontrolled_a + uncontrolled_b 
generate FI_epi_pw = FI_episodes/2 
 
 
*** primary outcome  
 
generate Responder_50 = 1 if FI_epi_pw2/FI_epi_pw0<=.5 
replace Responder_50 = 0 if FI_epi_pw2/FI_epi_pw0>.5 & 
!missing(FI_epi_pw2) & !missing(FI_epi_pw0) 
 
*** binary secondary outcomes: 25%, 75%, 100% improvement 
generate Responder_25 = 1 if FI_epi_pw2/FI_epi_pw0<=.75 
replace Responder_25 = 0 if FI_epi_pw2/FI_epi_pw0>.75 & 
!missing(FI_epi_pw2) & !missing(FI_epi_pw0) 
 
generate Responder_75 = 1 if FI_epi_pw2/FI_epi_pw0<=.25 
replace Responder_25 = 0 if FI_epi_pw2/FI_epi_pw0>.25 & 
!missing(FI_epi_pw2) & !missing(FI_epi_pw0) 
 
generate Responder_100 = 1 if FI_epi_pw2==0 
replace Responder_100 = 0 if FI_epi_pw2>0 & !missing(FI_epi_pw2) 
 
 
*** Gastrointestinal quality of life 
 
renpfix x_ 
 
foreach var of varlist GI2 GI4 GI6 GI8 GI9 GI11 GI12 GI13 GI14 GI16 
GI18 GI20 GI22 GI24 GI26 GI28 GI30 GI32 GI34 GI36 { 
*** reverse scoring 
g x_`var'=1 if `var'==5 
replace x_`var'=2 if `var'==4 
replace x_`var'=3 if `var'==3 
replace x_`var'=4 if `var'==2 
replace x_`var'=5 if `var'==1 
drop `var' 
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} 
 
renpfix x_  
order GI1 GI2 GI3 GI4 GI5 GI6 GI7 GI8 GI9 GI10 GI11 GI12 GI13 GI14 
GI15 GI16 GI17 GI18 GI19 GI20 GI21 GI22 GI23 GI24 GI25 GI26 GI27 GI28 
GI29 /// 
  GI30 GI31 GI32 GI33 GI34 GI35 GI36  
egen GIQoL_tot=rowtotal(GI1-GI36), missing 
egen mGIQoL = rowmiss(GI1-GI36) 
replace GIQoL_tot =. if mGIQoL ~= 0 
 
 
*** EQ-5D 
 
rename EQ1 mob 
rename EQ2 self 
rename EQ3 usual 
rename EQ4 pain 
rename EQ5 mood 
rename EQ6 VAS 
 
gen EuroQol = 1 
replace EuroQol = 1-.069 if mob == 2 
replace EuroQol = 1-.314 if mob == 3 
replace EuroQol = EuroQol-.104 if self == 2 
replace EuroQol = EuroQol-.214 if self == 3 
replace EuroQol = EuroQol-.036 if usual == 2 
replace EuroQol = EuroQol-.094 if usual == 3 
replace EuroQol = EuroQol-.123 if pain == 2 
replace EuroQol = EuroQol-.386 if pain == 3 
replace EuroQol = EuroQol-.071 if mood == 2 
replace EuroQol = EuroQol-.236 if mood == 3 
replace EuroQol = EuroQol-.081 if (mob ~= 1 |self ~= 1|usual ~= 
1|pain ~= 1|mood ~= 1)&(mob ~= . & self ~= . & usual ~= . & pain ~= . 
& mood ~= .) 
replace EuroQol = EuroQol - .269 if mob == 3|self ==3 |usual ==3 
|pain == 3|mood == 3 
replace EuroQol=. if mob == .|self == .|usual == .|pain == .|mood == 
. 
egen itemEuro = rownonmiss(mob self usual pain mood) 
generate invalidEuro = 1 if itemEuro > 0 & itemEuro < 5 
replace invalidEuro = 0 if itemEuro == 5 
egen mEuroQol = rowmiss(mob self usual pain mood) 
 
 
 
*** Patient Centred Outcomes 
egen PC_tot=rowtotal(PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8), missing 
egen PC_mean=rowmean(PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8) 
egen mPC = rowmiss(PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8) 
replace PC_mean=. if mPC ~= 0 
 
*** St. Mark's FI scale 
recode CC1-CC4 (1=0)(2=1)(3=2)(4=3)(5=4) 
recode CC5 CC6 (1=0) 
recode CC7 (1=0)(2=4) 
egen CC_tot=rowtotal(CC1 CC2 CC3 CC4 CC5 CC6 CC7), missing 
egen mCC = rowmiss(CC1 CC2 CC3 CC4 CC5 CC6 CC7) 
replace CC_tot = . if mCC ~= 0 
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*** SF-36 
rename SF1 q1 
rename SF2 q2 
rename SF3a q3 
rename SF3b q4 
rename SF3c q5 
rename SF3d q6 
rename SF3e q7 
rename SF3f q8  
rename SF3g q9 
rename SF3h q10 
rename SF3i q11 
rename SF3j q12 
rename SF4a q13 
rename SF4b q14 
rename SF4c q15 
rename SF4d q16 
rename SF5a q17 
rename SF5b q18 
rename SF5c q19 
rename SF6 q20 
rename SF7 q21 
rename SF8 q22 
rename SF9a q23 
rename SF9b q24 
rename SF9c q25 
rename SF9d q26 
rename SF9e q27 
rename SF9f q28 
rename SF9g q29 
rename SF9h q30 
rename SF9i q31 
rename SF10 q32 
rename SF11a q33 
rename SF11b q34 
rename SF11c q35 
rename SF11d q36 
 
foreach var of varlist q1 q2 q20 q22 q34 q36 { 
generate `var'_value=100 if `var'==1 
replace `var'_value=75 if `var'==2 
replace `var'_value=50 if `var'==3 
replace `var'_value=25 if `var'==4 
replace `var'_value=0 if `var'==5 
} 
 
foreach var of varlist q3-q12 { 
generate `var'_value=0 if `var'==1 
replace `var'_value=50 if `var'==2 
replace `var'_value=100 if `var'==3 
} 
 
foreach var of varlist q13-q19 { 
generate `var'_value=0 if `var'==1 
replace `var'_value=100 if `var'==2 
} 
 
foreach var of varlist q21 q23 q26 q27 q30 { 
generate `var'_value=100 if `var'==1 
replace `var'_value=80 if `var'==2 
replace `var'_value=60 if `var'==3 
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replace `var'_value=40 if `var'==4 
replace `var'_value=20 if `var'==5 
replace `var'_value=0 if `var'==6 
} 
 
foreach var of varlist q24 q25 q28 q29 q31 { 
generate `var'_value=0 if `var'==1 
replace `var'_value=20 if `var'==2 
replace `var'_value=40 if `var'==3 
replace `var'_value=60 if `var'==4 
replace `var'_value=80 if `var'==5 
replace `var'_value=100 if `var'==6 
} 
 
foreach var of varlist q32 q33 q35 { 
generate `var'_value=0 if `var'==1 
replace `var'_value=25 if `var'==2 
replace `var'_value=50 if `var'==3 
replace `var'_value=75 if `var'==4 
replace `var'_value=100 if `var'==5 
} 
 
drop q1-q36 
 
egen SF36_PF = rowmean(q3_value q4_value q5_value q6_value q7_value 
q8_value q9_value q10_value q11_value q12_value) 
egen SF36_RLPH = rowmean(q13_value q14_value q15_value q16_value) 
egen SF36_RLEM = rowmean(q17_value q18_value q19_value) 
egen SF36_EF = rowmean(q23_value q27_value q29_value q31_value) 
egen SF36_EM = rowmean(q24_value q25_value q26_value q28_value 
q30_value) 
egen SF36_SF = rowmean(q20_value q32_value) 
egen SF36_P = rowmean(q21_value q22_value) 
egen SF36_GH = rowmean(q1_value q33_value q34_value q35_value 
q36_value) 
 
 
*** QoL FI scale 
 
generate FI1_rev=1 if FI1==5 
replace FI1_rev=2 if FI1==4 
replace FI1_rev=3 if FI1==3 
replace FI1_rev=4 if FI1==2 
replace FI1_rev=5 if FI1==1 
 
egen FIQoL_lif = rowmean(FI2a FI2b FI2c FI2d FI2e FI2g FI2h FI3b FI3l 
FI3m) 
egen FIQoL_cop = rowmean(FI2f FI2i FI2j FI2k FI2m FI3c FI3h FI3j 
FI3n) 
egen FIQoL_dep = rowmean(FI1_rev FI3d FI3f FI3g FI3i FI3k FI4) 
egen FIQoL_emb = rowmean(FI2l FI3a FI3e)  
 
egen mFIQoL_lif = rowmiss(FI2a FI2b FI2c FI2d FI2e FI2g FI2h FI3b 
FI3l FI3m) 
egen mFIQoL_cop = rowmiss(FI2f FI2i FI2j FI2k FI2m FI3c FI3h FI3j 
FI3n) 
egen mFIQoL_dep = rowmiss(FI1_rev FI3d FI3f FI3g FI3i FI3k FI4) 
egen mFIQoL_emb = rowmiss(FI2l FI3a FI3e)  
 
replace FIQoL_lif =. if mFIQoL_lif ~= 0 
replace FIQoL_cop =. if mFIQoL_cop ~= 0 
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replace FIQoL_dep =. if mFIQoL_dep ~= 0 
replace FIQoL_emb =. if mFIQoL_emb ~= 0 
 
Variables to be used in the multilevel multiple imputation 
 
Outcomes that are reported as a group of domains will be imputed together where 
possible.  Baseline measures, mid-treatment (bowel diary data only) and end of 
treatment outcomes will be included together in the multivariate response.  Centre is 
the only level 2 variable (random intercepts) 
 
 Imputation Variables 
Outcomes To include in multivariate response Auxillary variables 
Mean number of FI episodes per 
week 
Mean number of FI episodes per 
week, St Mark’s Continence Score, 
Likert 
Age, Sex and random allocation 
GI QOL Index (reported as total 
score 
Mean number of FI episodes per 
week, St Mark’s Continence Score, 
GI QOL 
Age, Sex and random allocation 
Patient centered outcomes form Patient centered outcomes form Age, Sex and random allocation 
SF-36 (eight domains) SF-36 (4 domains at a time) Age, Sex and random allocation 
Quality of life scale for FI (four 
domains) 
QOL for FI Age, Sex and random allocation 
St Marks Continence Score Mean number of FI episodes per 
week, St Mark’s Continence Score 
Age, Sex and random allocation 
EQ-5D EQ-5D Age, Sex and random allocation 
 
 
List of case report forms (see statistics master file for detail) 
 
□ 
□ 
□ 
□ 
□ 
□
□ 
□ 
□ 
□ 
□  
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Appendix 7 Data and Safety Monitoring
Committee input
Data Safety and Monitoring Committee meeting timings
and conclusions
Meeting 1: 6 February 2012
Conclusions
The DSMC agreed to meet at least 3 weeks prior to each TSC to enable sufficient time for analysis and
interpretation of data prior to reporting to the TSC. It was also recognised that safety was not really an
issue (owing to the nature of the treatment) and therefore the DSMC would concentrate on the ethical
basis of the trial, assessing whether or not it was being conducted according to the protocol and whether
or not it was able to answer the clinical question being asked. The timelines for future meetings were
agreed, with the next scheduled for 5 months later to enable sufficient data to be collected. The remaining
meetings would be at 4-monthly intervals. The author and format of the DSMC charter was agreed and
the method of providing unblinded data by an independent statistician was confirmed. The trial statistician
also agreed to draft the statistical analysis plan in time for the next DSMC meeting.
At subsequent meetings, the trial manager and trial statistician presented reports on the trial progress to
date and reviewed the open data report, with the DSMC making clarifications or further elaborating as
required. The DSMC then conducted their review of the unblinded report at a closed meeting and
reported their recommendations and conclusions to the TSC in writing.
Meeting 2: 24 October 2012
Recommendations
The covariates for analysis were discussed and the per protocol analysis definitions agreed. The DSMC
recommended that concomitant medications usage be presented by treatment arm but also by relevance
and irrelevance to the treatment of FI. The DSMC was concerned there might be a significant difference
in the drop-out rate between arms and agreed to monitor this and centre effects closely. The format of
the report was discussed, with recommendations made for presenting the data. It was requested that
the stratification factors for randomisation be included in the next report so that the DSMC could assess
balance in the randomisation. It was also requested that AEs and SAEs by allocation be included in the
next report.
Conclusions
The DSMC concluded that its remit should be to assure patient safety (although not a major concern in
this trial), to ensure that the treatment is not futile, to assess whether or not the outcomes are sensitive
enough to measure change and to ensure that the statistical analysis plan is fair and appropriate. The
committee was delighted with the general progress of the trial, noting that centres were opening rapidly
and recruitment increasing appropriately. For a challenging invasive functional bowel disease trial, the CRF
returns also seemed satisfactory. Review of the unblinded data revealed no specific concerns and the
DSMC was happy for the trial to progress.
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Meeting 3: 18 March 2013
Recommendations
The DSMC made several recommendations for the formatting and presentation of data, particularly with
regard to outcome data, AEs and withdrawals. The committee was interested in the data provided for
the use of constipating agents and the use of bowel medication. The DSMC recommended providing
an additional two tables: the first table to show ‘use of bowel medication’ at baseline and at end of
treatment; the second table to show the numbers of people who increased their intake of constipating
agents or decreased their intake of constipating agents, and the same for bowel medication, for each of
the two groups. Finally, the DSMC suggested meeting again in 6 months before database lock, so that a
final review of the data set could be performed and so the committee could contribute to the final report.
Conclusions
The DSMC was delighted with the conduct and the progress in the trial. Recruitment was running close to
target and the trial was likely to close in the summer of 2013. The DSMC was pleased to see that the
completeness of the data collection was good and no concerns were raised at the open meeting.
Meeting 4: 25 November 2013
Recommendations
The DSMC recommended that SAEs needed to be categorised into probably related and unrelated.
The committee suggested analysing men separately as well as together with women, owing to the small
number of men in the study. It was also noted that urinary symptoms in men and women were very
different and these should also be analysed separately because of different physiological processes.
The committee also recommended including data from centres where fewer than five patients had
been recruited and analysing with and without these data, conducting sensitivity analysis if required.
The committee expected that there was unlikely to be any centre effect.
Conclusions
The committee reviewed the confidential report and had no concerns over the data. The committee
congratulated the team on a very successful trial. The committee did not consider another meeting to
be necessary; however, the chairperson offered to look over the final data set.
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Appendix 8 Data and Safety Monitoring
Committee Charter
CHARTER FOR DATA MONITORING COMMITTEE FOR THE
CONFIdeNT STUDY
DRAFT FOR APPROVAL
Introduction
Study name
CONFIDeNT: CONtrol of Faecal Incontinence using Distal NeuromodulaTion.
Study registration
ISRCTN88559475.
Objectives of the study
To determine the effectiveness of PTNS versus sham electrical stimulation, based on (primary outcome)
reductions in weekly FIEs and on (secondary outcomes) improvements in validated incontinence scores and
other symptoms and quality-of-life measures.
Purpose of charter
The purpose of this document is to describe the roles and responsibilities of the independent Data and
Monitoring Ethics Committee (DMEC) for the CONFIDeNT study, including the timing of meetings, methods
of providing information to and from the TSC, frequency and format of meetings and statistical issues.
Roles and responsibilities of the Data Monitoring and
Ethics Committee
Broad statement of aim of committee
To protect and serve study participants (especially regarding safety) and to assist and advise the chief
investigator so as to protect the validity and credibility of the trial.
Terms of reference
The DMEC will receive and review interim results of the study.
The DMEC is responsible to the TSC of the study. Although it may choose to communicate interim results
or make recommendations, the final decisions about the study rest with the TSC.
During the period of recruitment to the study, data will be supplied to the Chair of the DMEC as
frequently as is requested. Meetings of the committee, either in person or by phone, will be arranged
periodically, as considered appropriate by the Chair.
In the light of the interim data, the DMEC will inform the TSC if, in their view, there is proof beyond
reasonable doubt that the data indicate that the treatment under investigation is either clearly indicated or
clearly contraindicated.
If the DMEC does choose to inform the TSC that in their view the situation described above pertains,
the TSC will consider modifying or stopping intake into the study. Unless modification or cessation is
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recommended by the DMEC, however, the TSC, collaborators and administrative staff (except staff who
produce the confidential analyses) will remain ignorant of the interim results.
Collaborators, and all others associated with the study, may write directly to the Chair of the DMEC, to
draw attention to any concern they may have about the possibility of harm arising from the use of the
treatment under study, or about any other matters that may be relevant.
Specific roles of Data Monitoring and Ethics Committee
These will include interim reviews of the trial’s progress including:
l updated figures on recruitment and losses to follow-up
l data quality, including completeness and adherence to protocol by participants and investigators
l evidence for treatment harm, for example safety data and adverse events
l advice on any protocol modifications suggested by investigators or sponsors.
Before or early in the trial
Before the start of recruitment, the TSC met with the DMEC to discuss various aspects of the trial and
protocol. All DMEC members had the opportunity to see the study protocol, and will have the opportunity
to comment on the contents of this charter.
Among the points raised, it was suggested that a draft statistical analysis plan be drafted for the next
DMEC meeting. Other points raised, relevant to the DMEC, are mentioned later in this document.
Composition of Data Monitoring and Ethics Committee and
relationship to trial steering committee
Membership and size
The members are independent of the trial, and include a clinician and a statistician.
The members of the CONFIDeNT DMEC are:
Professor Dion Morton (chair)
Professor of Surgery
Academic Department of Surgery
University of Birmingham
Queen Elizabeth Hospital
Mindelsohn Way
Edgebaston
Birmingham, B15 2WB
E-mail: XX
Professor Elaine Denny (independent member)
Professor of Health Sociology
Birmingham City University
City North Campus
Birmingham, B42 2SU
E-mail: XX
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Dr Dan Altmann (independent statistician)
Senior Lecturer in Medical Statistics
Department of Medical Statistics
London School of Hygiene & Tropical Medicine
Keppel Street
London, WC1E 7HT
E-mail: XX
The responsibilities of the trial statistician
The trial statistician, Dr Stephen Bremner, in consultation with the senior trialstatistician Professor Sandra
Eldridge, will organise the interim reports to the DMEC. These reports will contain unblinded data,
although the trial statistician will not see the unblinded version. It is not expected that the trial statistician
will need to participate in DMEC meetings, but he should be available to respond to any queries arising
from the interim reports.
Payment to Data Monitoring and Ethics Committee members
Members will be reimbursed for travel to and from DMEC meetings if required.
Competing interests
Data Monitoring and Ethics Committee members should disclose to the TSC any competing interests, not
restricting to financial matters. DMEC members will respect the confidentiality of the interim reports, and
will not use interim results to influence or inform financial trading. The format for a short competing
interests form is given in Annex 1, and should be completed by DMEC members and returned to the chief
investigator [CI].
Organisation of Data Monitoring and Ethics Committee meetings
Timing of data monitoring and ethics committee meetings
The first DMEC meeting should be at 5 months, and will be held in Birmingham; subsequently meetings
will be held 3 to 4 weeks prior to planned TSC meetings. The format of subsequent DMEC meetings will
be decided by DMEC.
Trial documentation and procedures to ensure confidentiality
and proper communication
It is anticipated that the first interim report for DMEC, organised by the trial statistician, should contain
data presented, where possible, by unblinded trial allocation group, to include (1) recruitment flow chart
(showing attendance at scheduled visits and any reported non-adherence and withdrawal from the trial);
(2) primary and secondary outcomes; and (3) adverse events and any other safety-related data. A dummy
report before the first DMEC meeting, although helpful, is not necessary. Changes to format or content
may be requested by DMEC for subsequent DMEC meetings.
Access to the accumulating data and interim results
Data and Safety Monitoring Committee members do not have the right to share confidential information
with anyone outside the DMEC, including the CI and named applicants.
Responsibility for identifying and circulating external evidence
Identification and circulation of external evidence (e.g. from other trials/systematic reviews) is not the
responsibility of the DMEC members. The TSC will usually collate any such information if appropriate.
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To whom the data monitoring and ethics committee will communicate the
decisions/recommendations that are reached
The DMEC will report its recommendations in writing to the TSC, copying to the trial statistician, in time
for consideration at the next TSC meeting. It is hoped and anticipated that, routinely, if the trial is to
continue largely unchanged, then a note from the DMEC Chair back to TSC along the lines given in
Annex 2 will be sufficient response.
Ensuring safety of confidential papers
The DMEC members should store interim report papers safely after each meeting so they may check the
next report against them. After the trial is reported, the DMEC members should destroy all interim reports.
Decision-making
What decisions/recommendations will be open to the Data Monitoring and
Ethics Committee?
Possible recommendations could include:
l no action needed, trial continues as planned
l early stopping as a result, for example, of clear benefit or harm of a treatment, futility or
external evidence
l extending recruitment (based on actual control arm response rates being different to predicted)
or extending follow-up
l sanctioning and/or proposing protocol changes.
Statistical methods
Any planned interim analyses should be tabled by the trial statistician before the first DMEC meeting for
discussion and agreement.
How decisions or recommendations will be reached within the Data
Monitoring and Ethics Committee
Data Monitoring and Ethics Committee members must agree on a process of decision-making, including
whether or not there will be voting or other formal or informal methods of achieving consensus.
Every effort should be made by the DMEC to reach a unanimous decision. If the DMEC cannot achieve
this, a vote may be taken, although details of the vote should not be routinely included in the report to
the TSC, as these may inappropriately convey information about the state of the trial data. It is important
that the implications (e.g. ethical, statistical, practical, financial) for the trial be considered before any
recommendation is made.
When the Data Monitoring and Ethics Committee is quorate for decision-making
Owing to the relatively small size of the DMEC, decisions should involve all three members, but not
necessarily at a face-to-face meeting: teleconference or e-mail contact may be sufficient. DMEC members
who will not be able to attend a planned face-to-face meeting may pass comments to the DMEC Chair for
consideration during any discussions.
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Reporting
Minutes of meetings
Separate minutes of DMEC meetings will be taken by the Chair of the DMEC. The DMEC Chair must sign
off all minutes.
What will be done if there is disagreement between the Data Monitoring
and Ethics Committee and the trial steering committee?
If the DMEC has serious problems or concerns with the TSC decision, a meeting of these groups should be
held. The information to be shown would depend upon the action proposed and the DMEC’s concerns.
Depending on the reason for the disagreement confidential data may have to be revealed to all those
attending such a meeting. The meeting should be chaired by a senior member of the TSC or an external
expert who is not directly involved with the trial. The funder may be invited to such meetings.
After the trial
Publication of results
At the end of the trial there will be a meeting to allow the DMEC to discuss the final data with the chief
investigator and give advice about data interpretation.
The information about the Data Monitoring and Ethics Committee that will
be included in published trial reports
Data Monitoring and Ethics Committee members will be named and their affiliations listed in the main trial
report, unless they explicitly request otherwise. A brief summary of the timings and conclusions of DMEC
meetings should be included in the body of this paper.
Will the Data Monitoring and Ethics Committee have the opportunity to
comment on publications before submission?
The DMEC will be given an opportunity to read and comment on any publication before it is submitted.
Constraints on Data and Safety Monitoring Committee members divulging
information about their deliberations after the trial has been published
The DMEC may discuss issues from their involvement in the trial 12 months after the primary trial results
have been published.
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Annex 1 Competing interests form
Potential competing interests of DMEC members for CONFIDeNT, ISRCTN88559475.
The avoidance of any perception that members of a DMEC may be biased in some fashion is important for
the credibility of the decisions made by the DMEC and for the integrity of the CONFIDeNT study. Possible
competing interests should be disclosed: in many cases simple disclosure should be sufficient. Otherwise,
the DMEC member should remove the conflict or stop participating in the DMEC. Table 18 lists potential
competing interests.
Please complete the following section and return to the Chief Investigator.
______ No, I have no competing interests to declare
______ Yes, I have competing interests to declare (please detail below)
Please provide details of any competing interests:
_____________________________________________________________
Name: _______________________________
Signed: ______________________________ Date: ________________
TABLE 18 Potential competing interests
Stock ownership in any commercial companies involved
Stock transaction in any commercial company involved (if previously holding stock)
Consulting arrangements with the sponsor
Frequent speaking engagements on behalf of the intervention
Career tied up in a product or technique assessed by trial
Hands-on participation in the trial
Involvement in the running of the trial
Emotional involvement in the trial
Intellectual conflict, for example strong prior belief in the trial’s experimental arm
Involvement in regulatory issues relevant to the trial procedures
Investment (financial or intellectual) in competing products
Involvement in the publication
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Annex 2 Suggested report from the Data Monitoring and Ethics
Committee to the Trial Steering Committee where no
recommendations are being made
BOX 1 Suggested report from the DMEC to the TSC where no recommendations are being made
[Insert date]
To: Chair of Trial Steering Committee
Dear [Chair of Trial Steering Committee]
The Data Monitoring and Ethics Committee (DMEC) for the [insert trial name] trial met on [meeting date]
to review its progress and interim accumulating data. [List members] attended the meeting and reviewed
the report.
The trial question remains important and, on the basis of the data reviewed at this stage, we recommend
continuation of the trial according to the current version of the protocol [specify protocol version number and
date] with no changes.
We shall next review the progress and data [provide approximate timing]
Yours sincerely,
[Name of meeting Chair]
Chair of Data Monitoring and Ethics Committee
On behalf of the DMEC (all members listed below)
DMEC members:
(1) [Insert name and role]
(2) [Insert name and role]
(3) [Insert name and role]
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Appendix 9 Patient and public involvement
The CONFIDeNT trial has had active collaboration with the Bowel & Cancer Research charity from theearly stages of the trial and throughout trial implementation and dissemination of results. The chief
executive of this charity has been a lay representative on the TSC and has been influential in portraying the
lay understanding and interpretation of trial materials, reviewing the trial protocol and patient information
material, and aiding in the production of a lay summary of trial results for dissemination to patients and
user groups, a copy of which will be published on the Bowel & Cancer Research charity website.
The researchers recognise that there was limited patient and public involvement in the development of the
research question, in the grant application and in the review of patient materials because of the lack of an
established patient and public involvement network at the time of trial design. Through linking with the
Bowel & Cancer Research charity, and in collaboration with the National Centre for Bowel Research and
Surgical Innovation, we have strengthened our patient and public involvement position for future trials by
establishing a patient and public involvement group and now have an established patient and public
involvement group with over 70 members. This group is specifically interested in areas of bowel research
being conducted in the centre, including FI and constipation, inflammatory bowel diseases such as Crohn’s
disease and ulcerative colitis, bowel cancer and stomas. Now that this database of patient and public
involvement members has been established, we are able to consult members for feedback on surveys and
questionnaires, on trial design and acceptability and on acceptability of documentation developed for
patients, including advertising materials, patient information sheets, diaries and questionnaires, as well as
able to invite members for inclusion in TSCs and attendance at meetings and workshops.
This collaboration held a highly successful event at Barts and the London School of Medicine and Dentistry
in December 2012 to showcase the research being undertaken within the centre. Members of the PPI
group were invited to attend and patient representatives were also invited to speak about experience
participating in research. A similar event was run in April 2015, which involved more interactive workshops
to aid understanding of what it means to be involved in a patient and public involvement group and
deliver training on the various tasks that may be undertaken as a patient and public involvement member.
Finally, should HTA funding be agreed, we plan to develop a ‘pod’ and live science show at the Centre of
the Cell. This is a centre for public engagement which ‘combines an award-winning interactive science
centre plus live science shows, workshops, debates, science talks and a widening participation for East
London and beyond’.82 We have been in initial discussions with the Centre of the Cell, and have come up
with some fantastic ideas on how to disseminate the results of this trial while raising awareness of bowel
problems such as FI and try to improve education about the healthy bowel. As part of this, we plan to
develop a high-tech, multimedia, interactive pod show for children. This will provide longevity in
disseminating the message of preventing bowel disease from an early age and also educate children on
the type of medical research undertaken to help prevent and treat bowel disease.
The following text is a lay summary of the CONFIDeNT trial results, which has been edited by our patient
and public involvement group and will be sent out to all trial participants:
Thank you very much for participating in this important research project.
The aim of the study was to assess the effectiveness of PTNS (percutaneous tibial nerve stimulation)
compared to placebo or sham (pretend) electrical stimulation treatment in reducing FIEs.
In total, 227 patients from 17 NHS hospitals across the UK were involved in the study. Half of
the patients had PTNS treatment and half had sham treatment, each undergoing a course of
12 treatments over 12 weeks. We recorded your faecal incontinence episodes before treatment
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commencement, after 6 treatments and at the end of 12 treatments. Your treatment was deemed
successful if you experienced a 50% or more reduction in faecal incontinence episodes as recorded on
bowel diaries. We also measured changes in your quality of life from questionnaires.
This study is now complete and we write to you to share the results. There was no significant
difference between the number of patients in each group who experienced a 50% or more reduction
in faecal incontinence episodes. In the PTNS group, 38% of patients had successful treatment and in
the sham group 31% of patients had successful treatment. This does not amount to a significant
difference between the two groups. There was also no difference in improvement in quality of life
between the group that received real PTNS and those that received sham treatment.
Further analysis did however show that patients experienced a significant reduction in the overall
number of faecal incontinence episodes in the PTNS group, and this did not happen in the sham
group. This seemed to be a reduction in the ‘rush’ type episodes rather than the ‘no warning’
type episodes. This could be important for tailoring future treatment and further research into this
area is required.
The results of this study will be shared with doctors and other medical practitioners through national
and international conferences in a detailed scientific report.
If you would like to read more about these findings, please refer to the lay summary of results on the
Bowel & Cancer Research Charity website www.bowelcancerresearch.org. A full detailed report will be
available on the funder’s website, National Institute of Health Research www.nihr.ac.uk.
Once again thank you for your participation, without which we could not have completed the study.
We enclose with this letter an invitation for your continued involvement in our patient and public
involvement group (PPI group) and do hope you may be interested in working with us in the future to
promote public awareness and engagement with research, particularly in the area of bowel diseases.
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Appendix 10 Raw data
TABLE 19 Main bowel diary outcomes at baseline and at end of treatment
Outcome PTNS Sham Total
Total weekly FIEs at baseline
n 111 108 219
Mean (SD) 9.9 (11.2) 10.4 (10.9) 10.2 (11.0)
Median (IQR) 6.0 (2.0–14.0) 6.9 (2.5–16.0) 6.5 (2.0–14.6)
Minimum to maximum 0.0 to 57.0 0.0 to 71.0 0.0 to 71.0
Urge FIEs per week at baseline
n 114 109 223
Mean (SD) 5.3 (7.2) 4.8 (5.9) 5.1 (6.6)
Median (IQR) 3.0 (0.9–8.0) 2.5 (0.5–7.0) 3.0 (0.5–7.0)
Minimum to maximum 0.0 to 42.5 0.0 to 41.0 0.0 to 42.5
Passive FIEs per week at baseline
n 112 108 220
Mean (SD) 4.6 (6.0) 5.7 (7.6) 5.2 (6.8)
Median (IQR) 2.0 (0.0–7.5) 3.0 (0.0–8.0) 2.5 (0.0–7.5)
Minimum to maximum 0.0 to 27.0 0.0 to 43.0 0.0 to 43.0
Total weekly FIEs after treatment
n 105 104 209
Mean (SD) 6.4 (7.6) 9.1 (10.7) 7.7 (9.3)
Median (IQR) 3.5 (1.0–10.0) 4.8 (1.5–12.8) 4.0 (1.0–11.0)
Minimum to maximum 0.0 to 44.5 0.0 to 43.5 0.0 to 44.5
Urge FIEs per week after treatment
n 106 105 211
Mean (SD) 3.0 (4.2) 4.4 (6.5) 3.7 (5.5)
Median (IQR) 1.5 (0.0–4.5) 1.5 (0.5–5.5) 1.5 (0.0–4.5)
Minimum to maximum 0.0 to 23.5 0.0 to 35.5 0.0 to 35.5
Passive FIEs per week after treatment
n 105 105 210
Mean (SD) 3.4 (4.6) 4.7 (6.6) 4.0 (5.8)
Median (IQR) 1.5 (0.0–5.0) 1.5 (0.0–6.5) 1.5 (0.0–5.5)
Minimum to maximum 0.0 to 21.0 0.0 to 33.5 0.0 to 33.5
IQR, interquartile range; SD, standard deviation.
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TABLE 20 St Mark’s Continence Scores (baseline and end of treatment)
Outcome PTNS Sham Total
SMCS at baseline
n 110 101 211
Mean (SD) 14.4 (3.7) 15.4 (4.1) 14.9 (3.9)
Median (IQR) 14.0 (12.0–17.0) 16.0 (13.0–18.0) 15.0 (13.0–18.0)
Minimum to maximum 5.0 to 22.0 5.0 to 24.0 5.0 to 24.0
SMCS after treatment
n 104 101 205
Mean (SD) 13.9 (4.3) 14.6 (4.6) 14.3 (4.4)
Median (IQR) 14.0 (11.0–17.0) 15.0 (11.0–18.0) 14.0 (11.0–18.0)
Minimum to maximum 6.0 to 23.0 5.0 to 24.0 5.0 to 24.0
IQR, interquartile range; SD, standard deviation.
TABLE 21 Patient characteristics and past medical history
Outcome PTNS (N= 115) Sham (N= 112) Total (N= 227)
Sex
Male 11 (10%) 11 (10%) 22 (10%)
Female 104 (90%) 101 (90%) 205 (90%)
Age (years)
n 115 112 227
Mean (SD) 57.8 (12.4) 56.5 (12.1) 57.2 (12.2)
Median (IQR) 58.0 (50.0–67.0) 58.0 (48.0–65.0) 58.0 (49.0–66.0)
Minimum to maximum 20.0 to 85.0 23.0 to 79.0 20.0 to 85.0
Duration of symptoms (months)
n 112 110 222
Mean (SD) 112.6 (117.5) 79.7 (88.4) 96.3 (105.2)
Median (IQR) 60.0 (24.0–168.0) 48.0 (24.0–108.0) 60.0 (24.0–120.0)
Minimum to maximum 5.0 to 600.0 6.0 to 540.0 5.0 to 600.0
Number of vaginal deliveries
n 90 96 186
Mean (SD) 2.3 (1.2) 2.4 (1.1) 2.4 (1.2)
Median (IQR) 2.0 (2.0–3.0) 2.0 (2.0–3.0) 2.0 (2.0–3.0)
Minimum to maximum 1.0 to 7.0 1.0 to 7.0 1.0 to 7.0
Caesarean deliveries
No, n (%) 90 (95) 96 (100) 186 (97)
Yes, n (%) 5 (5) 0 (0) 5 (3)
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TABLE 21 Patient characteristics and past medical history (continued )
Outcome PTNS (N= 115) Sham (N= 112) Total (N= 227)
Obstetric history
No, n (%) 9 (9) 5 (5) 14 (7)
Yes, n (%) 95 (91) 96 (95) 191 (93)
Episiotomy/tear
No, n (%) 12 (13) 14 (15) 26 (14)
Yes, n (%) 78 (87) 82 (85) 160 (86)
Previous biofeedback
No, n (%) 56 (50) 48 (45) 104 (47)
Yes, n (%) 56 (50) 59 (55) 115 (53)
Previous sphincter repair
No, n (%) 101 (91) 101 (94) 202 (92)
Yes, n (%) 10 (9) 7 (6) 17 (8)
Previous treatment (other), n (%) 18 (17) 21 (21) 39 (19)
Increased stool frequency, n (%) 69 (61) 69 (62) 138 (62)
Urgency to pass stool, n (%) 99 (90) 99 (88) 198 (89)
Passive FI, n (%) 88 (77) 86 (77) 174 (77)
Urge FI, n (%) 94 (82) 93 (83) 187 (82)
Flatus incontinence, n (%) 74 (64) 83 (74) 157 (69)
Evacuatory difficulties, n (%) 44 (39) 49 (44) 93 (41)
Straining, n (%) 34 (30) 37 (33) 71 (31)
Prolapse, n (%) 4 (4) 8 (7) 12 (5)
Soils underwear, n (%) 104 (91) 103 (92) 207 (92)
Use pads, n (%) 77 (67) 73 (65) 150 (66)
Unable to defer defecation, n (%) 52 (47) 43 (41) 95 (44)
Unable to distinguish faeces from flatus, n (%) 44 (38) 38 (35) 82 (36)
Sense of rectal blockage or bulge, n (%) 21 (18) 22 (20) 43 (19)
Digitation required, n (%) 12 (10) 15 (13) 27 (12)
Anxiety/panic, n (%) 75 (65) 84 (75) 159 (70)
Urinary symptom history, n (%) 70 (61) 72 (64) 142 (63)
Increased frequency of urine, n (%) 44 (38) 43 (38) 87 (38)
Urinary urgency, n (%) 50 (43) 49 (44) 99 (44)
Urinary stress incontinence, n (%) 43 (37) 42 (38) 85 (37)
Urinary urge incontinence, n (%) 39 (34) 42 (38) 81 (36)
Other urinary symptoms, n (%) 15 (14) 12 (12) 27 (13)
IQR, interquartile range; SD, standard deviation.
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TABLE 22 Bowel diary data at baseline
Outcome PTNS (N= 115) Sham (N= 111) Total (N= 226)
Total weekly FIEs at baseline
n 111 108 219
Mean (SD) 9.9 (11.2) 10.4 (10.9) 10.2 (11.0)
Median (IQR) 6.0 (2.0–14.0) 6.9 (2.5–16.0) 6.5 (2.0–14.6)
Minimum to maximum 0.0 to 57.0 0.0 to 71.0 0.0 to 71.0
Urge FIEs per week at baseline
n 114 109 223
Mean (SD) 5.3 (7.2) 4.8 (5.9) 5.1 (6.6)
Median (IQR) 3.0 (0.9–8.0) 2.5 (0.5–7.0) 3.0 (0.5–7.0)
Minimum to maximum 0.0 to 42.5 0.0 to 41.0 0.0 to 42.5
Passive FIEs per week at baseline
n 112 108 220
Mean (SD) 4.6 (6.0) 5.7 (7.6) 5.2 (6.8)
Median (IQR) 2.0 (0.0–7.5) 3.0 (0.0–8.0) 2.5 (0.0–7.5)
Minimum to maximum 0.0 to 27.0 0.0 to 43.0 0.0 to 43.0
Controlled defecations per week at baseline
n 115 111 226
Mean (SD) 13.2 (12.2) 12.4 (9.5) 12.8 (11.0)
Median (IQR) 11.0 (4.7–17.5) 10.5 (6.5–17.0) 11.0 (6.0–17.0)
Minimum to maximum 0.0 to 83.5 0.0 to 51.5 0.0 to 83.5
Days of underwear staining per week at baseline
n 114 110 224
Mean (SD) 3.8 (2.2) 4.0 (2.4) 3.9 (2.3)
Median (IQR) 3.7 (2.0–6.0) 4.5 (2.0–6.0) 4.0 (2.0–6.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days using pad per week at baseline
n 112 106 218
Mean (SD) 3.6 (3.2) 3.7 (3.3) 3.6 (3.3)
Median (IQR) 4.5 (0.0–7.0) 4.3 (0.0–7.0) 4.5 (0.0–7.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days with an enema per week at baseline
n 112 107 219
Mean (SD) 0.3 (1.1) 0.2 (0.7) 0.2 (0.9)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
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TABLE 22 Bowel diary data at baseline (continued )
Outcome PTNS (N= 115) Sham (N= 111) Total (N= 226)
Days per week stool was mostly solid at baseline
n 108 109 217
Mean (SD) 2.6 (2.5) 2.6 (2.2) 2.6 (2.3)
Median (IQR) 2.0 (0.0–4.8) 2.3 (0.5–3.8) 2.0 (0.5–4.2)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days per week stool was mostly mushy at baseline
n 108 109 217
Mean (SD) 0.8 (1.4) 1.0 (1.4) 0.9 (1.4)
Median (IQR) 0.0 (0.0–1.2) 0.0 (0.0–1.5) 0.0 (0.0–1.4)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days per week stool was mostly liquid at baseline
n 108 109 217
Mean (SD) 3.5 (2.3) 3.4 (2.1) 3.5 (2.2)
Median (IQR) 3.5 (1.8–5.5) 3.5 (2.0–5.0) 3.5 (1.9–5.3)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
IQR, interquartile range; SD, standard deviation.
Patients must have at least 7 days of data for a bowel diary outcome to be computed at baseline.
TABLE 23 Other secondary outcomes at baseline
Outcome PTNS (N= 115) Sham (N= 112) Total (N= 227)
GIQoL at baseline
n 98 98 196
Mean (SD) 126.7 (18.8) 123.8 (20.2) 125.3 (19.5)
Median (IQR) 130.0 (113.0–41.0) 126.5 (109.0–139.0) 128.0 (112.0–140.0)
Minimum to maximum 78.0 to 162.0 68.0 to 160.0 68.0 to 162.0
EQ-5D at baseline
n 115 109 224
Mean (SD) 0.69 (0.27) 0.63 (0.34) 0.66 (0.31)
Median (IQR) 0.73 (0.62–0.85) 0.73 (0.62–0.85) 0.73 (0.62–0.85)
Minimum to maximum –0.18 to 1.00 –0.24 to 1.00 –0.24 to 1.00
SMCS at baseline
n 110 101 211
Mean (SD) 14.4 (3.7) 15.4 (4.1) 14.9 (3.9)
Median (IQR) 14.0 (12.0–17.0) 16.0 (13.0–18.0) 15.0 (13.0–18.0)
Minimum to maximum 5.0 to 22.0 5.0 to 24.0 5.0 to 24.0
continued
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TABLE 23 Other secondary outcomes at baseline (continued )
Outcome PTNS (N= 115) Sham (N= 112) Total (N= 227)
Patient-centred outcomes at baseline
n 100 92 192
Mean (SD) 8.5 (1.6) 8.7 (1.7) 8.6 (1.7)
Median (IQR) 8.9 (7.8–9.8) 9.2 (8.3–10.0) 9.0 (8.0–9.9)
Minimum to maximum 1.9 to 10.0 1.6 to 10.0 1.6 to 10.0
SF-36 physical functioning at baseline
n 108 107 215
Mean (SD) 65.7 (27.4) 61.4 (28.4) 63.6 (27.9)
Median (IQR) 70.0 (45.0–90.0) 65.0 (40.0–85.0) 70.0 (40.0–85.0)
Minimum to maximum 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0
SF-36 role-physical at baseline
n 111 107 218
Mean (SD) 46.4 (42.1) 36.4 (41.4) 41.5 (41.9)
Median (IQR) 50.0 (0.0–100.0) 25.0 (0.0–75.0) 25.0 (0.0–100.0)
Minimum to maximum 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0
SF-36 bodily pain at baseline
n 113 112 225
Mean (SD) 61.3 (30.0) 58.2 (31.5) 59.8 (30.7)
Median (IQR) 60.0 (40.0–90.0) 57.5 (32.5–90.0) 57.5 (32.5–90.0)
Minimum to maximum 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0
SF-36 general health at baseline
n 114 108 222
Mean (SD) 51.2 (23.4) 50.3 (23.8) 50.8 (23.6)
Median (IQR) 50.0 (35.0–70.0) 50.0 (30.0–70.0) 50.0 (35.0–70.0)
Minimum to maximum 0.0 to 100.0 0.0 to 95.0 0.0 to 100.0
SF-36 vitality at baseline
n 108 104 212
Mean (SD) 43.9 (22.1) 42.7 (22.8) 43.3 (22.4)
Median (IQR) 45.0 (30.0–57.5) 50.0 (30.0–60.0) 50.0 (30.0–60.0)
Minimum to maximum 0.0 to 85.0 0.0 to 95.0 0.0 to 95.0
SF-36 social functioning at baseline
n 115 112 227
Mean (SD) 58.4 (28.8) 59.3 (31.6) 58.8 (30.1)
Median (IQR) 62.5 (37.5–75.0) 62.5 (37.5–87.5) 62.5 (37.5–87.5)
Minimum to maximum 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0
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TABLE 23 Other secondary outcomes at baseline (continued )
Outcome PTNS (N= 115) Sham (N= 112) Total (N= 227)
SF-36 role-emotional function at baseline
n 113 111 224
Mean (SD) 56.3 (43.0) 48.9 (44.2) 52.7 (43.7)
Median (IQR) 66.7 (0.0–100.0) 33.3 (0.0–100.0) 66.7 (0.0–100.0)
Minimum to maximum 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0
SF-36 mental health at baseline
n 109 106 215
Mean (SD) 60.3 (21.0) 60.8 (21.6) 60.6 (21.3)
Median (IQR) 60.0 (44.0–76.0) 64.0 (48.0–76.0) 64.0 (44.0–76.0)
Minimum to maximum 12.0 to 100.0 0.0 to 96.0 0.0 to 100.0
FIQoL lifestyle at baseline
n 93 92 185
Mean (SD) 2.6 (0.9) 2.6 (1.0) 2.6 (1.0)
Median (IQR) 2.7 (1.8–3.4) 2.5 (1.7–3.6) 2.7 (1.7–3.5)
Minimum to maximum 1.0 to 4.0 1.0 to 4.0 1.0 to 4.0
FIQoL coping at baseline
n 79 77 156
Mean (SD) 1.9 (0.7) 1.9 (0.9) 1.9 (0.8)
Median (IQR) 1.7 (1.2–2.3) 1.6 (1.1–2.6) 1.7 (1.2–2.4)
Minimum to maximum 1.0 to 4.0 1.0 to 4.0 1.0 to 4.0
FIQoL depression at baseline
n 75 81 156
Mean (SD) 2.8 (0.9) 2.7 (0.9) 2.8 (0.9)
Median (IQR) 3.1 (2.0–3.4) 2.6 (2.0–3.7) 2.9 (2.0–3.6)
Minimum to maximum 1.1 to 4.1 1.0 to 4.1 1.0 to 4.1
FIQoL embarrassment at baseline
n 110 106 216
Mean (SD) 2.2 (0.8) 2.1 (0.8) 2.1 (0.8)
Median (IQR) 2.0 (1.7–2.7) 2.0 (1.3–2.7) 2.0 (1.3–2.7)
Minimum to maximum 1.0 to 4.0 1.0 to 3.7 1.0 to 4.0
IQR, interquartile range; SD, standard deviation.
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TABLE 24 Bowel diary data mid-treatment
Outcome PTNS (N= 110) Sham (N= 110) Total (N= 220)
Total weekly FIEs mid-treatment
n 97 99 196
Mean (SD) 6.1 (7.6) 9.6 (11.5) 7.8 (9.9)
Median (IQR) 4.0 (1.0–9.0) 6.0 (1.0–14.0) 4.0 (1.0–10.0)
Minimum to maximum 0.0 to 46.0 0.0 to 51.0 0.0 to 51.0
Urge FIEs per week mid-treatment
n 102 102 204
Mean (SD) 3.3 (4.3) 4.4 (6.3) 3.9 (5.4)
Median (IQR) 2.0 (0.0–5.0) 2.0 (0.0–7.0) 2.0 (0.0–6.0)
Minimum to maximum 0.0 to 25.0 0.0 to 29.0 0.0 to 29.0
Passive FIEs per week mid-treatment
n 100 102 202
Mean (SD) 3.0 (4.6) 5.0 (7.3) 4.0 (6.2)
Median (IQR) 1.0 (0.0–4.5) 1.0 (0.0–8.0) 1.0 (0.0–6.0)
Minimum to maximum 0.0 to 24.0 0.0 to 37.0 0.0 to 37.0
Controlled defecations per week mid-treatment
n 104 102 206
Mean (SD) 13.0 (11.5) 11.4 (7.6) 12.2 (9.8)
Median (IQR) 11.0 (6.0–15.5) 10.0 (7.0–15.0) 10.0 (7.0–15.0)
Minimum to maximum 0.0 to 84.0 0.0 to 44.0 0.0 to 84.0
Days of underwear staining per week mid-treatment
n 99 97 196
Mean (SD) 3.3 (2.3) 3.4 (2.6) 3.4 (2.5)
Median (IQR) 3.0 (1.0–5.0) 3.0 (1.0–6.0) 3.0 (1.0–6.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days using pad per week mid-treatment
n 99 99 198
Mean (SD) 3.7 (3.2) 3.8 (3.4) 3.8 (3.3)
Median (IQR) 4.0 (0.0–7.0) 7.0 (0.0–7.0) 5.5 (0.0–7.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days using an enema per week mid-treatment
n 95 97 192
Mean (SD) 0.2 (0.7) 0.2 (0.8) 0.2 (0.8)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Minimum to maximum 0.0 to 4.0 0.0 to 7.0 0.0 to 7.0
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TABLE 24 Bowel diary data mid-treatment (continued )
Outcome PTNS (N= 110) Sham (N= 110) Total (N= 220)
Days per week stool was mostly solid mid-treatment
n 65 70 135
Mean (SD) 3.2 (2.3) 3.2 (2.4) 3.2 (2.3)
Median (IQR) 3.0 (1.0–5.0) 3.0 (1.0–5.0) 3.0 (1.0–5.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days per week stool was mostly mushy mid-treatment
n 65 70 135
Mean (SD) 0.5 (1.0) 1.0 (1.7) 0.8 (1.4)
Median (IQR) 0.0 (0.0–1.0) 0.0 (0.0–2.0) 0.0 (0.0–1.0)
Minimum to maximum 0.0 to 4.0 0.0 to 7.0 0.0 to 7.0
Days per week stool was mostly liquid mid-treatment
n 65 70 135
Mean (SD) 3.3 (2.4) 2.8 (2.6) 3.1 (2.5)
Median (IQR) 3.0 (2.0–5.0) 2.5 (0.0–5.0) 3.0 (0.0–5.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
IQR, interquartile range; SD, standard deviation.
Patients must have complete data on an outcome, that is 7 days, for the outcome to be computed.
TABLE 25 Bowel diary data at end of treatment
Outcome PTNS (N= 109) Sham (N= 108) Total (N= 217)
Primary outcome
≥ 50% reduction in FIEs, n (%) 39 (38) 32 (31) 71 (35)
≥ 25% reduction in FIEs, n (%) 51 (50) 46 (45) 97 (47)
≥ 75% reduction in FIEs, n (%) 26 (25) 17 (17) 43 (21)
100% reduction in FIEs, n (%) 11 (11) 7 (7) 18 (9)
Total weekly FIEs after treatment
n 105 104 209
Mean (SD) 6.4 (7.6) 9.1 (10.7) 7.7 (9.3)
Median (IQR) 3.5 (1.0–10.0) 4.8 (1.5–12.8) 4.0 (1.0–11.0)
Minimum to maximum 0.0 to 44.5 0.0 to 43.5 0.0 to 44.5
Urge FIEs per week after treatment
n 106 105 211
Mean (SD) 3.0 (4.2) 4.4 (6.5) 3.7 (5.5)
Median (IQR) 1.5 (0.0–4.5) 1.5 (0.5–5.5) 1.5 (0.0–4.5)
Minimum to maximum 0.0 to 23.5 0.0 to 35.5 0.0 to 35.5
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TABLE 25 Bowel diary data at end of treatment (continued )
Outcome PTNS (N= 109) Sham (N= 108) Total (N= 217)
Passive FIEs per week after treatment
n 105 105 210
Mean (SD) 3.4 (4.6) 4.7 (6.6) 4.0 (5.8)
Median (IQR) 1.5 (0.0–5.0) 1.5 (0.0–6.5) 1.5 (0.0–5.5)
Minimum to maximum 0.0 to 21.0 0.0 to 33.5 0.0 to 33.5
Controlled defecations per week after treatment
n 104 107 211
Mean (SD) 13.0 (9.9) 11.6 (9.2) 12.3 (9.6)
Median (IQR) 11.0 (7.0–16.3) 10.5 (5.5–15.5) 11.0 (6.5–16.0)
Minimum to maximum 0.0 to 67.0 0.0 to 68.5 0.0 to 68.5
Days of underwear staining per week after treatment
n 106 106 212
Mean (SD) 3.1 (2.2) 3.3 (2.5) 3.2 (2.4)
Median (IQR) 2.5 (1.0–4.5) 3.0 (1.0–6.0) 2.8 (1.0–5.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days using pad per week after treatment
n 103 103 206
Mean (SD) 3.6 (3.2) 3.6 (3.3) 3.6 (3.3)
Median (IQR) 4.0 (0.0–7.0) 4.5 (0.0–7.0) 4.3 (0.0–7.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days using an enema per week after treatment
n 103 102 205
Mean (SD) 0.4 (1.3) 0.2 (0.9) 0.3 (1.1)
Median (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days per week stool was mostly solid after treatment
n 100 106 206
Mean (SD) 3.6 (2.4) 3.0 (2.4) 3.3 (2.4)
Median (IQR) 3.5 (1.7–5.5) 3.0 (0.5–5.1) 3.2 (1.0–5.4)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days per week stool was mostly mushy after treatment
n 100 106 206
Mean (SD) 0.7 (1.3) 0.9 (1.5) 0.8 (1.4)
Median (IQR) 0.0 (0.0–0.8) 0.0 (0.0–1.1) 0.0 (0.0–1.0)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
Days per week stool was mostly liquid after treatment
n 100 106 206
Mean (SD) 2.7 (2.1) 3.1 (2.1) 2.9 (2.1)
Median (IQR) 2.5 (1.1–4.0) 3.0 (1.5–4.5) 2.9 (1.4–4.5)
Minimum to maximum 0.0 to 7.0 0.0 to 7.0 0.0 to 7.0
IQR, interquartile range; SD, standard deviation.
Patients must have at least 7 days of data for a bowel diary outcome to be computed at end of treatment.
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TABLE 26 Other secondary outcomes after treatment
Outcome PTNS (N= 107) Sham (N= 107) Total (N= 214)
GIQoL after treatment
n 95 91 186
Mean (SD) 132.0 (20.6) 131.6 (20.5) 131.8 (20.5)
Median (IQR) 135.0 (115.0–48.0) 134.0 (120.0–146.0) 134.5 (118.0–148.0)
Minimum to maximum 86.0 to 167.0 74.0 to 171.0 74.0 to 171.0
EQ-5D after treatment
n 108 106 214
Mean (SD) 0.68 (0.28) 0.65 (0.34) 0.67 (0.31)
Median (IQR) 0.76 (0.62–0.85) 0.73 (0.56–0.85) 0.73 (0.62–0.85)
Minimum to maximum –0.02 to 1.00 –0.24 to 1.00 –0.24 to 1.00
Patient-centred outcomes after treatment
n 87 85 172
Mean (SD) 7.8 (2.0) 8.4 (2.1) 8.1 (2.1)
Median (IQR) 8.4 (6.9–9.4) 9.3 (7.6–10.0) 8.8 (7.0–9.8)
Minimum to maximum 1.0 to 10.0 1.0 to 10.0 1.0 to 10.0
SMCS after treatment
n 104 101 205
Mean (SD) 13.9 (4.3) 14.6 (4.6) 14.3 (4.4)
Median (IQR) 14.0 (11.0–17.0) 15.0 (11.0–18.0) 14.0 (11.0–18.0)
Minimum to maximum 6.0 to 23.0 5.0 to 24.0 5.0 to 24.0
SF-36 physical functioning after treatment
n 96 105 201
Mean (SD) 67.1 (27.7) 63.8 (29.0) 65.4 (28.4)
Median (IQR) 75.0 (47.5–90.0) 70.0 (45.0–90.0) 70.0 (45.0–90.0)
Minimum to maximum 5.0 to 100.0 0.0 to 100.0 0.0 to 100.0
SF-36 role-physical after treatment
n 108 106 214
Mean (SD) 54.4 (44.1) 46.2 (44.8) 50.4 (44.6)
Median (IQR) 62.5 (0.0–100.0) 25.0 (0.0–100.0) 50.0 (0.0–100.0)
Minimum to maximum 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0
SF-36 bodily pain after treatment
n 109 109 218
Mean (SD) 64.3 (28.3) 62.1 (31.0) 63.2 (29.6)
Median (IQR) 67.5 (45.0–90.0) 67.5 (35.0–90.0) 67.5 (37.5–90.0)
Minimum to maximum 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0
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TABLE 26 Other secondary outcomes after treatment (continued )
Outcome PTNS (N= 107) Sham (N= 107) Total (N= 214)
SF-36 general health after treatment
n 107 105 212
Mean (SD) 52.8 (24.6) 50.6 (23.9) 51.7 (24.2)
Median (IQR) 55.0 (30.0–75.0) 50.0 (35.0–70.0) 50.0 (30.0–70.0)
Minimum to maximum 0.0 to 100.0 0.0 to 95.0 0.0 to 100.0
SF-36 vitality after treatment
n 105 104 209
Mean (SD) 45.6 (22.2) 46.7 (23.1) 46.1 (22.6)
Median (IQR) 50.0 (25.0–60.0) 50.0 (35.0–65.0) 50.0 (30.0–60.0)
Minimum to maximum 0.0 to 100.0 0.0 to 95.0 0.0 to 100.0
SF-36 social functioning after treatment
n 109 109 218
Mean (SD) 66.4 (28.6) 60.6 (31.7) 63.5 (30.3)
Median (IQR) 75.0 (50.0–87.5) 62.5 (37.5–87.5) 62.5 (37.5–87.5)
Minimum to maximum 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0
SF-36 role-emotional after treatment
n 108 108 216
Mean (SD) 61.7 (45.3) 60.2 (44.1) 61.0 (44.6)
Median (IQR) 100.0 (0.0–100.0) 83.3 (0.0–100.0) 100.0 (0.0–100.0)
Minimum to maximum 0.0 to 100.0 0.0 to 100.0 0.0 to 100.0
SF-36 mental health after treatment
n 101 107 208
Mean (SD) 62.7 (25.1) 63.0 (21.4) 62.8 (23.2)
Median (IQR) 64.0 (48.0–84.0) 64.0 (52.0–76.0) 64.0 (52.0–84.0)
Minimum to maximum 4.0 to 100.0 0.0 to 100.0 0.0 to 100.0
FIQoL lifestyle after treatment
n 90 88 178
Mean (SD) 2.8 (0.9) 2.8 (1.0) 2.8 (1.0)
Median (IQR) 3.0 (2.2–3.7) 2.9 (1.9–3.7) 2.9 (2.0–3.7)
Minimum to maximum 1.0 to 4.0 1.0 to 4.0 1.0 to 4.0
FIQoL coping after treatment
n 68 71 139
Mean (SD) 2.0 (0.8) 2.0 (1.0) 2.0 (0.9)
Median (IQR) 1.9 (1.3–2.6) 1.7 (1.2–2.9) 1.8 (1.2–2.9)
Minimum to maximum 1.0 to 4.0 1.0 to 4.0 1.0 to 4.0
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TABLE 26 Other secondary outcomes after treatment (continued )
Outcome PTNS (N= 107) Sham (N= 107) Total (N= 214)
FIQoL depression after treatment
n 64 64 128
Mean (SD) 2.9 (1.0) 2.8 (1.0) 2.9 (1.0)
Median (IQR) 3.1 (2.2–3.7) 2.6 (2.0–3.9) 2.9 (2.1–3.9)
Minimum to maximum 1.0 to 4.4 1.1 to 4.4 1.0 to 4.4
FIQoL embarrassment after treatment
n 102 102 204
Mean (SD) 2.4 (0.8) 2.3 (0.9) 2.3 (0.9)
Median (IQR) 2.7 (1.7–3.0) 2.3 (1.7–3.0) 2.3 (1.7–3.0)
Minimum to maximum 1.0 to 4.0 1.0 to 4.0 1.0 to 4.0
Likert scale of success after treatment
n 110 107 217
Mean (SD) 4.0 (3.3) 3.2 (3.1) 3.6 (3.2)
Median (IQR) 4.8 (0.0–6.8) 2.1 (0.0–4.9) 3.4 (0.0–6.0)
Minimum to maximum 0.0 to 10.0 0.0 to 10.0 0.0 to 10.0
Do you think you had PTNS or sham?
Sham, n (%) 48 (46) 71 (69) 119 (57)
PTNS, n (%) 57 (54) 32 (31) 89 (43)
Did you have any adverse events?
No, n (%) 95 (87) 88 (81) 183 (84)
Yes, n (%) 14 (13) 20 (19) 34 (16)
Was there any effect on urinary symptoms?
No urinary incontinence, n (%) 47 (44) 41 (39) 88 (41)
Made it worse, n (%) 11 (10) 5 (5) 16 (8)
No effect, n (%) 42 (39) 52 (50) 94 (44)
Slight improvement, n (%) 6 (6) 5 (5) 11 (5)
Substantial improvement, n (%) 2 (2) 2 (2) 4 (2)
What was your loperamide use?
Did not use, n (%) 25 (34) 33 (46) 58 (40)
Decreased, n (%) 14 (19) 4 (6) 18 (12)
Same, n (%) 33 (45) 32 (45) 65 (45)
Increased, n (%) 2 (3) 2 (3) 4 (3)
What was your pad use?
Did not use, n (%) 23 (29) 24 (33) 47 (31)
Decreased, n (%) 12 (15) 10 (14) 22 (15)
Same, n (%) 44 (56) 35 (49) 79 (52)
Increased, n (%) 0 (0) 3 (4) 3 (2)
IQR, interquartile range; SD, standard deviation.
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Appendix 11 Past medical history
TABLE 27 Numbers of patients with relevant past medical history
Outcome PTNS Sham
Hysterectomy 30 24
Vaginal operation 3 2
Pelvic operation 19 16
Abdominal operation 28 30
Anal operation 6 9
Sphincter repair 4 4
Neck or back pain or back problem 15 21
OAB or bladder incontinence 15 7
Constipation 1 0
Diarrhoea 1 0
Diverticular disease 4 6
FI 8 11
Irritable bowel syndrome 1 4
Crohn’s disease/proctitis 1 1
Abdominal problem 3 2
Perianal or anal problem 4 3
Anxiety/depression/psychiatric illness 22 24
Breast problem or cancer 8 2
Cardiovascular problem 34 27
ENT problem 7 5
Eye problem or operation 11 7
Fatigue/fibromyalgia/myalgic encephalopathy 6 4
Gynaecological problem 6 9
Haematological disorder 6 3
Headache/migraine 4 6
HIV infection or infectious disease 1 2
Metabolic disorder 0 4
Minor operation 1 5
Neurological problem 5 4
Orthopaedic problem 23 16
Respiratory problem 14 22
Rheumatological problem (other than back or neck pain) 22 16
Rhinitis or hay fever 3 7
Skin disorder 7 9
Thoracic operation 0 1
Upper GI reflux 20 18
ENT, ear, nose, throat; GI, gastrointestinal; HIV, human immunodeficiency virus.
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Appendix 12 Regular medications
TABLE 28 Numbers of patients receiving regular medication
Medication PTNS Sham
Codeine phosphate 5 4
Laxative 5 11
Loperamide 30 30
Analgesia 20 26
Antimalarial 0 1
Antibiotic/antiviral/antifungal 3 3
Antidepressant/antianxiety/psychological medication 34 24
Antihistamine 5 8
Autoimmune condition medication 2 3
Cardiovascular medication 31 24
Chemotherapy 2 0
Cold or flu remedy 0 0
Eye medication 8 4
Gynaecological medication 2 0
Metabolic medication 0 0
Neurological condition medication 4 6
Other GI medications 0 0
Respiratory medication 13 22
Skin condition medication 4 5
Urinary incontinence/OAB medication 7 7
Vaccine 0 0
GI, gastrointestinal.
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Appendix 13 European Quality of Life-5
Dimensions summary
ANALYSIS OF EUROPEAN QUALITY OF LIFE-5 DIMENSIONS DATA
FROM THE CONFIDeNT TRIAL
Background
European Quality of Life-5 Dimensions data have been collected as part of the CONFIDeNT trial comparing
PTNS against a sham treatment (TENS) alongside other patient-reported outcome (PRO) measures,
symptom diaries and clinical outcomes.
York Health Economics Consortium has been requested by Queen Mary, University of London to conduct a
basic statistical analysis of the EQ-5D (Option 1).
Methods and results
Methods
A Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) data file containing the data was provided
by Queen Mary, University of London. The data were anonymised and comprised a unique study code for
each patient, the group (PTNS or sham) to which the patients had been allocated, the EQ-5D data for two
time points (week 2 baseline and week 14 end of study), that is the raw scores for mobility, self-care, usual
activities, pain/discomfort, anxiety/depression, the EQ-5D VAS score and the EQ-5D index score. The data
were analysed using Stata 12.1 software. The descriptive statistics were derived for the EQ-5D VAS score
and EQ-5D index score, that is the average VAS scores and index scores for each arm of the trial at the
two time points and the differences between the two arms, as well as the standard deviations, 95% CIs
and the average change and standard deviation of change. Descriptive statistics were also derived for the
categorical (ordinal) data (EQ-5D raw scores), consisting of the category frequencies at the two time
points, as well as a cross-tabulation to highlight changes over time in EQ-5D scores.
Results
Data were available from 227 patients: 115 in the PTNS arm and 112 in the sham arm. The mean scores
by group (arm) over time are shown in Table 29.
It may be seen that there were virtually no differences between the two arms either at week 2 (baseline) or
at week 14 in respect of both the EQ-5D VAS scores and the EQ-5D index scores, with scores on both
scales remaining unchanged over time.
The mean change from baseline (difference between week 14 and week 2) is shown in Table 30, for the
EQ-5D VAS and the EQ-5D index scores. It may be seen that there was a slight decrease in EQ-5D VAS
and EQ-5D index scores for the PTNS from baseline. For the sham treatment, VAS score increased slightly
from baseline, whereas the index score remained almost unchanged.
The mean differences between the two groups are shown in Table 31. As may be seen from Table 31,
although the PTNS were marginally higher at each point, the differences in scores between the two groups
were minimal.
The cross-tabulations for the individual EQ-5D domains are shown in Table 32. Few changes were
observed for the mobility and self-care domains both over time and between the two groups, that is the
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TABLE 29 Mean scores by time point and group
Variable Group n Mean SD Minimum Maximum LCL UCL
VAS week 2 PTNS 114 64.50 21.72 5.00 100 60.51 68.49
VAS week 2 Sham 112 64.04 21.24 20.00 100 60.10 67.97
VAS week 14 PTNS 109 64.25 22.32 8.00 100 60.06 68.44
VAS week 14 Sham 109 63.69 23.66 10.00 100 59.25 68.13
Index week 2 PTNS 115 0.69 0.27 –0.18 1 0.64 0.74
Index week 2 Sham 109 0.63 0.34 –0.24 1 0.57 0.70
Index week 14 PTNS 108 0.68 0.28 –0.02 1 0.63 0.74
Index week 14 Sham 106 0.65 0.34 –0.24 1 0.59 0.72
LCL, lower confidence limit; SD, standard deviation; UCL, upper confidence limit.
TABLE 30 Mean change from baseline by group
Variable Group n Mean SD
VAS PTNS 108 –0.67 18.88
VAS Sham 109 0.32 23.74
Index PTNS 108 –0.01 0.23
Index Sham 105 0.02 0.25
SD, standard deviation.
TABLE 31 Mean differences between groups over time
Variable Mean difference SE LCL UCL
VAS week 2 0.46 2.86 –5.17 6.10
VAS week 14 0.56 3.12 –5.58 6.70
Index week 2 0.05 0.04 –0.03 0.13
Index week 14 0.03 0.04 –0.05 0.12
LCL, lower confidence limit; SE, standard error; UCL, upper confidence limit.
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TABLE 32 Cross-tabulation of individual EQ-5D domains between the two time points
Mobility week 2
Mobility week 14
PTNS Sham
1 2 3 Total 1 2 3 Total
1 69 4 0 73 63 9 0 72
2 7 29 0 36 6 29 0 35
3 0 0 0 0 0 0 0 0
Total 76 33 0 109 69 38 0 107
Self-care week 2
Self-care week 14
PTNS Sham
1 2 3 Total 1 2 3 Total
1 92 3 0 95 90 5 0 95
2 7 7 0 14 0 10 0 10
3 0 0 0 0 0 1 0 1
Total 99 10 0 109 90 16 0 106
Usual activities week 2
Usual activities week 14
PTNS Sham
1 2 3 Total 1 2 3 Total
1 48 7 0 55 42 15 0 57
2 16 31 0 47 13 27 1 41
3 0 5 2 7 3 3 3 9
Total 64 43 2 109 58 45 4 107
Pain/discomfort week 2
Pain/discomfort week 14
PTNS Sham
1 2 3 Total 1 2 3 Total
1 28 13 2 43 26 8 0 34
2 12 43 3 58 14 38 4 56
3 0 3 4 7 1 5 9 15
Total 40 59 9 108 41 51 13 105
Anxiety/depression week 2
Anxiety/depression week 14
PTNS Sham
1 2 3 Total 1 2 3 Total
1 34 13 0 47 37 12 0 49
2 14 33 8 55 11 25 7 43
3 0 5 2 7 1 7 7 15
Total 48 51 10 109 49 44 14 107
The numbers in the column and row headings represent the raw scores on the individual EQ-5D domains.
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vast majority of patients did not record any change for these two domains. These domains were also the
only two for which patients did not record the more severe scores.
A greater number of changes were recorded for the other three domains. For usual activities, 26% and
32% of scores changed from week 2 to week 14 for the PTNS and sham arms respectively; for
pain/discomfort the figures were 31% for both arms; and for anxiety/depression they were 28% and
35% respectively.
For anxiety/depression there was an almost equal percentage change observed for improvement (e.g. a
change from 3 to 2, or 2 to 1) and deterioration in scores (e.g. 1 to 2, or 2 to 3) between the PTNS and
sham arms. For improvement in scores, the percentage changes were 17% and 18% respectively (PTNS
and sham), and 19% and 18% for deterioration in scores. For usual activities, the percentage change in
improvement was virtually the same between groups: 19% for PTNS and 18% for sham. However, there
was a greater percentage of deterioration in usual activities for the sham group: 6% for PTNS and 15% for
sham. This pattern was reversed for pain/discomfort: 14% (PTNS) and 19% (sham) for improvement and
17% and 11% for deterioration.
Conclusions
The results demonstrated that there were no differences between the two arms, PTNS and sham, in terms
of patients’ overall health (EQ-5D VAS) or their health status (EQ-5D index score). Furthermore, there were
no changes in the overall scores on these two measures over time. Differences were observed for the
individual domains of the EQ-5D, particularly for usual activities, pain/discomfort and anxiety/depression.
Patients in the sham arm experienced a greater degree of deterioration in their usual activities than those
in the PTNS arm. However, in contrast to this, those patients in the PTNS arm reported a greater degree of
pain/discomfort, whereas those in the sham arm noted an improvement in their levels of pain/discomfort.
These results should be interpreted in the context of the other outcome measures derived in the study,
and with the caveat that the EQ-5D may not be sensitive to change in this patient population; however,
the results suggest that the PTNS treatment – although it may not have an impact on overall quality of
life – may improve patients’ usual activities, but perhaps at the cost of an increased degree of pain
or discomfort.
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Appendix 14 Concomitant medications
TABLE 33 Concomitant medications
Allocation Medication Indication Duration (days) Ongoing
PTNS Cocodamol Arm pain 4 No
PTNS Cocodamol Headache 1 No
PTNS Codydramol Leg pain 1 No
PTNS Coproxamol Pain n/a Yes
PTNS Coproxamol Neck pain 2 No
Sham Coproxamol Dental pain n/a Yes
Sham Cocodamol Leg pain 3 No
Sham Morphine Osteoarthritis
and fibromyalgia
n/a Yes
Sham Tramadol Fractured coccyx 14 No
Sham Tramadol Abdominal pain n/a Yes
Sham Tramadol Knee pain n/a Yes
Sham Tramadol Chest pain n/a Yes
PTNS Ispaghula husk (Fybogel®, Reckitt Benckiser) Unknown Unknown Unknown
PTNS Ispaghula husk (Fybogel®, Reckitt Benckiser) Diarrhoea 2 Yes
PTNS Klean-Prep® (Norgine, Helsinn-Birex
Pharmaceuticals Ltd)
Preparation for
colonoscopy
1 No
PTNS Klean-Prep® (Norgine, Helsinn-Birex
Pharmaceuticals Ltd)
Preparation for
colonoscopy
1 No
PTNS Sodium picosulfate with magnesium citrate
(Picolax®, Ferring)
Preparation for
colonoscopy
1 No
Sham Ispaghula husk (Fybogel®, Reckitt Benckiser) Constipation 7 No
Sham Lactulose Post surgery 8 No
Sham Lactulose Constipation Unknown No
n/a, not applicable.
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Appendix 15 Subgroup analyses
TABLE 34 Results of subgroups analysis on primary outcome (n= 227)
Outcome
Main treatment effect Interaction term(s)
Interaction
term global
p-value
PTNS vs.
sham, OR 95% CI p-value
Interaction
term 1, OR
95% CI
Interaction
term 2, OR 95% CI
Moderator Male vs. female
Sex (male
vs. female)
1.143 0.629 to
2.078
0.661 5.418 0.451 to
65.065
n/a n/a 0.183
≥ 7 FIEs per
week base
vs. < 7
1.177 0.535 to
2.590
0.686 1.212 0.389 to
3.776
n/a n/a 0.740
Age groups (years) 40–60 vs. < 40 > 60 vs. < 40
< 40, 40–60,
> 60
1.575 0.205 to
12.106
0.662 0.745 0.075 to
7.371
0.857 0.088 to
8.385
0.957
Type of incontinence
Urge only vs.
urge and
passive
Passive only
vs. urge
and passive
Urge or
passive
or both
1.589 0.730 to
3.456
0.243 0.824 0.185 to
3.675
0.424 0.090 to
1.995
0.554
n/a, not applicable; OR, odds ratio.
Odds ratio corresponds to the adjusted OR for PTNS vs. sham from a logistic mixed-effects model, adjusted for baseline
mean FIEs per week and sex, and includes a random effect for study centre. Missing data were multiply imputed using
multilevel multiple imputation to create 10 complete data sets for analysis, the results of which were combined using
Rubin’s rules.
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Appendix 16 Sensitivity analysis 1
TABLE 35 Results of sensitivity analysis (excludes 16 patients with no FIEs in baseline bowel diary)
Outcome Type n Estimate LCL UCL p-value Model-based ICC
≥ 50% reduction in FIEs
(primary outcome)
OR 211 1.325 0.736 2.385 0.348 < 0.001
≥ 25% reduction in FIEs OR 211 1.314 0.747 2.311 0.344 < 0.001
≥ 75% reduction in FIEs OR 211 1.643 0.775 3.484 0.195 0.212
100% reduction in FIEs OR 211 1.670 0.596 4.674 0.330 0.008
Change in FIEs Beta 211 –2.468 –4.533 –0.403 0.019 < 0.001
Change in rush FIEs Beta 211 –1.557 –2.881 –0.232 0.021 < 0.001
Change in passive leakage FIEs Beta 211 –0.736 –1.850 0.378 0.195 0.1
FIQoL embarrassment Beta 211 0.049 –0.149 0.247 0.630 < 0.001
FIQoL coping Beta 211 0.021 –0.172 0.214 0.831 0.116
FIQoL lifestyle Beta 211 0.105 –0.070 0.280 0.236 < 0.001
FIQoL depression Beta 211 0.025 –0.294 0.344 0.873 < 0.001
SF-36 physical functioning Beta 211 –2.025 –7.515 3.464 0.469 < 0.001
SF-36 role-physical Beta 211 1.646 –8.860 12.152 0.758 n/a
SF-36 bodily pain Beta 211 –1.039 –7.114 5.036 0.737 < 0.001
SF-36 general health Beta 211 0.159 –4.759 5.076 0.949 < 0.001
SF-36 vitality Beta 211 –2.930 –8.194 2.334 0.273 n/a
SF-36 social functioning Beta 211 6.343 0.010 12.676 0.051 0.017
SF-36 role emotional Beta 211 –5.461 –15.881 4.959 0.302 n/a
SF-36 mental health Beta 211 0.031 –4.477 4.540 0.989 0.065
SMCS Beta 211 –0.139 –1.163 0.885 0.790 < 0.001
Patient-centred outcomes Beta 211 –0.562 –1.123 –0.001 0.050 < 0.001
EQ-5D index score Beta 211 –0.017 –0.081 0.048 0.610 0.019
GIQoL Beta 211 –1.558 –5.566 2.449 0.442 n/a
Likert scale of success Beta 211 0.786 –0.123 1.694 0.091 0.009
LCL, lower confidence limit; n/a, not applicable; OR, odds ratio; UCL, upper confidence limit.
Odds ratio corresponds to the adjusted OR for PTNS vs. sham from a logistic mixed-effects model, adjusted for baseline
mean FIEs per week and sex, and includes a random effect for study centre. Beta corresponds to the adjusted difference in
means for PTNS vs. sham from a linear mixed-effects model, adjusted for baseline level of outcome (except Likert scale of
success) and sex, and includes a random effect for study centre. n/a indicates that the unconditional ICC was < 0 and the
corresponding outcomes were modelled using linear regression without an adjustment for study centre. Missing data were
multiply imputed using multilevel multiple imputation to create 10 complete data sets for analysis, the results of which
were combined using Rubin’s rules.
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Appendix 17 Sensitivity analysis 2
TABLE 36 Results of sensitivity analysis excluding centres that recruited fewer than five patients (two centres,
four patients)
Outcome Type n Estimate LCL UCL p-value Model-based ICC
≥ 50% reduction in FIEs
(primary outcome)
OR 223 1.234 0.693 2.196 0.476 < 0.001
≥ 25% reduction in FIEs OR 223 1.220 0.698 2.132 0.485 < 0.001
≥ 75% reduction in FIEs OR 223 1.634 0.776 3.438 0.196 0.214
100% reduction in FIEs OR 223 1.690 0.609 4.693 0.315 0.006
Change in FIEs Beta 223 –2.158 –4.034 –0.283 0.024 < 0.001
Change in rush FIEs Beta 223 –1.501 –2.752 –0.25 0.019 < 0.001
Change in passive leakage FIEs Beta 223 –0.592 –1.637 0.453 0.267 0.094
FIQoL embarrassment Beta 223 0.020 –0.166 0.206 0.83 < 0.001
FIQoL coping Beta 223 0.017 –0.168 0.203 0.855 0.1
FIQoL lifestyle Beta 223 0.092 –0.072 0.257 0.27 < 0.001
FIQoL depression Beta 223 0.010 –0.301 0.321 0.945 < 0.001
SF-36 physical functioning Beta 223 –1.479 –6.674 3.717 0.576 < 0.001
SF-36 role-physical Beta 223 1.462 –8.684 11.608 0.777 n/a
SF-36 bodily pain Beta 223 –0.844 –6.712 5.024 0.778 < 0.001
SF-36 general health Beta 223 –0.021 –4.676 4.634 0.993 < 0.001
SF-36 vitality Beta 223 –3.857 –8.875 1.161 0.131 n/a
SF-36 social functioning Beta 223 5.419 –0.585 11.423 0.078 0.012
SF-36 role emotional Beta 223 –5.297 –15.405 4.811 0.303 n/a
SF-36 mental health Beta 223 –0.877 –5.237 3.483 0.693 0.031
SMCS Beta 223 0.052 –0.928 1.032 0.917 < 0.001
Patient-centred outcomes Beta 223 –0.575 –1.121 –0.029 0.039 < 0.001
EQ-5D index score Beta 223 –0.020 –0.082 0.042 0.524 0.017
GIQoL Beta 223 –1.269 –5.182 2.643 0.521 n/a
Likert scale of success Beta 223 0.856 –0.016 1.728 0.055 0.02
LCL, lower confidence limit; n/a, not applicable; OR, odds ratio; UCL, upper confidence limit.
Odds ratio corresponds to the adjusted OR for PTNS vs. sham from a logistic mixed-effects model, adjusted for baseline
mean FIEs per week, sex and includes a random effect for study centre. Beta corresponds to the adjusted difference in
means for PTNS vs. sham from a linear mixed-effects model, adjusted for baseline level of outcome (except Likert scale of
success), sex and includes a random effect for study centre. n/a indicates that the unconditional ICC was < 0 and the
corresponding outcomes were modelled using linear regression without an adjustment for study centre. Missing data were
multiply imputed using multilevel multiple imputation to create 10 complete data sets for analysis, the results of which
were combined using Rubin’s rules.
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Appendix 18 Adverse events
TABLE 37 All adverse events in PTNS patients
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
ANT002 Orthopaedic injury – Unrelated 73 Moderate Other Resolved
ANT007 Bleeding Rectal Unrelated 1 Mild Other Resolved
ANT007 Cough/cold/flu – Unrelated – Mild Concomitant
medication
given
Unresolved
ANT011 Fall – Unrelated 1 Mild No action
taken
Resolved
ANT011 Fall – Unrelated 1 Mild No action
taken
Resolved
ANT019 Breast lump – Unrelated – Mild No action
taken
Unknown
ANT019 Vomiting/nausea – Unrelated 2 Mild No action
taken
Resolved
ANT028 Cough/cold/flu – Unrelated 4 Mild No action
taken
Resolved
ANT040 Pain Back Unrelated 8 Moderate No action
taken
Resolved
BLT002 Headache/migraine – Possible 8 Moderate Concomitant
medication
given
Resolved
BLT002 Infection Chest Unrelated 8 Moderate Concomitant
medication
given
Resolved
BLT002 Pain Arm Unrelated 3 Mild No action
taken
Resolved
BLT002 Pain Back Unrelated 2 Moderate Concomitant
medication
given
Resolved
BLT003 Allergic reaction – Unrelated 25 Mild Concomitant
medication
given
Resolved
BLT003 Dizziness – Possible 1 Mild No action
taken
Resolved
BLT003 Infection Tooth/
gum
Unrelated 6 Mild Concomitant
medication
given
Resolved
BLT005 Diarrhoea – Possible 3 Mild No action
taken
Resolved
BLT005 Infection Skin Unrelated 14 Mild No action
taken
Resolved
continued
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TABLE 37 All adverse events in PTNS patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
BLT005 Infection Urinary
tract
Unrelated 9 Mild Concomitant
medication
given
Resolved
BLT005 Pain Leg Unrelated 14 Mild No action
taken
Resolved
BLT018 Dizziness – Possible 23 Mild No action
taken
Resolved
BLT018 Infection Tooth/
gum
Unrelated 32 Mild Concomitant
medication
given
Resolved
BLT041 Bruising Needle
site
Related 14 Mild No action
taken
Resolved
BLT041 Cough/cold/flu – Unrelated 7 Mild No action
taken
Resolved
BLT041 Cough/cold/flu – Unrelated 12 Mild No action
taken
Resolved
BLT041 Infection Ear Unrelated 19 Mild Concomitant
medication
given
Resolved
BLT042 Cough/cold/flu – Unrelated 5 Mild Concomitant
medication
given
Unresolved
BLT042 Cough/cold/flu – Unrelated 17 Mild Concomitant
medication
given
Resolved
BLT053 Cough/cold/flu – Unrelated 8 Mild Concomitant
medication
given
Resolved
BLT053 Pain Leg Possible 1 Severe No action
taken
Resolved
BLT053 Pain Leg Possible – Moderate Concomitant
medication
given
Unresolved
BLT066 Orthopaedic injury – Unrelated 48 Moderate No action
taken
Resolved
BLT068 Pain Back Unrelated 17 Moderate No action
taken
Resolved
BLT074 Headache/migraine – Possible 2 Moderate Concomitant
medication
given
Resolved
BLT074 Infection Urinary
tract
Unrelated 15 Moderate No action
taken
Resolved
BLT074 Pain Leg Possible 3 Moderate No action
taken
Resolved
BLT074 Pain Foot Possible 21 Severe No action
taken
Resolved
BLT074 Pain Leg Possible 1 Moderate No action
taken
Resolved
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TABLE 37 All adverse events in PTNS patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
BLT074 Skin disorder – Possible 9 Mild No action
taken
Resolved
CHH006 Pain Arm Unrelated 5 Mild Concomitant
medication
given
Resolving
GST003 Pain Leg Possible 10 Mild No action
taken
Resolved
LGI003 Dizziness – Possible – Mild Other Unresolved
PHT003 Altered sensation Leg Possible – Mild No action
taken
Unresolved
PHT003 Altered sensation Leg Possible – Mild No action
taken
Unresolved
PHT003 Fall – Unrelated – Mild No action
taken
Unresolved
PHT004 Cough/cold/flu – Unrelated 21 Moderate No action
taken
Resolved
PHT004 Rheumatoid
arthritis
– Unrelated – Moderate Concomitant
medication
given
Unresolved
PHT008 Anxiety/
depression/
psychiatric illness
– Possible – Mild Concomitant
medication
given
Resolving
PHT009 Altered sensation Foot Possible 1 Mild No action
taken
Resolved
PHT009 Altered sensation Foot Possible 1 Mild No action
taken
Resolved
PHT009 Dizziness – Possible 1 Mild No action
taken
Resolved
PHT009 Pain Back Possible Mild No action
taken
Unresolved
QMC002 Pain Needle
site
Related 16 Mild Other Resolved
QMC003 Diarrhoea – Possible 5 Moderate No action
taken
Resolved
QMC003 Pain Needle
site
Related 22 Mild Other Resolved
SMH001 Cough/cold/flu – Unrelated 26 Mild Concomitant
medication
given
Resolved
SMH001 Headache/migraine – Possible 3 Mild Concomitant
medication
given
Resolved
SMH001 Pain Neck Unrelated 6 Mild Concomitant
medication
given
Resolved
continued
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TABLE 37 All adverse events in PTNS patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
SMH010 Bruising Needle
site
Related 8 Mild No action
taken
Resolved
SMH010 Dizziness – Possible 1 Mild No action
taken
Resolved
SMH010 Pain Abdomen Possible 9 Moderate No action
taken
Resolved
SOT005 Diarrhoea – Possible 3 Mild Concomitant
medication
given
Resolved
SOT009 Vomiting/nausea – Unrelated – Mild Concomitant
medication
given
Resolving
STH002 Headache/migraine – Possible – Severe Concomitant
medication
given
Resolved
STH006 Altered sensation Needle
site
Related 1 Mild No action
taken
Resolved
STH007 Cough/cold/flu – Unrelated 8 Mild Concomitant
medication
given
Resolved
STH007 Cough/cold/flu – Unrelated 8 Mild Concomitant
medication
given
Resolved
STH013 Pain Needle
site
Related – Mild No action
taken
Unknown
SWB002 Vitamin D
deficiency
– Unrelated – Mild Concomitant
medication
given
Unresolved
SWB010 Renal problem – Unrelated – Mild Concomitant
medication
given
Unresolved
SWB021 Diarrhoea – Possible 6 Mild No action
taken
Resolved
SWB022 Pain Toe Possible – Mild No action
taken
Unknown
SWB022 Vomiting/nausea – Unrelated 3 Moderate No action
taken
Resolved
SWB023 Pain Heel Possible 2 Mild No action
taken
Resolved
UCL004 Infection Chest Unrelated – Mild No action
taken
Resolving
UCL008 Headache/migraine – Possible 2 Moderate No action
taken
Resolved
UCL013 Pain Leg Possible 2 Mild No action
taken
Resolved
UCL016 Pain Leg Possible 2 Moderate Concomitant
medication
given
Resolved
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TABLE 37 All adverse events in PTNS patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
UCL016 Pain Needle
site
Related 2 Mild No action
taken
Resolved
UCL016 Vomiting/nausea – Unrelated 1 Mild No action
taken
Resolved
ULH003 Pain Breast Unrelated – Mild Concomitant
medication
given
Unresolved
ULH003 Upper GI reflux – Unrelated 64 Moderate Concomitant
medication
given
Resolved
ULH011 Bleeding Rectal Unrelated 1 Moderate No action
taken
Resolved
ULH014 Operative
procedure/
hospital procedure
– Unrelated 3 Moderate Hospitalisation Resolved
USM005 Diarrhoea – Possible 4 Mild No action
taken
Resolved
USM023 Skin disorder – Unrelated 9 Mild Other Resolved
USM025 Infection Tooth/
gum
Unrelated – Mild Concomitant
medication
given
Unknown
USM026 Fall – Unrelated 1 Mild No action
taken
Resolving
USM030 Pain Heel Possible – Moderate No action
taken
Unresolved
WCU001 Pain Abdomen Possible 3 Mild No action
taken
Resolved
WCU004 Altered sensation Arm Unrelated 1 Moderate No action
taken
Resolved
WCU004 Infection Urinary
tract
Unrelated 6 Mild Concomitant
medication
given
Resolved
WCU004 Pain Toe Possible 1 Moderate No action
taken
Resolved
WCU004 Pain Leg Possible 1 Moderate No action
taken
Resolved
WCU010 Diarrhoea – Possible 2 Mild No action
taken
Resolved
WCU011 Bleeding Rectal Unrelated 1 Moderate Concomitant
medication
given
Unresolved
WCU011 Pain Abdomen Possible 4 Mild No action
taken
Resolved
WCU012 Pain Abdomen Possible – Mild No action
taken
Unresolved
continued
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TABLE 37 All adverse events in PTNS patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
WCU014 Infection Chest Unrelated 6 Mild Concomitant
medication
given
Resolved
WCU021 Infection Urinary
tract
Unrelated 11 Mild Concomitant
medication
given
Unknown
WCU021 Vomiting/nausea – Unrelated 2 Mild No action
taken
Resolved
WCU033 Diarrhoea – Possible 1 Severe Concomitant
medication
given
Unknown
WCU033 Operative
procedure/hospital
procedure
– Unrelated 1 Severe Hospitalisation Resolved
WCU038 Headache/migraine – Possible 2 Moderate Concomitant
medication
given
Resolved
WCU038 Skin disorder – Unrelated 4 Mild No action
taken
Resolved
WCU043 Pain Groin Unrelated 1 Moderate No action
taken
Resolved
WCU043 Pain Ear Unrelated 3 Moderate No action
taken
Resolved
WCU049 Diarrhoea – Possible – Mild No action
taken
Resolved
GI, gastrointestinal.
TABLE 38 All adverse events in sham patients
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
ANT001 Skin disorder – Unrelated – Moderate No action
taken
Unknown
ANT008 Pain Leg Possible 70 Mild No action
taken
Resolved
ANT014 Operative
procedure/
hospital
procedure
– Unrelated 1 Mild Concomitant
medication
given
Resolved
ANT018 Altered sensation Toe Related 1 Mild No action
taken
Resolved
ANT038 Operative
procedure/
hospital
procedure
– Unrelated 8 Moderate No action
taken
Resolved
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TABLE 38 All adverse events in sham patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
ANT041 Infection Chest Unrelated 8 Mild Concomitant
medication
given
Resolved
ANT041 Orthopaedic injury – Unrelated 15 Moderate Concomitant
medication
given
Resolved
ANT044 Upper GI reflux – Unrelated – Moderate Concomitant
medication
given
Resolving
BLT001 Cough/cold/flu – Unrelated 3 Mild Concomitant
medication
given
Resolved
BLT001 Diarrhoea – Possible 2 Moderate No action
taken
Resolved
BLT013 Bruising Needle site Related 5 Mild No action
taken
Resolved
BLT013 Infection Chest Unrelated 19 Moderate Concomitant
medication
given
Resolved
BLT013 Pain Ankle Possible 8 Mild No action
taken
Resolved
BLT019 Altered sensation Perineum Possible 1 Mild No action
taken
Resolved
BLT019 Altered sensation Perineum Possible 1 Mild No action
taken
Resolved
BLT019 Operative
procedure/
hospital
procedure
– Unrelated 1 Moderate No action
taken
Resolved
BLT019 Orthopaedic injury – Unrelated 3 Mild No action
taken
Resolved
BLT019 Pain Shoulder Unrelated 2 Mild Concomitant
medication
given
Resolved
BLT026 Cough/cold/flu – Unrelated 14 Moderate Concomitant
medication
given
Resolved
BLT026 Cough/cold/flu – Unrelated 4 Mild Concomitant
medication
given
Resolved
BLT026 Urinary symptoms – Possible 1 Mild No action
taken
Resolved
BLT031 Headache/
migraine
– Possible 3 Mild No action
taken
Resolved
BLT031 Pain Back Unrelated – Moderate Concomitant
medication
given
Unresolved
continued
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TABLE 38 All adverse events in sham patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
BLT046 Cough/cold/flu – Unrelated 7 Mild No action
taken
Resolved
BLT046 Diarrhoea – Possible 2 Mild No action
taken
Resolved
BLT046 Pain Abdomen Possible 13 Mild No action
taken
Resolved
BLT046 Pain Abdomen Possible 22 Mild No action
taken
Resolved
BLT046 Urinary symptoms – Possible – Moderate No action
taken
Resolving
BLT051 Cough/cold/flu – Unrelated 5 Mild Concomitant
medication
given
Resolved
BLT051 Headache/
migraine
– Possible 1 Moderate No action
taken
Resolved
BLT058 Altered sensation Lip Unrelated 8 Mild No action
taken
Resolved
CHH002 Diarrhoea – Possible 1 Mild No action
taken
Resolved
CHH004 Infection Tooth/gum Unrelated 8 Mild Concomitant
medication
given
Resolving
LRI002 Pain Leg Possible 3 Mild Concomitant
medication
given
Resolved
LRI002 Skin disorder – Unrelated 3 Moderate Concomitant
medication
given
Resolved
LRI006 Anxiety/
depression/
psychiatric illness
– Possible – Moderate Other Unresolved
LRI007 Headache/
migraine
– Possible 5 Moderate Concomitant
medication
given
Resolved
PHT005 Upper GI reflux – Unrelated – Moderate Concomitant
medication
given
Unresolved
PHT006 Bleeding Rectal Unrelated 2 Mild No action
taken
Resolved
PHT010 Pain Back Unrelated 1 Mild No action
taken
Resolving
QMC001 Infection Skin Unrelated 8 Mild No action
taken
Resolved
QMC001 Pain Needle site Related – Mild No action
taken
Resolved
QMC001 Pain Needle site Related 30 Mild No action
taken
Resolved
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TABLE 38 All adverse events in sham patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
QMC004 Infection Chest Unrelated 9 Mild Concomitant
medication
given
Resolved
SMH007 Cough/cold/flu – Unrelated 156 Mild Concomitant
medication
given
Resolved
SMH007 Urinary symptoms – Possible – Mild No action
taken
Unknown
SMH013 Pain Leg Possible 11 Moderate Concomitant
medication
given
Unresolved
SOT002 Infection Chest Unrelated 6 Moderate Concomitant
medication
given
Resolved
STH012 Pain Leg Possible – Moderate No action
taken
Unknown
SWB016 Infection Chest Unrelated 7 Mild Concomitant
medication
given
Resolved
SWB020 Headache/
migraine
– Possible 6 Severe Concomitant
medication
given
Resolved
SWB020 Headache/
migraine
– Possible – Mild No action
taken
Unknown
UCL002 Infection Chest Unrelated 8 Mild Concomitant
medication
given
Resolving
UCL006 Infection Chest Unrelated 4 Moderate Concomitant
medication
given
Resolving
UCL006 Infection Cold sores Unrelated 6 Mild Concomitant
medication
given
Resolving
UCL010 Cough/cold/flu – Unrelated 9 Mild Concomitant
medication
given
Resolved
UCL012 Skin disorder – Unrelated 8 Mild No action
taken
Unresolved
ULH001 Infection Urinary
tract
Unrelated 6 Moderate Concomitant
medication
given
Resolved
ULH001 Infection Chest Unrelated 7 Moderate Concomitant
medication
given
Resolved
ULH006 Infection Urinary
tract
Unrelated 8 Moderate Concomitant
medication
given
Resolved
continued
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TABLE 38 All adverse events in sham patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
ULH007 Infection Chest Unrelated 8 Moderate Concomitant
medication
given
Resolved
ULH009 Bleeding Rectal Unrelated 3 Mild No action
taken
Resolved
ULH013 Water retention – Unrelated – Mild No action
taken
Resolved
ULH018 Operative
procedure/
hospital
procedure
– Unrelated 1 Mild No action
taken
Unknown
ULH018 Operative
procedure/
hospital
procedure
– Unrelated 1 Moderate No action
taken
Unknown
ULH018 Operative
procedure/
hospital
procedure
– Unrelated 3 Mild No action
taken
Unknown
ULH022 Bleeding Needle site Related 4 Mild No action
taken
Resolved
USM019 Upper GI reflux – Unrelated – Mild Concomitant
medication
given
Resolving
USM022 Infection Urinary
tract
Unrelated 8 Mild Concomitant
medication
given
Resolved
USM022 Upper GI reflux – Unrelated – Moderate Concomitant
medication
given
Unknown
USM028 Fall – Unrelated 1 Moderate No action
taken
Resolved
USM028 Pain Leg Possible 11 Moderate No action
taken
Resolved
USM028 Vomiting/nausea – Possible 6 Moderate No action
taken
Resolved
USM032 Infection Diverticulitis Unrelated 14 Moderate Concomitant
medication
given
Resolved
WCU003 Weakness Leg Possible 1 Moderate No action
taken
Resolved
WCU006 FI – Possible 4 Mild No action
taken
Resolved
WCU006 Infection Skin Unrelated Mild Other Unknown
WCU006 Skin disorder – Unrelated 1 Mild No action
taken
Resolved
WCU008 Infection Skin Unrelated 26 Moderate Hospitalisation Resolved
WCU008 Operative
procedure/
hospital
procedure
– Unrelated 1 Severe Hospitalisation Resolved
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TABLE 38 All adverse events in sham patients (continued )
Personal
information
number Adverse event Site Related
Duration
(days) Grade Action taken Outcome
WCU008 Vomiting/nausea – Unrelated 2 Mild No action
taken
Resolved
WCU017 Pain Rib Unrelated 1 Severe Concomitant
medication
given
Resolving
WCU017 Pain Rib Unrelated – Severe Concomitant
medication
given
Resolving
WCU018 Constipation – Possible – Mild Concomitant
medication
given
Unresolved
WCU018 Headache/
migraine
– Possible 2 Mild Concomitant
medication
given
Resolved
WCU018 Pain Perineum Possible 2 Moderate No action
taken
Resolved
WCU018 Pain Leg Possible 1 Moderate No action
taken
Resolved
WCU018 Pain Leg Possible 1 Moderate No action
taken
Resolved
WCU029 Infection Urinary
tract
Unrelated – Mild Concomitant
medication
given
Unresolved
WCU029 Infection Urinary
tract
Unrelated Mild No action
taken
Unresolved
WCU029 Pain Ankle Possible 1 Moderate No action
taken
Resolved
WCU029 Pain Needle site Related 1 Mild No action
taken
Resolved
WCU035 Pain Foot Possible 1 Moderate No action
taken
Resolved
WCU041 Bleeding Needle site Related 1 Mild No action
taken
Resolved
WCU041 Cough/cold/flu – Unrelated 9 Mild Concomitant
medication
given
Resolved
WCU041 Headache/
migraine
– Possible 67 Mild Concomitant
medication
given
Resolved
WCU047 Infection Urinary
tract
Unrelated 6 Mild Concomitant
medication
given
Resolved
WCU047 Urinary symptoms – Possible – Mild No action
taken
Unresolved
GI, gastrointestinal.
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